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KOPSA VILKUMS
Bakteriju izraisltas infekcijas slimibas vienmer ir apdraudejusas cilveci, un,
spriezot pee musdienu situacijas, vel ilgi netiks uzvaretas. Klrnijterapijas pinnas
veiksmes driz vien aizenoja zalu rezistento mikroorganismu paradisanas. Piemerarn,
multirezistentais tuberkulozes izraisitajs Mycobacterium tuberculosis ir nejutigs
vismaz pret diviem pinnas rindas kirnijterapijas Iidzekliem: rifampicinu un
izoniazidu. Tapat bistams ir nozokomialo infekciju izraisitajs, meticilina rezistentais
stafilokoks, kurs iegust rezistenci vienlaicigi pret visiem p-Iaktamiem un
cefalospormiem. Tade] atrai un precizai zalu jutibas noteiksanai ir izsl}irosa lorna
arstesanas kursa izstradasana, un Iidz ar to bakteriju izraisitas infekcijas apkarosana.
ST darba galvenie merki bija Mituberculosis un Staphylococcus spp.
mikroorganismu dazadu rezistences mehanismu petijumi molekularaja Iirneni. Ta,
zalu rezistence mikobakterijas ir saistita ar genu spontanam mutacijam. Savukart,
stafilokoki rezistenci pret p-Iaktamiem iegust ar mobilo genetisko elementu
parnestiem geniem, Sai darba, atkariba no rezistences mehanisma, tika pielietotas
vairakas rnolekularas metodes, balstitas uz genetiska materiala pavairosanu ar PCR.
Dazadu metozu izskirtspeja tika salidzinata ar in vitro zalu jutibas testu rezultatiem, If
novertets molekularo metozu pielietosanas lietderiba zalu jutibas noteiksanai klmiskas
laboratorijas vajadzibarn,
Mutacijas analizeja 145 Mtuberculosis kulturu DNS izolatos, iegutos Latvija
perioda no 1999 Iidz 2002 gadam no plausu tuberkulozes slimniekiem. STs kulturas
reprezenteja ap 30% no visarn sai perioda Valsts Tuberkulozes un Plausu Slimibu
Centra iegutam Mtuberculosis kulturam. 126 no 145 kulturam bija multizalu
rezistentas un 19 bija zalu jutigas; pedejas veidoja kontroles grupu. Ar rezistenci pret
pinnas rindas prettuberkulozes kimijterapijas Iidzekliem rifampicinu, izoniazidu,
streptomictnu, etambutolu un pirazinamidu saistitas mutacijas izpetija attiecigi, rpoB,
katG, rpsL un rrs, embB un pncA genes. Mineto genu mutacijas ir zinamas ka
visbiezakais attiecigo agentu rezistences celonis. Ir paradlts, ka rnutacijas vienos
genes ir biezakais zalu rezistences celonis, tados ka rpoB (rifampina rezistence), kur
mutacijas tika konstatetas 93,6%, un kaIG (izoniazTda rezistence) gena - 99,1%
gadijumos, un citos, savukart, bija konstatetas retak, noradot, ka ir svariga lorna ari
citiern, mazak izpetltiem zalu rezistences mehanismiem. Ta, rpsL un rrs genu
mutacijas kopa bija atrastas 85% streptomicina rezistentiem, pncA - 82%
pirazinamida rezistentiem un embB - tikai 52% etambutola rezistentiem paraugiem.
Kopuma mutaciju noteiksanai tika pielietotas un izvertetas vairakas molekularas
metodes, tacu to jutiba pielietojot uz dazadiem geniern atskiras atkariba no mutaciju
lokalizacijas; vispreclzaka bija nukleinskabju sekvenesana.
Lai novertet PCR metozu lietderTbu Mtuberculosis kompleksa identificesanai
un za]u jutibas noteiksanai kliniskaja materiala, tika aprobeta IS611 O-PCR metode uz
170 kliniska material a paraugiem. Paradits, ka IS6110-PCR ir atra un specifiska
M tuberculosis kompleksa identificesanas metode. Ar citu PCR metodi,
spoligotipesanu, var vienlaicigi identificet un analizet Mtuberculosis celmu genetisko
radniecibu. Ar so metodi ir raksturotas Latvija dorninejosas M.tuberculosis genetiskas
grupas 143 (109 zalu rezistentu un 34 zalu jutigu) Mtuberculosis kultiiru DNS
paraugiem. Ir salidzinats rpoB un katG genu mutaciju biezums starp 109
multirezistento izolatu spoligotipu veidotam lielakam, t.s. Beidiing un ne-Beidiing
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genetiskam grupam, un tas bija lidzigs abas grupas, iznemot rpoB gena
dubultmutacijas, kuras Beidiing grupa tika konstatetas biezak.
Paraleli tika izveidota DNS kolekcija no 102 stafilokoku kulturam (36
Siaureus - 28 meticilinrezistenti un 8 jutigi, un 66 koagulazes negativie stafilokoki -
65 rneticilinreizstenti un 1 jutigs), izoletam Latvijas Traumatologijas un Ortopedijas
slimnica perioda no 2000. Iidz 2003. gadam. Ar PCR metodi analizeja mecA gena
klatbutni, kas, kodejot PBP2a proteinu, nodrosina bakterijas rezistenci pret visiem ~-
laktamiem un cefalosporiniem. PCR rezultatus salidzinaja ar cetram in vitro jutibas
noteiksanas metodem. Visiem meticilinrezistentiem stafilokokiem atklaja mecA gena
fragmentu, apliecinot augstu metodes jutibu. Savukart, mecA genu atklaja ari vienam
in vitro jutigam Siepidermtdis paraugam, kas neapsaubami liecina par Si parauga
rezistenci pret meticilinu. mecA-PCR metode veiksmigi introduceta kliniskas
laboratoratorijas prakse; ta ir seviski ieteicama in vitro jutigu kultiiru apstiprinasanai,
Sis darbs ir izstradats laika perioda no 2000. Iidz 2003.gadam. Petijumi tika
veikti LV Biomedicinas Petijumu un Studiju Centra, LV Prof. V.Baumana vadita
molekularas mikrobiologijas laboratorija un daleji Staten Serum Instituta,
Kopenhagena, Danija, Dr. Y.O-Thomsen vadita starptautiska Mikobakteriologijas
laboratorija. Petijumi tika veikti sadarbiba ar Valsts Tuberkulozes un Plausu Slimibu
Centra laboratoriju (vad. MD G. Steenders) un Latvijas Traumatologijas un
Ortopedijas slimnicas laboratoriju (vad. LV Prof. Dr. habil. med. A. Zilevica). Darbu
finanseja EV Inco-Copernicus projekts nr. 15-CT98-0328; LZP projekts nr.
2.0011.15.1 "Infekcijas agentu multirezistences un genetiskas mainibas molekulari
epidemiologiska izpete"; Si darba autori personigi finansiali atbalstija LZP
doktorantiiras grants nr.69/71 un FEBS Isterrnina stipendija.
Tracevska T. 2004. Molecular studies of drug resistance mechanisms in
Mycobacterium tuberculosis and Staphylococcus species. 48 pp.
SUMMARY
Infectious diseases caused by pathogenic bacteria have affected people for
many centuries. The invention of chemotherapy was an important step to eradicate
pathogens, however, it led to the emergence of drug-resistant forms of bacteria. For
instance, multidrug-resistant Mycobacterium tuberculosis complex bacteria, the main
causative agent of tuberculosis, is resistant at least to rifampin and to isoniazid, the
first-line antitubercular drugs. At the same time, methicillin-resistant Staphylococcus
spp., accepted as a major agent of nosocomial infections, simultaneously acquire
resistance to all l3-lactam antibiotics and to cephalosporines. That's why precise and
rapid drug susceptibility testing is of great significance for prescribing an adequate
treatment course.
An investigation into different drug resistance molecular mechanisms in
Mtuberculosis and Staphylococcus spp. is the main goal of this study. Mtuberculosis
gain drug resistance via chromosomal gene alterations, which modify target
molecules. In contrast, Staphylococcus spp. acquire resistance, particularly, to 13-
lactams, by transfer of the resistance-determining gene. In the present study, various
PCR-based methods are evaluated, depending on the drug resistance mechanism.
Reliability of the methods is evaluated and the practical value for implementation in
clinical laboratory practise is estimated.
The study of antitubercular drug resistance involved 145 M tuberculosis
culture DNA isolates (126 multi-drug resistant and 19 drug susceptible) obtained
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from pulmonary tuberculosis patients in Latvia during the time period from 1999 to
2002. The cultures represented about 30% of all cultures obtained at the State
Tuberculosis and Lung Diseases Centre during the period of study. Mutations were
analysed in genes most frequently associated with resistance to the first-line anti- TB
drugs: rifampin (rpoB gene), isoniazid (katG gene), streptomycin (rpsL and rrs gene),
ethambutol (embB gene), and pyrazinamide (pncA gene). It was shown that mutations
in some genes, i.e. rpoB and katG (93,6% and 99.1%, respectively), are of the highest
frequency and can be used as corresponding drug resistance markers. In contrast,
mutations in remaining genes were less common. Mutations in rpsL and rrs genes
were found in 85% of streptomycin resistant, in pncA gene - in 82% of pyrazinamide
resistant and in embB gene - in 52% of ethambutol resistant isolates, respectively.
Different molecular screening methods were evaluated for the rapid detection of
mutations. However, reliability of the methods varied and was dependent on mutation
location. The nucleotide sequencing method was the most discriminative and was
used as a confirmatory method.
To evaluate reliability of PCR-based methods for the identification and drug
susceptibility testing in clinical specimens, initially IS61l0-PCR was applied to 170
clinical specimens. IS611O-PCR was shown as a rapid and specific method in
comparison with commonly used methods. Another PCR method, spoligotyping, was
further used for the simultaneous identification and typing of M tuberculosis.
Predominant in Latvia genotype groups have been characterised by spoligotyping on
143 (109 drug resistant and 34 drug suscpetible) Mtuberculosis culture DNA isolates.
The frequency of rpoB and katG gene mutations was compared between two major
groups, so named Beijing and non-Beijing, formed by 109 drug resistant isolates. The
higher frequency ofrpoB gene double mutations occurred in Beijing group.
In parallel, 102 DNA samples from staphylococcal cultures isolated in
Hospital of Traumatology and Orthopedics from 2000 to 2003 were analysed for
resistance to methicillin. Among them, there were 36 coagulase-positive S.aureus (28
methicillin resistant and 8 methicillin susceptible S.aureus) and 66 coagulase negative
staphylococci group, including 65 methicillin resistant isolates and one methicillin
susceptible isolate. The presence of the mecA gene, producing PBP2 protein, indicates
resistance to methicillin and other ~-lactams. Results ofmecA-PCR were compared to
four in vitro susceptibility methods. The method correctly identified all
phenotypically methicillin-resistant 28 S. aureus and 65 coagulase-negative
staphylococci. Additionally, mecA gene was detected in one in vitro susceptible
S.epidermidis isolate, giving clear evidence of the method's value in screening
phenotypically susceptible cultures. Altogether, this study showed high sensitivity of
mecA-PCR method, and it has been already implemented in routine laboratory
practice.
The present study was carried out during the time period from 2000 to 2003 in
the Laboratory of Molecular Microbiology (led by MD, LU Prof. VBaumanis),
Biomedical Research and Study Centre, Riga, Latvia and partially in the Reference
Laboratory of Mycobacteriology (Dr. Va-Thomsen), Statens Serum Institute,
Copenhagen, Denmark. The study was conducted in collaboration with the State
Tuberculosis and Lung Disease Centre, (MD G.Skenders) and the Hospital of
Traumatology and Orthopedy, (MD, LU Prof. Dr.habil.med A. Zilevica), Riga,
Latvia. The project was funded by the EU Inco-Copernicus 15-CT98-0328 grant and
the Latvian Council of Sciences (nr. 2.0011.15.1). The author was supported by the
Latvian Council of Sciences (grant nr.69/71 for doctoral students) and the FEBS
short-term fellowship.
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Tpaxeecxaa T. 2004. MOJIeKYJlApHble HCCJle~OBaHHA MexaHH3MOB
JleKapCTBeHHoH ycrOHIIHBOCTH y Mycobacterium tuberculosis H Staphylococcus
spp. JIaTBHHcKHH YHHBepCHTeT, Para, 48 c.
ABBOT AIJ.lUI
qeJIOBeK scerna 6bIJI nonsepscen HH<peKUHOHHbIM 3a6oJIeBaHIDIM,
Bbl3bIBaeMbIM naroreunsnra 6aKTepIDIMH. TIpHMeHeHHe aHTH6HOTHKOB na nepasrx
nopax 6blJIO ycneumsus BOMHOrHX 06JIaCTIDC Me,llHI.{HHbI, HO scxope npHBeJIO K
nOHBJIeHHIO aHTH6HOTHK-YCTOHlJHBbIX <pOPM MHKpoopraHH3MoB. HaH6oJIbllIYJO
onaCHOCTb npe,llCTaBJUDOT TaK nassrsaesnre MYJIbTHpe3HCTeHTHbIe <pOpMbI, TaKHe, KaK
Mycobacterium tuberculosis, KOTOpbIH YCTOHIJHB KaK MHHHMYM K pH<paMnHl..{HHY H
H30HHa3ID1,lly, nepaoouepezmsur npOTHBDTy6epKYJIfuHbIM cpencrsaw.
MYJIbTHpe3HCTeHTHOCTb ecrs TaK)l(e y HeqyBCTBHTeJIbHoro K MeTHI..{J1JIJIHHYH ,llpyrHM
[3-JIaKTaMaM CTa<pHJIOKoKKa, HCTOlJIDIKa H030KOMHaJIbHbIX HH<peKUHH. TI03TOMY
caoespesreaaoe BbIaBJIeHHe TaKHX <pOPM 6aKTepHH B~HO ,llJIH npaaansnoro aufiopa
xypca JIelJeHIDI.
rJIaBHOH UeJIblO 3TOH pa60TbI 6blJIO HCCJIe,llOBaHHe MexaHH3MOB
JIeKapCTBeHHoH YCTOHlJHBOCTH y 6aKTepHH Mituberculosis H Staphylococcus spp.
ECJIH YCTOHIJHBOCTb Y Muuberculosis CBH3aHa B OCHOBHOM C nOSIBJIeHHeM
CnOHTaHHbIX MYTaUHH, TO y Staphylococcus spp. YCTOHlJHBOCTb K MeTHUHJIJIHHY
KO,llHpyeTCH renaua, xoropsre nepeHOCHTCH Mo6HJIbHbIMH reHeTWIeCKHMH
3JIeMeHTaMH. B ,llaHHOM HCJIe,llOBaHHH, B 3aBHCHMOCTH OT MexaHH3Ma
pe3HCTeHTHOCTH, 6blJIH HCnOJIb30BaHbI pasasie MOJIeKYJIapHbIe MeTO,llbI, OCHOBaHHbIe
na nOJIHMepa3HOH uenaoii peaKUHH (Tll.Il'). TOIIHOCTb MeTO,llOB nposepanacs B
cpaBHeHHH C pe3YJIbTaTaMH TPa,llHUHOHHOro TeCTHpOBaHHa in vitro H OueHHBaJIaCb
,llJIHnansneiiurero BBe,lleHIDI B JIa60paTOpHYJO npaKTHKY.
AHaJIH3 MYTaUHH 6bIJI npoassenen na 145 Mituberculosis ):(HK ofipasuax
nOJIy4eHHbIX H3 KYJIbTYP, BbI,lleJIeHHbIX B )laTBHH 1999 no 2002 ron y 60JIbHbIX
ry6ePKYJIe30M. 3Ta BbI60pKa npe,llCTaBJIHJIa OKOJIO30% acex KYJIbTYP Mituberculosis
BbI,lleJIeHHbIX B )laTBHH sa nepnozt HCCJIe,llOBaHHa. 126 113 145 KyJIbTYP 6bIJIH
MYJIbTHpe3HCTeHTHbI H 19 IIYBCTBHTeJIbHbl. MYTaUHH, CBH3aHHbie C
YCTOHlJHBOCTblO K nepaoo-repennsra npoTHBory6epKYJIe3HbIM cpencrsav
pH<paMnHHY, H30HHa3H.llY, CTPenTOMHUHHY, 3TaM6YToJIY H napaaanascmy 6blJIH
npOaHaJI113HpOBaHbI, COOTBeTCTBeHHO, B renax rpoB, katG, rpsL H rrs, embB H pncA.
IibIJIO yCTaHOBJIeHO, 1JTOMYTauHH B O.llHHX reaax (rpoB (pH<paMnHH-YCTOHlJHBOCTb), -
93,6%, katG (H30IDIa3H,ll-YCTOHl.fHBOCTb) - 99,1%) BCTPelJaJOTcH C BbICOKOH lJaCTOTOH
H no 60JIbllIOH lJaCTH onpenenmor YCTOHIJHBOCTb. B npyrax reaax MYTau,HH 6bIJIH
KOHCTaTHpoBaHbI peace (rpsL H rrs (CTPenpOMHu,HH-YCTOHlJHBOCTb) BMeCTe 85%,
pncA (nHpa3HHaMH,ll-YCTOHlJHBOCTb) - 82%, embB (3TaM6YToJI-YCTOHlJHBOCTb) -
TOJIbKO 52%), YKa3bIBaa na HaJIWIHe npyrax MexaHH3MoB, TPe6YJOlIlHX
,llOnOJIHHTeJIbHbIX HCCJIe,llOBaHHH. qYBCTBHTeJIbHOCTb HCnOJIb30BaHHbIX
MOJIeKYJIapHbIX MeTO,llOB sapsnpcsana B 3aBHCHMOCTH OT JIOKaJI113aUHHMYTauHH.
qT06bI OueHHTb nparoztaocrs III..lP MeTO,llOB nns ,lleTeKUHH Mituberculosis
KOMnJIeKCa H onpeneneaas ero IIYBCTBHTeJIbHOCTH K JIeKapCTBeHHbIM npenaparav
npsvo na KJIHHHl.feCKOM MaTepHaJIe, CHalJaJIa aa 170 KJIHHHlJeCKHX ofipasuax 6bIJI
onpofosan IS611 O-IJI.U> MeTO,ll. IS6110-IJI.U> OKa3aJICH 6bICTPbIM, IIYBCTBHTeJIbHbIM
H cneUH<pHl.fHbIM KMituberculosis KOMnJIeKcy. ):(pyroH oCHoBaHHbIH na IJI.U> MeTO,ll,
CnOJIHroTHnHpoBaHHe, 6bIJI snenpea ,llJIH ,lleTeKUHH H onnospeaenaoro
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reHOTHnHpOBaHIDI M tuberculosis llITaMMOB. C novomsio aroro MeTOAa 6bIJIH
xapaxrepnsoeansr AOMHHHpYlOIllHe B JIaTBHH reaera-iecxae rpynnsr cpenu 143
Mtuberculosis (l09 MYJIbTHpe3HCTeHTHblX H 34 qyBCTBHTeJIbHblX) )UIK. Taioxe
CpaBHHJIH l.{aCTOTYMYTaUHH B rpoB H katG renax cpenn 109 MYJIbTHpe3HCTeHTHblX
,Z..J;HK H30JUlTOB, 06Pa3Y1OIllHX ABe 60JIbillHe reHeTHl.J.eCKHerpynnsr, T.H. lieHWKHHr H
ne-B eliWKH Hr. qaCToTa MYTaUHH 6bIJIa CXO;KeH B o6eHX rpynnax, sa HCKJIIOl.{eHHeM
ABOHHblX MYTaUHH B rpoB rene, xoropsre xame BCTpel.{aJIHCbB rpynne lieHWKHHr.
TIapaJIJIeJIbHO 6bIJIa C03.naHa KOJIJIe~IDI ,Z..J;HK H3 102 CTacPHJIOKOKKOBblX
xynsryp (36 S.aureus, H3HHX 28 - MeTHUHJIJIHH-YCTOHl.{HBbleH 8 - qyBCTBHTeJIbHble,
a TalOKe 66 xoarynaanerarasasrx, H3 mIX 65 MeTHUHJUlHH-YCTOHl.{HBble H OAHH -
l.{YBCTBHTeJlbHbIH) BblAeJIeHHbIX B 60JIbHHue TpaBMaTOJlOrHH H OpTOneAHH (2000-
2003 rOAbI). C nosroursro rn.u> MeTOAa aHaJIH3HpOBaJIH namrxae mecA rena,
xoropsrii KOAHpyeT npOTeHH PBP-2a, OTBel.{aIOIllHH sa YCTOWIHBOCTbK MeTHUHJIJIHHY
H ApyrHM ~-JIaKTaMaM. Pe3YJIbTaTbl CpaBHHJIH C l.{eTblpbWl in vitro MeTOAaMH
oJIpeAeJIeHIDI qyBCTBHTeJIbHoCTH. Y scex in vitro MeTHUHJUlHH-YCTOHl.{HBblX
CTacPHJIOKOKKOBo6Hapy)KJ1JIH mecA rea, .nOKa3aB BblCOKYIO l.{YBCTBHTeJIbHOCTb
MeTOAa. KpOMe TOro, mecA rea 6blJl HaHAeH y ozmoro in vitro qyBCTBHTeJIbHoro
ofipasua S.epidermidis, YKa3bIBasI na YCTOWIHBOCTb K MeTHUHJIJIHHY. mecA-PCR
MeTOA 6bIJI ycneunro sneztpen B npaKTHKY KJIHHHl.{eCKOHJIa60paTopHH H ocofienno
pexossenayercs ztns nposepxa cPeHoTHnHl.{eCKHqyBCTBHTeJIbHblX xynsryp.
MCCJIe.noBaTeJIbCKasI pafiora 6bIJIa nponenaaa B C 2000 no 2003 ron B
JIa60paTopHH MOJIeKyJUlpHoH MHKpo6HOJIOrHH (PYK. Tlporp. JIY B.liaYMaHHC) npa
lJ,eHTPe IiHOMeAHUHHCKHX MCCJIeAOBaHHH JIaTBHHcKOro YHHBepCHTeTa (Pnra,
JIaTBIDI) H l.{aCTHl.{HOB Statens Serum MHCTHTYTe (Koneararen, ):(aHIDI), JIa60paTopHH
MHKo6aKTepHOJIOrnH (pyx, ):(po B. O-TOMceH). Msi BeJIH COrpYAHHl.{eCTBO C
JIaTBHHcKHM lJ,eHTPOM Ty6epKYJIe3a H 3a6oJIeBaHHH JIerKHX (PyK. JIa60paTopHH
FLllxeanepc), a 'raiose C JIaTBHHcKHM I.J:eHpoM TpaBMaTOJlOrHH H OpToneAHH (pyx.
nafioparopnn Ilporp. JIY A. )l{HJIeBHua). Pafiory cPHHaHCHpOBaJIH EU Inco-
Copernicus npoexr nr. 15-CT98-0328; npoexr JIaTBHHcKoro COBeTa HayKH nr.
2.0011.15.1 H JIHl.J.HOasropa pa60TbI - npoexr JIaTBHHcKoro COBeTa HayKH AJUI
AOKTOpaHTOBnr.69/71 H KpaTKOCpOl.{HbIH npoexr FEBS .nJIjf crynerrros.
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ABBREVIA TIONS
BCG - Mycobacterium bovis BCG
CoNS - coagulase-negative staphylococci
CSF - cerebrospinal fluid
CTAB - cetyltrimetylammonium brmide
DOTS - directly observed therapy short-course
DR - drug resistance
ECL - enhanced chemical luminescence
EMB - ethambutol
ERDR - ethambutol resistance determining region
ETH - ethionamide
FQ - fluorquinolones
HIV - Human Immunodeficiency Virus
HTO - Hospital of Traumatology and Orthopedy
INH - isoniazid
INNO-LiPA - "Innogenetics" line probe assay
IS - insertion sequence
LCx - lygase chain reaction
MDR - multi-drug resistance
MET - methicilin
MIC - minimal inhibitory concentration
MRSA - methicillin resistant Staphyloccocus aureus
MRSE - methicillin resistant Staphyloccocus epidermidis
MSSA - methicillin susceptible Staphyloccocus aureus
MTC - Mycobacterium tuberculosis complex
NCCLS -National Committee for Clinical Laboratory Standarts
PAAG - polyacrilamide gel
PASS - paraaminosalicylic acid
PBP - penicillin-binding protein
peR - polymerase chain reaction
PFGE - pulsed-field gel electrophoresis
PZA - pyrazinamide
RAPD - randomly amplified DNA polymorphism
RD - region deleted
RFLP - DNA restriction fragment length polymorphism
RIP - rifampin
SM - streptomycin
SSCmec - staphylococcal chromosomal cassette, mec determinant
SSCP - single-stranded DNA conformation polymorphism
STLDC - State Tuberculosis and Lung Disease Centre of Latvia
SVA - Public Health Agenture of Latvia
TB- tuberculosis
WHO - Word Health Organisation
WT - wild type
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"You will begin to touch heaven, Jonathan,
in the moment that you touch perfect speed. And
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million, or flying at the speed of light. Because
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Without warning, Chiang vanished and appeared
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1. INTRODUCTION
In the last fifty years since chemotherapy was found to be effective against
microorganisms many infectious diseases seemed to have won. Partially, recovery of
such antibacterials like streptomycin, isoniazid and rifampin have lowered the
incidence of tuberculosis caused by Mycobacterium tuberculosis complex. Similarly,
the introduction of penicillin and its chemically modified analogues was highly
effective against Staphylococcus species. Staphylococci are known as major causative
agents of community-acquired and hospital-acquired infections causing sometimes
death of previously healthy people. Unfortunately, rash use of antibacterials led to the
emergence and subsequent spread of drug resistant bacteria.
Plasmid- or transposon- mediated transfer of drug resistance genes is the most
common mechanism of drug resistance in many bacteria. Therefore, such resistance
mechanisms are well-explored in many bacteria, like E.coli, the universal object of
microbiology. Highly pathogenic nature, slow growth and genomic divergence of
Mtuberculosis (e.g., unclear function of transposons and absence of plasmids) could
not assist to such studies. That's why until the last time little was known about the
mechanism of action of many antitubercular drugs and about the ways of gaining
resistance. However, the introduction of new molecular techniques allowed scientists
to build trustful scenarios. The realisation of complete genome sequencing
programmes for such microorganisms as Mtuberculosis, M.bovis BeG, Mavium,
Mleprae, S.aureus, and S.epidermidis was an essential step in deciphering
biochemical pathways in bacteria, therefore, highlighting putative genes involved in
drug metabolism and resistance.
To investigate molecular basis of drug resistance, two species of
microorganisms were selected: Mycobacterium and Staphylococcus spp. There were
various reasons that determined the selection of these particular bacteria.
Staphylococcus is the most common cause of nosocomial infections, and
Mycobacterium tuberculosis complex causes tuberculosis, a severe infectious disease.
It would be interesting to compare the molecular mechanisms of drug resistance of
particular microorganisms from a region where a problem of high-level drug
resistance persists, such as Latvia. Moreover, it is important to estimate the frequency
of resistance determining mutations or genes and to compare it with that in other parts
of the world. High prevalence of some mutations may indicate the spread of particular
genotypes, which points at ongoing transmission, e.g. has high epidemiological value.
Therefore, genotyping techniques were applied to analyse molecular relatedness of
microorganisms.
Knowledge of frequently occurring mutations M tuberculosis at specific
codons that correlate with the genetic relatedness ofMDR strains should contribute to
our understanding of resistance to the first-line anti- TB drugs both at regional and
international levels. This information may be used further in order to develop and
adopt molecular methods for testing M tuberculosis drug susceptibility and molecular
typing directly in clinical specimens. This is a welcome feature of molecular biology
due to prolonged (2-6 weeks) cultivation usually required for Mtuberculosis complex
species. The evaluation of insertion-sequence-based Mtuberculosis detection method
was an additional objective of this study.
In order to control the spread of resistance among Staphylococci, appropriate
infection control practices should be applied in hospitals, including precise
microbiological diagnosis and detection of antimicrobial susceptibility. Therefore,
another objective of this study was introduction and evaluation of molecular methods
for testing methicillin susceptibility in S.aureus and in coagulase-negative
staphylococci culture isolates compared to in vitro methods routinely used in clinical
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laboratories. This part of the study contributes to the further studies of particular
groups of staphylococci strains that may hypothetically spread among Latvian
hospitals.
2. REVIEW OF LITERATURE
2.1. Short history of chemotherapy
Paul Erlich is thought to be a founder of chemotherapy. He explored and
showed antimicrobial properties of salvarsan, an atoxyl descender, in order to treat
syphilis. The first antimicrobial agent widely introduced in medical practice was
penicillin discovered in 1929 by A. Fleming by a lucky chance (Fleming, 1929).
Natural drugs with bacteria demolishing and inhibiting properties produced by fungi,
bacteria, actinomiceta, plants and animals, were called antibiotics. Choice of a
particular agent was based on the mechanism of action and on its sterilizing or
bacteriostatic effect.
Later, antibacterial activity was found in many chemically synthesized agents,
especially when used in combination with natural antibiotics. Particularly, the
discovery of antibacterial and antitubercular properties of streptomycin in 1944
(Schatz and Waksman, 1944), and both isoniazid and pyrazinamide in 1952 (Kushner
et aI., 1952; Middlebrook, 1952), led to effective chemotherapies what decreased
tuberculosis mortality rates worldwide. New effective drugs against TB were
discovered in the 1970s and are still used for the treatment of TB. Today more than
hundred chemotherapeutic agents are known, which are used to treat grampositive and
gramnegative bacteria caused disorders, as well as some viral, protozoal and fungal
infections. However, the widest application of chemotherapy drugs occurred in
mycobacteria and grampositive cocci, particularly, in staphylococci caused infections.
2.2. Acquired drug resistance as a consequence of
chemotherapy
Prolonged and inappropriate chemotherapy regimens compounded by non-
compliance of patients in completing the prescribed course of treatment led to the
appearance of drug-resistant strains. The first alarming sign was the appearance of
penicillin-resistant staphylococci and multiple resistant enterococci, which caused
serious nosocomial (hospital-acquired) infections in 1960-s (Dalhoff, 1999). In 1977
the appearance of high level resistance to penicillin in Streptococcus pneumoniae
which cause respiratory diseases such as pneumonia was detected in South Africa
(Jakobs et al, 1978). In the mid-1980s the number of tuberculosis cases also increased
worldwide accompanied by the growth of multi-drug resistant cases (Blanchard et aI,
1996).
Nowadays many bacteria-caused diseases are increasingly difficult to treat
because of the emergence of drug-resistant microorganisms. Eradication of such
diseases requires profound studies of drug resistance molecular mechanisms in
bacteria and determination of bacterial evolution pathways. This important
information can be further used in the search for new antibacterial agents.
2.3. Natural and acquired mechanisms of microbial drug resistance
There are various mechanisms of drug resistance acquisition, mostly based on
the ability to produce drug-inactivating enzymes and on the modifications in bacterial
DNA, RNA or protein structures, which directly interact with the agent. There are
natural (inner) and acquired factors of antimicrobial agent resistance.
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Natural resistance is based on the bacterial cell limitation for antibacterial
agent diffusion or active transport. For example, Pseudomonas spp. is naturally
resistant to ~-Iactam antibiotics and aminoglycosides. Recently drug-specific and
multi-drug efflux pumps have been identified to playa major role in the resistance of
many species to antibacterials (e.g. resistance of Gram-negative bacteria to
tetracyclines) (Li & Nikaido, 2004).
At present, two major mechanisms of acquired drug resistance can be
distinguished: non-genetically and genetically determined acquired drug resistance.
Non-genetically determined acquired drug resistance may be caused by the
lowering metabolitic activity in the bacterial cell. Most antimicrobial agents are active
against actively reproducing cells and, therefore, will not be effective against dormant
bacteria. Also under pressure of chemotherapy the number of bacteria-agent
interaction ligands can decline, this way lowering the inclusion of drug in the host
cell.
In contrast, genetically determined acquired drug resistance can be encoded by
the chromosomal DNA of bacteria or by the plasmids. This mechanism includes gene
mutations, changing structure of target proteins or agent modifying enzymes,
acquisition of drug resistance genes, transferred bl plasmids. Gene mutations occur
spontaneously in bacteria with frequency 10-7_10-1 and themselves playa minor role
in a huge population of bacteria. However, further selection of viable cells with
mutations or gained genes leads to the domination of particular strains in the
population. Plasmids or episomes contain one or various genes encoding proteins that
inactivate, modify or extract antimicrobial agents from the cell. Multiple-resistance
genes may be encoded by the transposons integrated into plasmids. Plasmids have an
ability to transfer their resistance factors and to rise epidemic resistance by various
mechanisms: conjugation, transfection or transduction.
Two distinct mechanisms of genetically determined resistance will be
described further in this paper, generally focusing on two pathogens, Mycobacterium
tuberculosis and Staphylococcus spp. and taking into account different mechanisms of
drug resistance development. Although both mechanisms are genetically determined,
drug resistance in Mituberculosis is usually determined by chromosomal mutations,
whereas staphylococci have various mechanisms. However, an acquisition of drug
resistance genes by plasmid transfer remains the main drug resistance mechanism in
staphylococci as well as in most microorganisms, which, probably, has more
advantages than gene mutations.
2.4. Characterisation of M.tuberculosis complex
2.4.1. Tuberculosis in Latvia and worldwide.
M tuberculosis complex (MTC) remains the leading infectious cause of
morbidity and mortality. Tuberculosis (TB) is a chronic infectious disease, affecting
mostly pulmonary organs. TB causes about 8 million pulmonary TB cases and more
than two million deaths per year worldwide (Espinal et aI., 2001). In humans and
cattle, tuberculosis is generally caused by M tuberculosis complex including
Mtuberculosis, M bovis, M cfricanum and M.microtti species. However, in the
industrialised world, Miavium complex (including Miavium, Miintracellulare and an
intermediate group) has become the major cause of mortality in HIV -infected patients
(Horsburgh, 1991). In Latvia, M tuberculosis is the most common pathogen isolated
in case ofTB.
The incidence of tuberculosis was increasing in Latvia from the 1980ties at
about 5% to 10% of annually notified cases. The highest incidence was observed in
1998 (1820 TB patients, with prevalence 74.0 per 100.000 of population). The
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invention of directly observed therapy short-course programme (DOTS) in 1995 and
DOTS-plus programme in 1998 decreased TB incidence by 13% from 1998 to 2003.
In a survey of 1334 registered TB patients in Latvia in 2003 incidence was 57.0 per
100.000 of population (SVA report, 2003). The comparison of TB situation in Latvia
with the nearest North-European countries in 2002 is shown in Table 1. As one can
see from Table 1, situation with TB incidence in the former US countries is much
worse than in Scandinavian countries, where incidence is less than 10 per 100 000 of
population.
At the same time, the positive tendency in TB treatment in Latvia has been
affected by a very high incidence of drug resistant cases. Today a high proportion of
TB patients in Latvia hosts multi-drug resistant (MDR) strains, i.e. resistant at least to
Table 1. Epidemiological data on incidence of TB (total) in the Baltic Sea region
in 2002.
Country/Region Total number of a new cases
in 2002
1535
Prevalence (per 100.000
population)
65.4Latvia
Estonia
Lithuania
Finland
Iceland
St.Petersburg Region
Kaliningrad Region
522 38.2
2097 60.5
429 8.0
256 5.7
418 4.7
475 9.1
8 3.0
1026 65.2
1042 110.0
Denmark
Norway
Sweden
rifampin (RIF) and isoniazid (INH). Multi-drug resistance to TB in 2000 in Latvia
seemed to be one of the highest in Europe, with primary multi-drug resistance (MDR)
in 9.3% of new cases and acquired! MDR in 27.9% cases. In comparison, the average
primary MDR rate in Europe as a whole is only 4%. Many of the culture isolates from
MDR M tuberculosis patients show resistance not only to RIF and INH, but also to
other first-line antituberculous agents: streptomycin (SM), ethambutol (EMB) and,
less frequently, to pyrazinamide (PZA) (Espinal et al., 2001; EuroTB, 2003). The
incidence ofMDR TB cases in previous years is shown in Figure 1.
Figure 1. Multi-drug resistant TB in Latvia, 1998-2002 (STLDC data).
~.O% I
25.0%,-
20.0%--
28.0010
• PriI"l1i:lY M:R-lB
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2.4.2. Mycobacterial genome
MTC belongs to Mycobacteriaceae family, which is a member of the order
Actinomicetales. These are gram-positive bacteria (according to Bergey's taxonomy)
that are distinguished by the high G+C content of their DNA (60-70%) and an
unusual cell wall. Besides a slightly atypical peptidoglycan (Rastogi & Barrow,
1994), mycobacteria have a unique polysaccharide component, arabinogalactan
(Daffe et al, 1993). Arabinogalactan layer contains covalently bound long, branched
lipids, termed mycolic acids, which can be from 40 to 90 carbons long.
Mycobacterial genome of Mtuberculosis laboratory virulent strain H37Rv
was completely sequenced in 1998, followed by revealing the complete genome
sequence of clinical strain CDC1551 in 2002 and Mbovis in 2003 (Cole et al, 1998,
Fleischmann et al., 2002; Gamier et al., 2003). The total nucleotide sequence
determined for Mtuberculosis strain H37Rv genome was 4,4U,529bp long
containing approximately 4000 putative genes (Figure 2). 60% of genes have
predicted functions providing M tuberculosis with a wide range of metabolic
Figure 2. Circular map of the M.tuherculosis H37Rv strain genome (PbiUip
et al., 1998, Cole et ai, 1998). OriC ~ replication origin, IS6UO and ]S108] -
insertion sequences, DR ,--direct repeat region.
pathways. Many genes are involved in lipid metabolism due to the complexity and
diversity of lipid content in the mycobacterial cell wall (Cole et al, 1998). A high
number of regulatory genes, indicating high adaptability to changing conditions, is
consistent with the environmental origins of mycobacteria, which could have become
a human pathogen only 15000 years ago. (Sreevatsan et al, 1997). At the same time,
genome of different Mycobacterium species has a highly clonal nature without
detectable lateral gene exchange (Alland, 20tn, Supply et al, 2(03). High
conservation of mycobacterial genome with slowly occurring mutations prevailing
above region deletions defines that mycobacteria is an evolutionary young organism.
Interestingly, Mleprae complete genome sequence showed a critically shortened
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genome (reduced to 3,2 Mb) containing around 1600 genes, pointing at the reductive
evolutional pathway for pathogenic mycobacteria (Brosch et aI, 2002).
Mycobacterial genome contains many repetitive genes and transposons, such
as two large families of glycine-rich proteins, Pro-Glu (PE) and Pro-Pro-Glu (PPE),
and insertion sequences, mostly of unknown function. Studies of the PE proteins
demonstrated their role in mycobacterial virulence (Ramakrishnan et aI, 2000). Both
PEIPPE and Esat-6 protein (a central T-cell antigen in human) families enter the RDl,
a region deleted inM bovis BCG Pasteur vaccine strain, confirming the considerable
interest about these proteins as virulence factors (Tekaia et aI., 1999; Bange et al.,
1999, Brosch et aI., 2002). In conclusion, no plasmids were found in MTC species,
whereas there are some data about plasmids in nonpathogenic M.scrofulaceum and
Mintracellulare species (Cole et aI, 1998). Episomal or transposon-mediated transfer
of resistance genes into M tuberculosis has never been demonstrated, although this is
a common mechanism for the acquisition of drug resistance in other bacteria (Cole,
1994). Absence of extra chromosomal DNA indicates that phenotypic changes in
MTC occur due to genome DNA mutations.
2.4.3. Antitubercular agents and drug susceptibility testing
The main anti- TB chemotherapy agents are so called first-line drugs: INH,
RIP, SM, EMB and PZA. The second-line drugs are used mostly as a supplement to
main chemotherapy due to their lower efficacy and high toxicity, for example,
kanamycin, capreomycin, ethionamide, paraaminosalycilic acid (PASS), cycloserine,
ofloxacin, thioacetazone, viomicin etc. Some antituberculars, known as antibiotics,
are naturally produced like RIF and SM; others are chemically synthesized (INH,
PASS, EMB, PZA). The directly observed short-course chemotherapy prescribed by
WHO, consists of a two-month treatment with the four first-line drugs (INH, RIP,
PZA and SM or EMB) followed by four-month therapy with two first-line drugs INH
and RIF, or, alternatively, a six-month course with INH and EMB in combination
with second-line drugs (Vareldzis et aI, 1994).
There are various methods for MTC growing and for drug susceptibility
testing. Drug susceptibility testing is traditionally performed in vitro on cultures
grown on solid medium (Lowenstein-Jensen, Middlebrook etc) for several weeks by
the absolute concentration method or by the proportional dilution method (Hawkins et
aI., 1991). In the absolute concentration method, used in Latvia, resistance is defined
as growth on solid media containing graded concentrations of drugs greater than a
20CFU at a specific drug concentration. In the last decade, the BACTEC radiometric
method (Becton Dickinson, Sparks, Md.) for drug susceptibility testing has been
developed. Here, MeT is cultivated for a slightly shorter time on liquid medium with
added anti- TB agent at minimal inhibiting concentration (Roberts et aI., 1991). Cell
growth is estimated automatically.
However, slow growth of pathogenic mycobacteria requiring weeks and even
months to obtain drug susceptibility results is the main disadvantage of the mentioned
methods. This delays appliance of chemotherapy and, if it was incorrectly started,
leads to selection and accumulation of drug resistant clones in population. Also,
sometimes weak growth or even absence of growth can be observed, especially for
MDR mycobacteria. The reasons for that can be reduced fitness, or low reproductive
effectiveness of MDR bacteria due to mutations affecting metabolism, as proposed by
Cohen a et aI. (2002). This is another disadvantage of the in vitro methods, because
they are based on phenotypic characteristics. The problem could be solved by the
molecular methods, based on bacterial genome features, which can be used with
various aims like species identification, typing and drug susceptibility testing.
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Molecular methods may precisely determine the molecular basis of drug resistance,
indicate spread of particular strains and, most significantly, they supply data about
possible epidemiological links. Additionally, these methods can be used to study the
evolution of particular mycobacteria groups and their virulence levels.
2.4.4. Molecular mechanisms of drug resistance in M.tuberculosis
Mycobacteria develop drug resistance via a limited number of mechanisms.
Structural and functional changes in the enzymes that either activate
antimycobacterial drugs or are themselves the target of drug action are most
commonly observed in Mtuberculosis. That means that gene mutations in
Mtuberculosis genes are responsible for resistance to the first - and second-line
drugs (Musser, 1995, Sander&Bottger, 1999). Resistance to each drug develops
independently except for those with the similar mechanisms of action (e.g. INH and
ethionamide). No drug eftlux mechanisms have yet been described that can account
for drug resistance in M tuberculosis, although diffusion and transport into
mycobacterial cells is an extremely important variable in the drug activity. The drug
targets, mechanism of action and mechanisms of drug resistance in Mtuberculosis
have all been extensively studied and partially discovered over the last ten years.
Mode of action of commonly used first- and second- line anti- TB drugs and
mechanisms of resistance inM. tuberculosis are summarised in Table 2.
By the mode of action, anti- TB drugs can be divided into nucleic acid, protein
or cell membrane synthesis inhibitors. Taking into account higher therapeutic value of
the first-line anti-TB drugs, the mechanisms of action and mechanisms of bacterial
resistance to RIF, SM, INH, EMB and PZA will be paid more attention to further in
the text.
Inhibitors of nucleic acid synthesis
This group of antituberculars includes agents inhibiting DNA or RNA synthesis.
Molecular mechanisms ofRIF resistance are well studied (Table 2).
Rifampin (RIF) was introduced in practice in 1972 as an antitubercular drug
(Woodley, 1972 no BL). RIF is extremely effective against Mtuberculosis (MIC 0.1-
0.2 mkg/ml) shortening the course of treatment (Heifets, 9:84-103, 1994noBl).
Resistance to RIF is used as a molecular marker for MDR. By irreversible binding to
the ~-subunit of RNA polymerase, RIF is inhibiting transcription reaction at the first
stages, as it was shown in RIF-susceptible Msmegmatis strains (Fischl et ai, 1992).
However, some additional mechanisms of action can not be excluded.
Mutations in the 81bp hypervariable region of the 3.534bp long rpoB gene
encoding the RNA polymerase ~-subunit cause RIF resistance in 96% of cases.
Among these, missense mutations in codons S531, H526 and D516V are the most
frequent (Telenti et al., 1993; Musser, 1995). RNA polymerase is a typical enzyme for
all bacteria cells. Therefore, RIF is not antibiotic specific to mycobacteria only. It is
also effective against grampositive (e.g. staphylococci) and gramnegative bacteria
inhibiting their growth. Mutations lead to conformational changes in ~-subunit
preventing it from binding to RIF. In 81bp long hypervariable region, most common
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Table 2. Mechanisms of resistance to anti- TB drugs in M.tuberculosis (By
Musser, 1995; Cole 1998; Sander & Bottger, 1999)
11 st or 2nd line anti- TB drug I Gene associated I
(ibythe mode of action) ~Target in bacterial cell with resistance Gene product
1.Inhibitors of nucleic acid
Isynthesis
Rifampin (1st line) RNA synthesis rpoB (3.534bp) 11- subunit of RNA
po~ymerase,
Fluorguinolones (2nd line) ONA replication and gyrA (2.S17bp) a-subunit of DNA
Ciprofloxacin RNA transcription gyrase,
I
Levofloxacin
Ofloxaein
2. Inhibitors of protein
synthesis; Aminoglycosides
Streptomycin (1st line) I Protein synthesis rpsl: (372bPl} Ribosomal protein S12
rrs (1.464bp) 16S rRNA
Kanamycin
IAmikacin
Gentamicin (2nd line)
I rrs (1.464bp) 16S rRNACapreomycin
Tobramicin
IViomicin
3. Inhibitors of cell waD
synthesis:
I IIsoniazid (I" line) Mycolic acid synthesis katG Catalase-peroxidase,
inhA lI-enoyIACPreductase,
I
ahpC A:lkyilhydroperoxide
reductase,
kasA IJ-ketoacilACPsinthase,
IThioacetazone (2nd line)
ndh NADH dehydrogenase
I
Mycolic acid synthesis ? ?
Pyrazinamide (1st line)
I
Have to be defined pncA Pyrazinamidase
IEthionamide (2nd line) Mycolic acid synthesis inhA EnoylAOPreductase
Ethambutol (1st line) Arabinogalalactan, embB Arabinosyltransferase
Cycloserine (2nd line)
lipoarabinomannan
Proteoglican synthesis DdlA (?) D-alanin-alaninlygase
Paraaminosalicylic acid
I
Mycobactins,folic Mbt saime (?) Mycobactins(2nd line) acids Rv0802c (?), Acetyltransferase
I'---.- Rv3700c (?)
- -
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are single point mutations changing amino acid (Figure 3). Deletions or insertions of
several nucleotides are less frequent. Double mutations, occurring simultaneously at
two codons, are of special interest. According to data presented by J. Musser, about
4% of Rlli-resistant isolates don't show mutations in particular region, therefore, an
additional mechanism conferring resistance to RIP can exist. These can be mutations
in other RNA polymerase subunit coding genes or selective permeability of cell wall
(Musser, 1995).
~
~oo~.l~ i'/j'l!l,
iF IOI'!i-'I.M(J'p-~·
l"- '~ ••• ~~I5lI. t
Figure 3. Hypervariable region of the rpoB gene correspendmg to 507~533
amino acid sequence. The prevalent mutations are .shown in boxes (Sander &
Bottger, 1999).
Since RIP is a marker for MDR, rapid revealing of RIP resistant strains is of
great clinical value. For that aim, molecular testing of RIF susceptibility can be
focused on detection of mutations in a single hypervariable region of the rpoB gene.
Inhibitors of protein synthesis
SM and related aminoglycosides shown in Table 2, affect bacteria by
inhibiting prokaryotic protein translation at ribosomes (Table 2). A common
mechanism of resistance to aminoglycoside antibiotics in other bacteria, e.g. to
tobrarnycin and to gentamycin in staphylococci, is drug inactivation by drug-
modifying enzymes encoded by plasrnids or transposons (Chambers, 1997). In
mycobacteria, initiation of mRNA translation appears to be inhibited or translational
accuracy is affected (Finken et al., 1993).
SM acts by binding to the small 30S ribosomal subunit instead of
arninoacetylated tRNA, thereby interfering with polypeptide synthesis by inhibiting
translation (Winder, 1982). Two genes, rpsL and rrs, encoding the ribosomal protein
S12 and the 16S rRNA are known to be responsible for the high level SM resistance
in 80% of cases (Douglas et al, 1993). Two thirds of the resistant mutants show
mutations in the highly conserved region of the 372bp long rpsL gene, converting
protein S12 lysine residues K43 and K88 to arginine or threonine. Corresponding
mutations have been also previously found in SM-resistant E.coli (Finken et al, 1993;
Meier et al., 1994). The remaining one third of the SM-resistance conferring
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mutations occur in two regions of the 1.464bp long rrs gene encoding 16S ribosomal
RNA: 530 loop and the 915 region known as SM binding site (Moazed&Noller,
1987). Structural model of 16S RNA with known affected sites is shown in Figure 4.
Rearrangements of Watson-Crick base pairs G=C to wobble pairs G.U or C.U at
nucleotide positions 495-GGC-497 and 514-GCC-516 attenuates the tertiary structure
of 530 loop inhibiting binding to SM. Those positions are crucial for functioning of
the ribosome. Three mutation sites have been detected in the highly conserved 915
region: at nucleotide positions 904 (C~A or G), 905 (A~G) and 906 (A~T), as
shown in Figure 4. In contrast to other bacteria, Mtuberculosis has a single rrs operon
increasing the chance for acquiring resistance to SM.
Figure 4. 168 rRNA secondary structure in M.tuberculosis (Honore et al.,
1995). Nucleotide positions are marked by numbers, nucleotide insertions are
shown by arrows, mutated nucleotides are encircled and the underlined
nucleotides are involved in Watson-Crick interactions.
Mutations described in rpsL and rrs genes generally confer to the high or
medial level of SM resistance (MIC from 500 to 250-50llg/ml). About 20% of
remaining cases of SM resistant isolates had the wild type genes. In those isolates,
low level resistance (MIC 25-50llg/ml) is observed, probably, caused by changes in
cell wall permeability (Meier et al., 1996). SM resistance is frequently associated with
resistance to other aminoglycosides. Nevertheless, these secondary-line drugs can be
effectively used for the treatment of polyresistant Mtubeculosis and other
mycobacteria caused infections due to a different mechanism of resistance.
Particularly, analysis of 16S rRNA operon in all isolates resistant to arninoglycosides
differentiated a single point mutation G~ A at nucleotide position 1408
(Prammananan et al., 1998).
Therefore, to determine SM susceptibility at the molecular level, two genes,
rpsL and rrs, should be analyzed simultaneously ..
Inhibitors of cell wall synthesis
Isoniazid (INH) is most often used for TB treatment because of the very high
sensitivity of the Mycobacterium tuberculosis to this drug (MIC is 0.02-0.05Ilg/ml)
(Bernstein et al., 1952). It is clarified that INH is acting by inhibition of synthesis of
mycolic acids (Sacchetini&Blanchard, 1996), branched alfalipids attached to
arabinogalacan polymers (Table 2). Decrease of catalase-peroxidase activity in INH
resistant isolates was known already 50 years ago indicating the important role of this
enzyme in metabolism of INH. Here we see another mechanism of resistance, where
12
prodrug transformation to active drug form is prevented by diminishing enzyme
activity That mechanism is opposite to those realized in most bacteria via gaining
additional biochemical activity, e.g. with drug inactivating enzymes. INH is a prodrug
activated after inclusion in mycobacterial cell by catalase-peroxidase encoded by the
katG gene. An activated drug inhibits enoyl-acylPP reductase encoded by the 810bp
long inhA gene which product participates fatty acid elongation cycle (Rawat et a1.,
2003).
As one can see from Table 2, at least five genes, katG, inhA, ahpC, kasA and
ndh, are known to confer INH resistance, but in 60-70% of cases the INH resistance is
associated with mutations in the 2359bp long katG gene at codon 315 (Ser-e-Thr)
(Heym et a1., 1993). Most frequently observed substitutions at codon 315 are ACG
change for ACC (Ser-e-Thr, in 82%) and less frequently ACG change for AAC (Asn),
ATC (lIe) and CGC (Arg) (Dobner et aI., 1997; Haas et aI., 1997). In comparison to
RIF resistance, there is a higher rate of INH resistant M tuberculosis mutants occurred
in vitro (mutation rate 10-5_10-7) partially explaining quick acquisition of resistance to
INH. There are several reasons for that. One of them, as it was mentioned before, is a
probable summary effect of mutations occurring in any of five known genes, which
products are involved in INH metabolism (felenti et al., 1997; Zhang et aI., 1996; Lee
et al., 2001). That factor of many genes may be explained by plenty of enzymes
involved in synthesis of mycolic acids. The product of the katG gene is not essential
for mycobacterial cell methabolism and bacteria with mutated katG gene, even with
lowered vitality and virulence, is able to accumulate mutations in other genes.
Additionally, the katG gene is localized in unstable region of the chromosome and can
easy undergo structural changes (Zhang et aI., 1994). Mutations CGG~CTG
(Arg~Leu) at codon 463 of the katG gene have been also described in INH resistant
M tubeculsosis isolates, but later studies showed that mutation occurs in INH
susceptible strains as well and is not associated with INH resistance (Rouse et al.,
1995; Haas et ai, 1997).
There is less known about the association of INH resistance with the ahpC,
kasA and ndh genes. For example, an over-expression of ahpC gene which is,
probably, caused by mutations in a promoter region, was observed in ll-IN-resistant
isolates with the wild-type katG and inhA genes (Telenti et a1., 1997). AhpC gene
codes for an alkyl hydroperoxide reductase that protects from the toxic to bacilli to
organic peroxides. Such over-expression is proposed also a compensatory mechanism
in case of the loss of catalase-peroxidase activity (Sherman et a1., 1996). Lee et al.
demonstrated mutations in a ketoacyl-acyl protein synthase coding kasA gene in 10%
of INH resistant isolates, and recent studies of Lee et aI. (2001) showed mutations in
ndh gene with the same frequency.
So, molecular analysis of the corresponding genes in INH resistant cases
supplemented by molecular genotyping is significant due to various reasons. First of
all, Van Soolingen et aL (2000) showed correlation of most common S315 single
mutation in the katG gene with the high level resistance to INH. Secondly, the katG
mutation R463 is an important marker for deciphering phylogenetic groups of
mycobacteria, particularly, for identification of phylogenetic group I, which includes
well known Beijing genotype, giving an insight into evolution of more virulent forms
of mycobacteria (Brosch, 2002).
Ethambutol (EMB) is another effective and highly specific first-line agent
used in chemotherapy in combination with other drugs (British Thoracic Association,
1984). It is believed that EMB is targeting arabinosyltransferases that catalyse the
incorporation of arabi nan into cell wall polymers arabinogalactan and
lipoarabinomannan (Table 2) (Deng et ai, 1995, Wolucka et ai, 1994). The 12-domen
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protein with arabinosyltransferase activity, encoded by the embB gene, is integrated
into mycobacterial membrane. The embB gene is one of the three genes, joined in a
single lOkb embABC operon. In recent study, mutations associated with resistance to
EMB have been detected in about 68% in the embB gene and were most common at
codon 306 (Met~ He, Leu, or Val) (Ramaswamy et al., 2000). It was proposed that
Met306 is located in a protein loop in cytoplazma where it is functioning as EMB-
resistance determining region (ERDR) as shown in Figure 5. Additionally,
Ramaswamy et al. also showed mutations associated with EMB-resistance in eleven
other genes, reaching 67% together with mutations in the embB gene.
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Figure 5. Schematically shown transmembranal protein EmbB encoded
by the embB gene with resistance-associated amino acid replacements modeled
by Ramaswamy et al (2000). Putative ERDR loop includes codon M306 and
others.
It is obvious, that molecular testing of EMB susceptibility in Mtuberculosis
can meet various problems because less than 70% of EMB resistant isolates show
mutations in the embB gene. In the remaining cases, there may be various genes
which can be associated with EMB resistance and which are only partially studied
nowadays.
Pyrazinamide (PZA) is also a very effective anti-ill agent particularly when
used in combination with RIP and INH shortening the time of chemotherapy from 12-
18 to 6 months (British Thoracic Association, 1984). It is effective against semi-
dormant pathogenic mycobacteria, which are usually missed by other anti- TB agents.
The naturally resistant M bovis is the only exception for PZA. PZA works in
mycobacterial cell when bacterial pyrazinamidase converts the inactive PZA to toxic
for mycobacteria pyrazinoic acid (Zhang & Mitchison, 2003). PZA resistance in
Mtuberculosis strains is associated with the loss of pyrazinamidase and
nicotinamidase activity due to mutations in different locuses in the 561bp long pncA
gene that lead to amino acid changes or to premature chain termination. Molecular
analysis of the naturally resistant Mbovis and Mbovis BeG strains revealed mutation
His57~Asp in the pncA gene (Konno et al., 1967; Scorpio and Zhang, 1996). Recent
studies by microarray analysis have showed a whole group of new genes associated
with the PZA resistance: JadE24, mabA, Rv1772, Rv1592 etc (Ramaswamy et al,
2003).
Measuring PZA susceptibility in vitro by classical methods on solid medium is
problematic since PZA is active in acidic medium, which inhibits growth of
Mtuberculosis. Therefore, testing of PZA susceptibility by molecular methods is of
crucial importance.
Since Mituberculosis is lacking extrachromosomal DNA elements like
plasmids, genome alterations play a major role in drug resistance development.
Transposons don't transfer resistance in Mtuberculosis, however, those were
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postulated to provoke genome rearrangements. Moreover, it was hypothesized that
different Mtuberculosis genotypes develop drug resistance with non-equal intensity.
That could depend on the mechanism of drug resistance selected by each particular
genotype. Detailed studies of transposable elements and molecular genotyping of
MDR M tuberculosis could help to answer the questions posed.
2.4.5. Insertion sequence IS6110 as molecular marker for M tuberculosis
complex in clinical specimens
Mobile genetic elements like insertion sequences (IS) and transposons are
found in bacteria, archaebacteria and eukaryotes. Insertion sequences are DNA
fragments encoding their own ability to transpose within the genome. The function of
most mobile genetic elements is unknown and they are usually considered to be
genome parasites. In genus Mycobacterium, there are 3 groups of IS, which are
usually host specific. IS are between 880 bp and 2260 bp long and are found in the
chromosome in 1 to more than 20 copies (Guilhot et.aI., 1999). One of those, a 1361
bp long insertion sequence named IS6110, is present in MTC only. It was first
described by Thierry et al (1990). Insertion sequence IS61 10 is a mobile genetic
element integrated in M tuberculosis genome and is typical only for species of M
tuberculosis complex.
Due to a narrow host range insertion element 6110 can be used for rapid
identification of pathogenic mycobacteria. The majority of investigated MTC strains
contained between 5 and 20 copies of IS61 10 located in various places of genome
(van Soolingen et al. 1993). PCR-based methods are sensitive enough to detect a
presence of even a few bacteria DNA in a specimen. In this study, evaluation of
IS 1660-based MTC detection method was done in order to apply PCR-based methods
further for drug susceptibility testing and genotyping directly on clinical specimens.
2.4.6. Studies of Mituberculosis complex genotypes
Since M tuberculosis strains can differ by virulence, ability to gain resistance,
to transmit and to rise epidemies, it is important to known whether it is associated
with certain genotype features. Many outstanding molecular techniques such as
IS6110-restriction fragment length polymorphism (IS6110-RFLP), spoligotyping,
mixed-linker PCR, typing by using mycobacterial interspersed repeat units (MIRVs)
(Figure 6) and others have been developed especially for mycobacteria fingerprinting
(Barnes & Cave, 2003).
Standardised genotyping techniques revealed a number of genotype families
or groups with more than 70% similarity by IS611O-RFLP, which can predominate in
population. For example, the genetically highly conserved genotype family of strains
named Beijing have caused large outbreaks of TB worldwide (Bifani et 1., 2002). The
Beijing genotype strains are often resistant to INH and SM and are associated with
multi-drug resistance. In addition, the Beijing genotype is reported to have a selective
advantage over the other M tuberculosis genotypes and induces a febrile response to
treatment (Soolingen et aI., 1995, van Crevel et aI., 2001). The Beijing genotype
predominates in China and some geographic areas of Asia, and now seems to be
spreading to other areas in the world (Anh et aI., 2000). The high prevalence of MDR
Beijing genotype has been recently shown in the neighbouring countries - Estonia and
Russia (Kruuner et al., 2001, Marttila et al., 1998). The comparison of different
genotypes ofMDR and drug susceptible strains from many countries is available now
trough the database created in the frames of ED Concerted Action TB project leaded
by the Dick van Soolingen. The database includes genotypes revealed by the IS611 0-
RFLP method, considered the "golden standard" for typing mycobacterial strains
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(Van Soolingen et al, 1991). However, IS6110-RFLP method is time-consuming and
requires a large amount of DNA available only after bacteria culturing.
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Figure 6. Chromosome of M.tuberculosis hypothetical strain X and
genotyping of M.bovis BeG, the M.tuberculosis laboratory strain H37Rv, and
strain X on the basis of IS6110 and MIRVs. DR locus is used in spoligotyping.
Fragments a through f are the products of DNA digestion with Pvull; M is
molecular weight marker and A-D are PCR products of MIRV loci (By Barnes
& Cave, 2003).
As alternative to RFLP, spoligotyping have been introduced for identification
of MTC and for revealing of major genotype groups, especially for Beijing genotype
family (Kamerbeek et al, 1997). In comparison to IS-6110-RFLP, PCk-based
spoligotyping method is more rapid and can be applied directly on clinical specimens.
The major spoligotype families of Mtuberculosis are presented today in "SpolDB4"
database created by C.Sola and N.Rastogi and containing patterns from more than
30000 individual strains (Filliol et al, 2003). Strain family definition is based on
spoligotyping technique and phylogeographic specificity, evaluated subsequently.
That way many spoligotypes have been grouped in families: Manila family (Douglas
et aI., 2003), Ethiopian family (Hermans et aI., 1995), Finland families (Puustinen et
aI., 2003), Haarlem family, Latin American & Mediterranean (LAM) family, X
fam.ily, already mentioned Beijing family etc.
In this study, spoligotyping was applied to MDR Mtuberculosis isolates to
reveal the prevalent genotype groups between MDR Mtuberculosis in Latvia and to
COmparethe prevalence ofMDR-associated mutations between several groups.
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2.5. Characterisation of Staphylococcus species
2.5.1. Infections caused by S.aureus and related species
Staphylococci are opportunistic pathogens that colonise and infect both
hospitalised patients with decreased host response and healthy, immuno-competent
people in the community. Staphylococcus genus species, especially S.aureus and
S.epid.ermidis, are most frequently isolated from clinical specimens in surgical
hospitals besides other gram-positive cocci. The pathogenity of staphylococci is
mainly due to their aggression factors: blood coagulase and many toxins. Also
staphylococci are characterised by the ability to gain MDR rapidly, which, in contrary
to Mtuberculosis, can be transferred horizontally by extrachromosomal DNA
elements. Drug resistant staphylococci are dangerous by their ability to colonise in
healthy people and in medical personal for a long time and to spread when appropriate
conditions appear.
Siaureus have been isolated from intensive-care patients, transplant recipients
or victims of accidents (Dalhoff, 1999). Coagulase negative Staphylococci (CoNS),
particularly the S epidermidis and S.haemolyticus, have emerged as important cause
of nosocomial (acquired due to health-care) infections in recent twenty years. This
group is diagnostically distinguished from Siaureus by its inability to produce
coagulase. The high prevalence of Siepidermidis can be explained of by the increased
use of indwelling catheters and implanted devices. The pathogenity of S.epidermidis,
which has been regarded for a long time as relatively innocuous inhabitant of the
human skin, is mainly due to ability to form biofilms on indwelling medical devices
(Voung&Otto, 2002). Another nosocomial pathogen, Sihaemotyticus, is characterised
by a tendency to develop multi-antibiotic resistance, with a unique predisposition to
glycopeptide resistance.
2.5.2. Occurrence and spread of methicillin-resistant staphylococci
Frequent use of penicillin introduced in hospitals in the early 1940s resulted in
the occurrence in resistant strains, producing penicillinase (p-lactamase). In the 1960-
s, shortly after introduction of semisynthetic penicillinase-resistant penicillins (i.e.
oxacillin/methicillin (MET) and other p-lactam ring containing antibiotics) into the
clinical practice, first methicillin resistant Siaureus (MRSA) were detected in UK
(Jevons, 1961). Since then MRSA intrinsically resistant to virtually all p-lactams has
become one of the leading causes of nosocomial infections worldwide. In the last
decades the multitude of resistant strains of S. aureus have developed and spread
globally (Fluckiger&Widmer, 1999).
The incidence of MRSA among the clinical isolates of S aureus varies from
country to country, but in Europe, a north-south gradient is observed. MRSA is kept
at controllable level in Scandinavian countries as well as in Switzerland « 2%).
However, the level of MRSA incidence is more than 30% in Mediterranean hospitals
(France, Italy etc) and USA, reaching 60% in Portugal and Japan. Prevalence of
particular genotypes gaining resistance to methicillin was shown in epidemic
Staphylococcus aureus strains. Using molecular typing techniques - primarily pulsed-
field gel electrophoresis (PFGE), the five major clonal lineages (the Iberan, Brazilian,
Hungarian, New York/Japan and paediatric pandemic MRSA clones), have been now
identified. These strains accounted for 70% of over 3000 MRSA isolates recovered in
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hospitals mainly of southern and eastern Europe, South America, and the USA (Blanc
et al, 2002; Oliveira et al., 2002; Stefani & Varaldo, 2003).
The proportion of MRSE among hospital CoNS has increased from 8 to 30%
in the 1980s to 80% and even 90% nowadays (Bouza, 2002, Carratala, 2002).
Analysis of staphylococcal cultures isolated in Hospital of Traumatology and
Orthopedics (Riga, Latvia) showed that local situation with MRSA remains stable in
five last years with the maximal level 4.64% in 2001, as shown in Figure 7. In
opposite, analysis of MET -resistance in CoNS demonstrated that there is a tendency
of growing it from 4% in 1998 to 36% in 2002. Among CoNS, the following species
have been isolated most frequently in Latvia: S epidermidis, Shaemolyticus, Scohnii,
S warneri and Sihominis (A. Zilevica, 2001). Nevertheless, the number of resistant
forms is not as high as reported by authors from other countries. Unfortunately, a
complete picture of situation with emergency of MRSA and MRSE in Latvia is still
unclear due to lack of centralised data collection from all hospitals of Riga and
regions,
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Figure 7. Incidence rate of MET -resistance in staphylococci in Hospital of
Traumatology and Orthopedics, 1998-2002.
2.5.3. Characterisation of g. Staphylococcus phenotype and genome
Genus Staphylococcus belongs to Family Micrococcaceae, in which however,
staphylococci exhibit a number of different molecular features among other gram-
positive cocci (W.Witte, 2000). Most species are natural inhabitants of the
mammalian skin and mucous membranes. Scaureus can be phenotypically
differentiated by the coagulase-positive test-tube reaction. A thick cell wall of
staphylocci represents an impermeable barrier to many antibiotics. It is formed a very
thick peptidoglycan layer with pentaglycine cross-bridges and teichoic acids.
(Schleifer, 1983; Novick, 1990).
A complete S.aureus genome sequencing project have been realised by the
group of Hiramatsu in 2001 in Japan (Kuroda et al., 2001). The entire chromosome of
Siaureus standard strain NCTC 8325 is about 2,8 megabases. Compared to
mycobacteria, staphylococci has a low G+C content in DNA (32-34%) and well-
known virulence factors. As revealed by the Hiramatsu group, Staphylococcus
genome is composed of a complex mixture of genes, many of which seem to be
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acquired by lateral gene transfer. Most of the antibiotic resistance genes are carried
either by plasmids or by mobile genetic elements including a unique resistance island.
Three classes of new pathogenicity islands were identified in the genome: a toxic-
shock-syndrome toxin island family, exotoxin islands, and enterotoxin islands. In the
latter two pathogenicity islands, clusters of exotoxin and enterotoxin genes were
found closely linked with other gene clusters encoding putative pathogenic factors.
The analysis also identified 70 candidates for new virulence factors. Repeated
duplication of genes encoding superantigens explains why S.aureus is capable of
infecting humans of diverse genetic backgrounds, eliciting severe immune reactions.
The genome of S.epidermidis, sequenced in 2003, consisted of a single
2.499.279bp chromosome and six plasmids. It contained 2419 protein coding
sequences, among which 230 putative novel genes were identified. To compare to the
virulence factors in S.aureus, aside from two kinds of haemolysins, no other toxin
genes were found (Zhang et aI., 2003). An important virulence factor in pathogenic
Sieptdermidis is biofilm production in indwelling devices mediated by the expression
of the icaADBC operon, which is, however, absent in commensal strains (Cho et aI.,
2002; Otto, 2004).
There is a high heterogeneity between related species and subspecies,
indicating that Staphylococcus is an evolutionary old microorganism. Low C+G
content and high heterogenity allows application of macrorestriction analysis of
pathogenic strains with rarely cutting Sma! enzyme and subsequent pulse-field gel
electrophoresis, which provides a profile composed of 15 to 20 fragments (Weller,
2000).
Plasmids. As it was mentioned above, staphylococci usually contain plasmids
that encode various factors: drug resistance, metabolism etc. Plasmids have been
detected in about 90% of methicillin-resistant S.epidermidis (MRSE) and in 50% of
MRSA. There are three major types of plasmids in staphylococci. One group contains
small multicopy plasmids ranging in size from 2.5 to 5 K in copy number from 10 to
50. Each plasmid has a single resistance determinant for tetracycline, SM,
chloramphenicol, macrolides, kanamycin or cadmium salts. These plasm ids are able
to replicate in other gram-positive species, and relative plasmids were found in other
genera. A second type consists oflarger plasmids, 25 to 35Kb in size and about five
copies per cell. These usually carry resistance to penicillin and inorganic ions and
have not been observed to replicate in other genera. A third type includes larger (40-
60Kb) conjugative plasmids, typically carrying resistance to gentamycin, penicillin,
neomycin and such compounds as ethidium bromide (Novick, 1990).
Genes can be transferred horizontally by transposons and located either on
plasmids or integrated in the chromosomal genome and further transferred vertically.
2.5.4. Spectrum of antibiotics and chemical agents used for treatment of
staphylococcal infections
Initially, a wide spectrum of chemotherapy agents (p-Iactams,
aminoglycosides, fluorquinolones, macrolides, streptogamin combinations etc.) was
effectively used against staphylococci-caused infections (Witte et al., 1997).
However, occurrence of MET -resistant staphylococci, an intrinsically resistant to
virtually all ~-lactams, lead to MDR, e.i., simultaneous resistance to cephalosporins,
erythromycin, ciprofloxacin, gentamicin, trimethoprim and related products. The
glycopeptides, vancomycin and teicoplanin, makes the only exception in that group.
Resistance to so wide spectrum of agents can be explained by the mechanism of
MET - resistance, which will be described later.
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It is clear that the number of appropriate chemotherapy agents effective
against MRSA and MET-resistant CoNS is not high. The available antibiotics used
today are vancomycin, rifampin, fusidic acid, clindamycin, linezolid and quinipristin-
dalfopristin (Lowy, 2003). However, rifampin, fusidic acid and clindamycin can be
used only in combination with other agents. At the same time, use of linezolid is
restricted, at least in Latvia, due to its high cost. Vancomycin is widely used to treat
MRSA, however, the emergence of vancomycin-resistant strains has been already
reported in USA (Ten over et al., 2004). This shows the clinical importance of
extensive molecular studies of MET -resistant staphylococci in order to prevent
uncontrollable spread.
2.5.5. Drug resistance mechanisms in Staphylococcus spp, Mechanisms of
resistance to Jl-Iactams with the special reference to methicillin
The astounding ability to respond in a short time to the antibiotic challenge in
staphylococci can be explained by a multiple resistance mechanisms, encoded by
plasmids, transposons and by chromosomal genes. The last, chromosome-based
mechanism of drug resistance can include acquisition of new DNA fragments with
necessary genes or, similarly to mycobacteria, chromosomal gene mutations.
Resistance-encoding genes can be horizontally transferred by transformation of intact
cells or protoplast, plasmid- or trasposon-mediated conjugation and transduction, even
between related species (Berger-Bachi, 1997). In that way, staphylococci realise
genetic exchange of determinants of resistance to erythromycin, spectinomycin,
penicillin, gentamycin and MET.
Besides drug resistance genes, there is less common mechanism of resistance
in staphylococci, which, like in Mtuberculosis, is caused by mutations in drug target
encoding genes. For example, in that way resistance to rifampin (mutations in the
rpoB gene) and to fluorqiunolones (mutations in grlA and gyrA genes) is acquired
(O'Neill et al., 2001). At the same time, investigation of fusidic acid resistance
showed that, in parallel to resistance-associated mutations in elongation factor G,
fitness-compensatory mutations occur at the same region of S.aureus genome. This
data suggest that compensatory evolution to reduce the fitness costs associated with
drug resistance is a frequent occurrence in the clinical environment (Nagaev et aI.,
2001). This idea correlates with the study of Sherman et al (1996), suggesting that the
loss of catalase-peroxidase (KatG) activity in INH-resistant Mtuberculosis can be
compensated by overexpression of AhpC. Overproduction of that enzyme occurs due
to ahpC gene mutations and provides ability to withstand oxidative stress.
MET, one of 13-lactam antibiotics, is a penicillin descender and has a similar
to penicillin mode of action. It is important to know the mode of action and
mechanism of resistance to penicillin for better understanding of interaction between
staphylococci and MET.
Penicillin acts as analogue of acyl-D-alanil-D-alanin, a substrate of the
penicillin-binding proteins (PBP). It covalently binds to the PBP active-site serine,
forming a covalent complex and inactivating enzyme. PBPs catalyse penicillin-
sensitive transpeptidation reaction of two muropeptide side chains (linkage of glycine
and alanine) essential for peptidoglycan polymerization, the final stages of bacterial
cell wall biosynthesis (Ghuysen, 1994). Binding of 13-lactams by PBP leads to a
defective cell wall building and finally to cell death and lysis. The introduction of first
penicillins stimulated selection of strains with 13-lactamase (penicillase) activity. 13-
lactamases are encoded by blaZ gene, located on plasmids or embedded in
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chromosome and are easily transferred by bacteriophages. Today more than 90% of
staphylococci produce f3-lactamases (Lowy, 2003).
Next generation of f3-lactams, such drugs as semisynthetic methicilin were
resistant to f3-lactamase activity. Nevertheless, MET -resistant strains have emerged
soon in many areas of high antibiotic pressure, with high ability to spread and to
accumulate not related resistance determinants (Berger-Bachi, 1997). MET-resistant
strains have acquired an additional 76-kDa penicillin-binding protein, termed PBP2a,
exhibiting low affinity to f3-lactam antibiotics and therefore protecting cell from
antibiotic action. PBP2a differs from other PBPs in that its active site blocks binding
of all f3-lactams but allows the transpeptidation reaction to proceed (Lim &
Strynadka, 2002). PBP2a protein is encoded by the 2kb long mecA gene. Since mecA
gene is not found in MET -susceptible strains, it is molecular marker for MET-
resistance. The gene is a part of the MET resistance determinant mec, termed also
staphylococcal chromosomal casette (SCCmec). (Katayama, 2000) This is a 21 to
67kb long DNA element, integrated in a specific site of the chromosome of
staphylococci, near the pur-nay-his gene cluster, as shown at Figure 8 (Kuhl, 1978).
SSCmec cassette is bound by inverted repeats suggesting that it might be a
transposon. Aside from mecA gene, SSCmec cassette contains mecI and mecRl,
regulatory elements controlling mecA transcription, and 20 to 45kb of mec-associated
DNA (Hiramatsu et aI., 1995). Besides mec operon, encoded by approximately 5kb of
DNA, mec-associated DNA that may contain up to 100 open reading frames, includes
transposons, like Tn554 (which contains the ermA gene, associated with erythromycin
resistance), and insertion sequences, like IS43 1. The ability ofIS 431 elements to trap
and cluster resistance determinants with similar IS via the homologous recombination
explains the multi-drug resistance that is characteristic for MRSA and MET -resistant
CoNS (Chambers, 1997). That's how MET -resistant strains gain additional resistance
to other groups to antibiotics. Today, there are known four types of SSCmec cassettes,
differentiated by size, structure and by carriage of antibiotic resistance genes
(Hiramatsu et aI., 2001).
mecI and mecRl genes represent a negative regulatory center for PBP2a
production. They are similar in sequence, structure, function, and mechanism of
regulation to staphylococcal f3-lactamase regulatory elements, blal and biaRl
(Gregory et aI., 1997). The gene products are the repressor Mecl and transmembrane
~-lactam sensing protein MecR1, needed for induction of the mecA gene. Normally,
mecA is repressed and no PBP2a is synthesised. Interestingly, MET and oxacillin are
poor inducers of the mec operon. That's why in experimental studies strains with mec
determinant may appear phenotypically susceptible. Nevertheless, a majority of
clinical strains constitutively produce PBP2a in high amounts due to mutations or
deletions in repressor or due to mutations in promoter regions (Suzuki et aI., 1993).
Simultaneously, blal and biaRl, the penicillase (blaZ) gene regulatory elements can
regulate expression of the mecA gene (Figure 8) (Hackbarth&Chambers, 1993).
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The origins of SSCmec are obscure. Today one or several MRSE strains are
considered reservoirs of antimicrobial resistance genes that were transferred to other
Staphylococci, so contributing to the development of methicillin resistance among
microorganisms Hypothetically, the mecA gene was transferred from "outside" by
transposition to S epidermidis and then to S aureus. It was shown, that l3-lactamase
plasmid of Suiureus may provide a temporary insertion site for the mec-containing
transposon (Hiramatsu, 1995). Cuoto et al. (2003) identified a mecA gene in a MET-
sensitive Sisciurl suggesting that a possible source of the mecA element in Siaureus.
MET resistance was proposed to spread clonally from a few ancestral strains resulting
in several lineages of clonal descendants. When acquired, SSCmec is permanently
included in bacterial genome and transferred vertically (Hiramtsu et al, 2002).
2.5.6. Methicillin-resistant phenotype and susceptibility testing in staphylococci
When SSCmec is present, the MET -resistant phenotype in staphylococci can
be masked due to chromosomal genes, physically distinct from mec, termed fem
(factor essential for MET resistance), which are present in both susceptible and
resistant strains. Mutations in sixfem genes,femA, -B, -C, -D, -E and -F, were shown
to alter peptidoglycan composition reducing MET -resistance level (Berger-Bachi,
1994).
Additionally, low-level or borderline MET-resistant staphylococci strains
lacking mec determinant can be isolated. In that case, structural modifications of
membrane proteins PBP2 and PBP4 that lower the affinity to MET, may occur for due
to multiple mutations (Henze&Berger-Bachi, 1995). Some authors postulate that
hyperproduction of l3-lactamase or activity of methicillinase encoded by another
gene, which is not identified yet, can also contribute to a low-level resistance in
staphylococci (Barg et al., 1991; Massida et al., 1994). That studies show that bacteria
constantly develop new resistance mechanisms, via the gene mutations or via the
acquisition of foreign genes. To note, these MET -resistance mechanisms do not result
in development ofMDR, in contrary to mec-mediated resistance.
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MET resistance is strongly influenced by external factors, like temperature,
salts, light etc. suggesting that environmental conditions also may affect the
expression of resistance. The resistance levels to MET (or oxacillin, which is
routinely used as a test substance) and other p-Iactams may vary between strains
(MIC ranging from 2 to IOOO~g/ml), independent from the amount of PBP2a
produced. Also, heterogeneous resistance of one strain is specific property of
staphylococci. For example, in a low-level resistant population, some cells (between
10-4down to 10-7) express high level resistance (Matthews&Stewart, 1984).
Because of heteroresistance, it is recommended by the National Committee
(NCCLS) to use at least two in vitro methods for the detection of MRSA and MR
CoNS. Traditionally, disc diffusion method is used on agar media. Additionally, an
agar screening test is recommended prescribing to incubate bacteria for 24 hours at
35°C on Mueller-Hinton media containing 6~g/m1 oxacillin with supplement of 2-4%
NaCI (NCCLS, 2000). An example of commercial test systems is E-test, where MIC
value is estimated with an oxacillin-saturated strip. The automated systems for rapid
detection of MET resistance have been also developed. For example, the BBL crystal
system in VITEK II allows a computer-assisted reading of results already after 3-4
hours of incubation. The VITEK II system has a high sensitivity but less specificity
for detection of MET -resistant CoNS in comparison to test for presence of mec
determinant (Cuny et al, 1999).
Studies of MET resistance and susceptibility testing by molecular methods are
of special interest because of its clinical importance and resistance transfer
mechanisms. Amplification of mecA gene in PCR is stated today as a "golden
standard" for MET susceptibility testing in S.aureus and CoNS. The method was first
described by Murakami et al. (1991) and was recommended for routine laboratory use
in parallel to standard susceptibility testing methods. Presence of the mecA gene
always indicates on MET -resistant strain. Therefore, heterogeneous strains can be also
revealed by the PCR-based mecA gene detection.
In this study, mecA-PCR analysis was done in order to evaluate method's
correlation with the commonly used susceptibility methods for further application for
the laboratory screening needs. Additionally, it was the first step to the further studies
of staphylococci strains involved in epidemies in hospitals of Latvia, for example, by
the identification of SCCmec cassette types and by subsequent genotyping of strains.
It could contribute to our knowledge about MET -resistant strains circulating in Latvia
and to examine epidemic links between hospitals at local and international level.
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3. METHODICAL APPROACH
3.1. Analysis of genes associated with the first-line drug resistance in
M. tuberculosis
3.1.1. Culturing and isolation of DNA
Cultures of the Mycobacterium tuberculosis complex were grown at Latvian
Centre of Tuberculosis and Lung Diseases on Lowenstein-Jensen medium for 4-6
weeks. Drug susceptibility was determined both by the absolute concentration method
on slants with the H37Rv strain as the positive control and by the BACTEC radiometric
method (Becton Dickinson, Sparks, Md.) (Hawkins et aI., 1991; Roberts et al., 1991).
In the absolute concentration method, resistance was defined as growth on solid media
containing graded concentrations of drugs greater than a 20CFU at a specific drug
concentration. The MICs on Lowenstein-Jensen medium were 0.21lg/ml and 2.0llg/ml
for INH, 40.01lg/ml for RIF, 4.01lg/ml for SM and 2.0llg/ml for EMB. PZA
susceptibility was tested by BACTEC method at IOuug/rnl concentration ofPZA.
Native genomic DNA was isolated from the mycobacterial cultures by an
internationally standardised procedure with lysozyme/proteinase K, N-cetil-N,N,N,-
trimethyl ammonium bromide and precipitated with isopropanol (Van Soolingen et aI.,
1999). Purified DNA was dissolved in 20-50111of TE buffer (lOmM TrisHCI, ImM
EDTA [pH 8]). DNA isolated from MT14323, H37Rv and Mycobacterium bovis BCG
strains was used for controls. DNA concentration method (Boom et al. 1990) was used
for extraction of DNA from several clinical specimens (CSF and bronchial washings).
3.1.2 Amplification of fragments of Muuberculosis genes associated with the first-
line drug resistance.
The information about sets of primers used for particular gene analysis, gene
accession number, the fragment length and the temperature of annealing (Tan) are
summarised in Table I.
10-20ng of culture-isolated Mituberculosis DNA diluted in TE buffer or 10111of
prepared clinical specimen was added to the standard PCR mix to a final volume 50111.
The number of amplification cycles was 30-35 for culture-isolated DNA and 40 for
uncultivated DNA. In each set of reactions one negative and one positive control (from
a drug susceptible strain of Mycobacterium bovis BCG) was included. PCR products
were analyzed in 1.2-% or 2.0% agarose gels depending of fragment length.
3.1.3. Analysis of the rpoB gene (RIF resistance) by the "INNO-LiPA ™ Rif" kit.
Commercial kit INNO-LiPA TM Rif (Innogenettcs N. V, Belgium) was used for
the detection of rpoB gene mutations. Ten III of each PCR product obtained with
biotinylated primers, was used for the INNO-LiP A hybridization, performed according
to manufacturer's instructions. Each INNO-LiP A strip contains one probe specific for
MTC, five partially overlapping wild-type probes and four probes specific for the most
cornmon rpoB mutations within the 509-534 amino acid region - D516V, H526Y,
H526D and S531L (Innogenetics N V, Belgium). Manual sequencing of rpoB gene was
performed using Cycle Reader™ DNA sequencing kit (Fermentas, Lithuania).
Radioactively labeled primers used for manual sequencing were identical to those used
for the PCR amplification.
24
Table 1. The anal sed M.tuberculosis enes and corres
Agent Gene Set of primers, references
fragment,
accession nr.
rpoB (256bp)
NC000962
RIF
INH katG (704bp)
X68081
SM rpsL (306bp),
L08011;
rrs (530 loop,
238bp) and
rrs (912 reg.,
240bp),
X58890
rimers
Tan
71.B - 5'-GGTCGGCATGTCGCGGATGG-3'*
72.B - 5' -GCACGTCGCGGACCTCCAGC-3' *
ossau et aI, 1997
74-5' -CGGGATCCGCTGGAGCAGATGGGC-3'
75-5' -CGGAATTCCAGGGTGCGAATGACCT -3'
obner et al., 1997
SMI-5'-CCAACCATCCAGCAGCTGGT-3' and
SM2- 5'-ATCCAGCGAACCGCGGATGA-3';
SM3-5' -GATGACGGCCTTCGGGTTGT -3' and
SM4-5' -TCTAGCTGCCCGTATCGCC-3';
SM5-5' -GTAGTCCACGCCGT AAACGG-3' and
SM6-5' -AGGCCACAAGGAACGCCT A-3'
(Honore & Cole 1994; Kempsell et.al., 1992).
EMB EmbB 46-5'-CTGCTCTGGCATGTCAT-3'
(l03bp), 47-5' -AGCGGAAATAGTTGGAC-3'
Z80343 Ramaswam at el., 2000
PZA pncA (720bp) PI-5'-GTCGGTCATGTTCGCGATCG-3'
U59967 P6-5' -GCTTTGCGGCGAGCGCTCCA-3'
Sco io et aI., 1997
* - biotinylated primers (with biotin at 5'end)
3.1.4. Single-stranded DNA conformation polymorphism (SSCP) analysis of the
rpoB and embB genes
SSCP analysis is based on the ability of single stranded DNA to undergo a
conformational change when a single nucleotide is altered. Such alterations or
mutations then can be detected because of change of DNA mobility in polyacrylamide
gel. SSCP analysis was used to analyse point mutations in the rpoB and embB genes,
256bp and 103bp fragments, respectively.
To achieve better SSCP results, the 256bp fragment of the rpoB gene was
amplified with one biotinylated (reverse) primer 72.B for better strand separation. The
biotinylated DNA strand was separated from the unbiotinylated by "Dynal" streptavidin
magnetic beads using the single-stranded DNA purification kit (Labsystems, Finland).
After heating for 5 min at 96°C with an equal volume of loading buffer containing
95% formamide, the gene fragments were snap-cooled and immediately loaded onto the
6% polyacrylamide gel gel. The SSCP analysis was performed on a cooled gel plate
(BioRad, USA). The separated DNA bands were visualized by ethidium bromide and by
silver staining.
3.1.5. Analysis of the katG and the rpsL genes by endonuclease digestion
The katG 704bp fragment was analysed for mutations at codon 315 by restriction
with endonuclease AciI (New England BioLabs, USA). AciI can be used for
determining changes in codon 315. After two hours of incubation at 37°C with the 5U
of AciI digestion products were separated on 6% PAAG.
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306bp fragments of the rpsL gene from each of the SM resistant DNA isolates
were digested with Mbo!! endonuclease recognising changes in codon K43 for 15 min
at 37°C and separated on 6% PAAG.
In each set of reaction, drug susceptible Mycobacterium tuberculosis sample,
BCG and the Mtl4323 strain were used as controls.
3.1.6. Automatic nucleotide sequencing
In order to confirm the results of INNO-LiP A, SSCP and endonuclease
digestion methods, the relevant PCR products of all analysed genes were applied for
automatic nucleotide sequencing. As mutations in pncA gene are usually dispersed,
PZA resistant and PZA susceptible MDR M tubeculosis isolates were analysed only
by automatic sequencing of the 720bp fragment containing the promoter, pncA gene
and downstream sequence. Also, fragments of the rrs gene encoding the 16S rRNA
530 loop and 912 region were analysed by nucleotide sequencing.
The purified PCR products (DNA purification kit, BioRad, USA) were applied
for automatic nucleotide sequencing. Each of the DNA chains was amplified with
fluorescence-labeled dideoxynucleotide terminators using the ABI PR1S~ Big Due
™ Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems, USA) and
with the same primers as those that were used for the PCR amplification. The
nucleotide sequences were read by the ABI PRISM 3100 DNA Analyser (Applied
Biosystems, Inc., Foster City, Calif.). The data were assembled using Applied
Biosystems software and nucleotide sequences were compared to the published
sequences of the genes in GenBank (www.ncbi.nlm.nih.gov).
3.2. Detection of M.tuberculosis complex by IS-6110-based peR
Since PCR-based methods of TB detection and genotyping are more rapid and
sometimes, more precise, it was important to evaluate specificity and sensitivity of
such methods. For that aim, prior to application of PCR-based methods like
spoligotyping for MTC detection and genotyping directly on clinical material, we
have evaluated a more simple, IS-611 O-based PCR method, commonly used for MTC
detection.
All specimens (bronchial washings, sputum, cerebrospinal fluid, urine, smears
and stomach washings) were collected at Latvian Centre of Tuberculosis and Lung
Diseases and processed by the standard N-acetyl-L-cysteine-NaOH procedure (Kubica
et al. 1963), preparing it for LCx (Lygase Chain Reaction) assay. Ready DNA isolates
for LCx reaction contained 0.5ml LCx buffer, 27mM MgCh, NaN3 and glass beads.
After the LCx analysis samples were directly applied to IS6110-PCR. DNA
concentration method (Boom et al. 1990) was used for extraction of DNA from
several smear-negative specimens of CSF and bronchial washings received in year
2001.
The 245 bp fragment of the IS6110 (from 633 to 877 nucleotide positions) was
amplified using primers 5'-CGTGAGGGCATCGAGGTGGC-3' and 5'-
GCGTAGGCGTCGGTCACAAA-3' (Hermans et al. 1990). Five f.!lof DNA isolate
in LCx buffer was added to the PCR mixture and amplified according to optimised
cycling protocol on the "Progene" cycler (Techne, Cambridge, England).
PCR products were analyzed by electrophoresis in 2 % agarose gel (BioRAD,
Hercules, USA) and visualized with ethydium bromide. Positive PCR signal indicated
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the presence of MTC genome. In each set of reactions, one negative control and one
positive control (DNA from M bovis BeG vaccine strain) were included. Specimens
with negative amplification results were repeated with an external addition of control
DNA from M bovis BeG strain in order to evaluate the presence ofPCR inhibitor.
3.3. Spoligotyping method
Spoligotyping (spacer oligonucleotide typing) method, which is one of the
more effective and rapid strategy .alternative to IS6110-RFLP for detection and
simultaneous typing of M tuberculosis clinical samples. It can be regarded as the
golden standard for the identification of strains of M. tuberculosis, particularly, for
investigation of various genotype groups like Beijing (Glynn et aI., 2002).
Spoligotyping is based on Reverse Line Blotting (RBL), or hybridization of the
polymorphic Direct Repeat (DR) locus amplified products, with 43 spacer
oligonucleotides covalently bound to a membrane. Hybridization of M tuberculosis
DNA to spacers 35 to 43 is 100% specific for the Beijing genotype. Additionally,
spoligotyping can identify some species other than MTC. To compare with RFLP,
spoligotyping analysis does not require cultured mycobacteria, it is enough with l Ong
of isolate DNA to obtain epidemiologically comparable pattern.
Spoligotyping analysis was performed in the Reference Laboratory of
Mycobacteriology at Statens Serum Institut, Copenhagen, Denmark. For
spoligotyping, a 20-fold dilution of M tuberculosis culture-isolated DNA was used
for PCR and subsequent hybridization reactions as previously described. The H37Rv
strain was used as a positive control. Two negative controls were included as well.
Later, spoligotyping was introduced in Biomedical Reasearch and Study
Centre (Riga, Latvia) in order to detect and to genotype MTC bacteria on clinical
samples. The DNA was isolated at STLDC by the QIA Amp DNA Mini kit ("Qiagen"
GmbH, Germany) and 10 III of isolate was applied to spoligotyping.
peR. 50111ofthe following reaction mixture was used for the PCR:
5III of the target DNA dilution (10-20ng), 4III of each primer Dra
(biotinylated) and Drb (lsogen Bioscience B. v., Utrecht, The Netherlands), 4111
deoxynucleotide triphosphate mixture (200mM of each dNTP), 5111ofPCR buffer and
0.2-0.41l1 Taq+ polymerase. The cycling conditions (Perkin-Elmer PCR system,
Norwalk, Conn.) were as follows: 3 min at 96°C, 30-40 cycles [I min at 96°C, I min
55°C, 30 sec at 72°C] and finally, 5 min at 72°C.
Hybridization. The spoligomembrane (lsogen Bioscience B. v., Utrecht, The
Netherlands) was activated by washing it for 5 min in 250 ml 2xSSPE/0.I%SDS at
60°C. Afterwards the membrane was placed in a miniblotter apparatus in such a way
that the slots were perpendicular to the line pattern of the applied spacers. 35 III of
the PCR products was added to 130-150IlI of 2xSSPE/0.I %SDS, heated at denaturing
temperature an snap-cooled for 10 min. The denatured product was pipetted to into
the channels of miniblotter. The membrane was hybridized for 1 hour at 60°C. After
aspiration of PCR products, the membrane was transferred to a hybridization tube and
washed twice in 250ml of 2xSSPE/O.5%SDS 10 min at 60°C. The membrane was
then incubated in lOml 2xSSPE/0.5%SDS with 2.51l1 of streptavidin-peroxidase
conjugate (Boehringer) for 45 min at 42°C. After 10 min wash twice with
2xSSPE/0.5%SDS at 42°C and 5 min with 2xSSPE at room temperature, membrane
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was incubated for 1 min in 20ml ECL detection liquid (ECL ™ Direct System,
Amersham). The membrane was covered by with a transparent plastic sheet and an
autoradiograme (Hyperfilm-ECL, Amersham), exposed for 1 to 10 min and
developed.
Analysis of results. Autoradiograms were scanned and analysed using the
GelCompar software version 4.0 (Applied Maths, Kortritjk, Belgium), and similarity
analysis were based on the Jaccard correlation coefficient (max. tolerance 2.0%) and
the UPGMA clustering method. All spoligopattems identified by the GelCompar
software as more than 80% identical were controlled visually. A cluster was defined
as two or more isolates having spoligopattems that were 100% identical.
3.4. Detection of methicillin resistance in Staphylococcus spp. by
amplification of mecA gene fragment
3.4.1. Staphylococcus spp. culturing and isolation of bacterial DNA
The collection and laboratory analysis of staphylococci strains was carried ot
in HTO (Riga, Latvia). Staphylococcal cultures (S.aureus, S. epidermidis, S.
haemolyticus, S. hominis, S. capitis and S. warneri) were isolated mainly from
indwelling artificial devices, blood and abscesses and were collected in a HTO. The
isolates were identified to a species level by conventional tests such as coagulase
reaction, phosphatase activity, haemolysis, susceptibility to novobiocin, etc. and the
automated BBL Crystal system (Becton-Dickinson).
Antimicrobial susceptibility was tested by the disk diffusion method according
to the NCCLS guidelines using Mueller-Hinton agar (MHA, Oxoid, UK) against the
following panel of antibiotics: penicillin, gentamicin, cefazolin, erythromycin,
clindamycin, vancomycin, ciprofloxacin, trimethoprim-sulfamethoxazole. MET
resistance was also tested by a commercial oxacillin screen plate (potency Iug of
oxacillin). Plates were incubated at 35°C for 24h when zones of inhibition were
measured. Plates with S.epidermidis cultures were incubated for 48h. S.aureus strain
ATCC 29213 was used as MET-susceptible control.
Staphylococcal DNA was extracted in Biomedical Research and Study Centre
(Riga, Latvia) from the overnight cultures by the lysostaphin-CT AB method as
described by Hookey et al. (1998). The DNA was diluted in sterile distilled water and
applied to mecA-PCR. In addition to that, Slidex MRSA detection kit (BioMerieux,
Lyon, France), was introduced to detect production of PBP2a encoded by the mecA
gene. Also, some strains have been analysed by PFGE at Robert Koch Institute,
(Wernigerode, Germany) in collaboration with research group of W.Witte to
investigate epidemiological links between some patients.
3.4.2. peR amplification and detection of the mecA gene
MecA-PCR was performed with the following primers, previously designed by
Geha et al. (1994): mecAl (5'-GTA GAA ATG ACT GAA CGT CCG ATA A) and
mecA2 (5'- CCA ATT CCA CAT TGT TTC GGT CTA A). The PCR reagent mixture
consisted of 200 ~ concentrations of dNTPs, IOmM Tris (pH 8.3), 50mM KCI,
1.5mM MgCh, a 0.25 ~ concentration of each primer, and 1.25U of Tag
polymerase (Fermentas, Lithuania). DNA amplification thermal cycling profile was
as follows: initial denaturation at 94°C for 5 min, followed by 30 cycles of
amplification (94°C for 15 sec, 55°C for 15 sec and 72°C for 30 sec), ending with the
noc for 2 min. A positive result was indicated by the presence of the 31O-bp
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amplified DNA fragment revealed by electrophoresis on a 1.5% agarose gel. In order
to ensure the accuracy of the PCR, each isolate was analysed by PCR twice. Each
reaction set included MET-resistant strain DNA as positive control and MET-
susceptible strain ATCC 29213 DNA as negative control.
In order to approve specificity of primers, an amplified 3 10bp fragment of the
mecA gene was sequenced with the same primers as those used for the PCR.
Automatic sequencing reaction and analysis of results was done as described above.
The similarity of the fragment to the Siaureus SCCmec type element (Accession
number AY271717) was examined.
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4. RESULTS AND DISCUSSION
4.1. Final results of the study on mutations associated with the first-
line drug resistance in Mycobacterium tuberculosis, examined using
various methods and confirmed by automatic nucleotide sequencing
(APPENDIXES 1, 3, 5 and 6)
This part of the study involved the total of 145 Mtuberculosis DNA samples
(126 MDR and 19 drug susceptible) isolated in STLDC during the time period from
1999 to 2002 from Latvian pulmonary TB patients, one isolate from each. This set of
isolates represented about 30% of all cultures obtained in STLDC during the period of
study. Mutations were analysed in genes most frequently associated with resistance to
the first-line anti-TB drugs: rifampin (rpoB) and isoniazid (katG), ethambutol (embB),
streptomycin (rpsL, rrs) and pyrazinamide (pncA). A set 109 MDR and 19 drug
susceptible M tuberculosis DNA isolates, obtained in 1999-2001, was analysed for the
presence of mutations in the rpoB and the katG genes. Subsequently, a set of 66 MDR
isolates obtained in 2001-2002 (all of those were resistant to SM, 33 were resistant to
EMB and 28 were resistant to PZA) was analysed for mutations in the rpsL, rrs, embB
and pncA genes.
Different molecular screening methods such as SSCP (rpoB and embB genes)
INNO-LIPA (rpoB gene), endonuclease digestion (katG and rpsL genes) and, finally,
nucleotide sequencing analysis (rrs, pncA and all previously mentioned genes) were
evaluated for the rapid detection of mutations in the amplified gene fragments. The
summary of prevalent mutations in the analysed DNA from resistant isolates, as
showed by sequencing, the percentage of mutated genotype cases and of wild type
genotype cases (not mutation identified) is given in Table 1.
Table 1. Summary of the mutations in genes associated with the first-line drug
resistance, detected in MDR Mstuberculosis isolates by nucleotide sequencing
Anti- TB agent Gene Mutated Predominant mutations Wild type No of
genotype (%) genotype resistant
(%) (%) isolates
Rifampin RpoB 93.6% Ser531 Leu -52.2 % 6.4% 109
Asp516VaI- 14.7%
Isoniazid KatG 99.1% Ser315Thr - 99.1 % 0.9% 109
Streptomycin RpsL together Lys43Arg - 61% together 66
Rrs 85% 513.A---+C, 516C---+T 24% 15%
Ethambutol EmbB 52% Met306VaI / De - 48.0% 48.0% 33
Pyrazinamide PncA 82% Thr76Pro - 18% 18% 28
Tyrl03His - 18%
The rpoB gene (Appendix 1, 3) fragment sequencing results were available for
the 109 MDR and 19 drug susceptible M tuberculosis isolates. In total, 16 variants in
single and double codon mutations were found in 102 (93.6%) of 109 MDR isolates
including the isolate with the combination of codon deletion and two codon mutations
at positions 524-527 (see Table 1). The following rpoB gene mutations predominate:
S531L in 52.2% and D516V in 14.7% of the 109 isolates. Altogether, nine (8.2%)
double mutations were detected; six of which were located at different pairs of codons.
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Four of the rpoB gene double mutations had not been previously described (D516V
plus P535S, Q510H plus H526Y, D516V plus K519T and R529P plus S531L). Several
isolates (6.4%) did not contain mutations in the region examined. No mutations were
detected in drug susceptible isolates.
In parallel, 34 of 109 MDR and 19 drug susceptible DNA isolates were analyzed
by the reverse hybridization-based INNO-LiP A to determine RIF susceptibility. The
results were in fine agreement with the in vitro susceptibility testing. One of the
analysed MDR isolates, however, was a mixture of wild-type (WT) and mutant H526Y
strains. Altogether, nine different patterns were found for the 34 RIF resistant samples.
The most frequent rpoB gene mutations were S531L, D516V and H526D. Mutations
were clearly demonstrated in 27 of the 34 RIF resistant samples by INNO-LiP A. The
remaining seven RIF resistant samples with unclear INNO-LiP A patterns were further
examined by manual nucleotide sequencing. Sequencing results showed the double
mutations in five cases and mutation L533P in two cases. So, INNO-LiP A was
effective in identifying the four most common rpoB mutations D516V, H526D, H526Y
and S531L. Unfortunately, the method could not identify double mutations which are
common in Latvian Mtuberculosis DNA isolates.
Additionally, the SSCP method was used to examine 23 of the same DNA
isolates, eight from drug susceptible and 15 from RIF resistant Mycobacterium
tuberculosis cultures. Drug resistant isolates with the most common rpoB gene
mutations in Latvia were selected to evaluate the discriminative power of the SSCP
method including five isolates of the S531L, three isolates of the D516V, two isolates
of the H526D and five isolates of the D516Y plus P5335S substitutions. The SSCP
analysis showed a strand mobility difference between the RIF susceptible and the RIF
resistant samples, except for the five samples with the S531L mutation. Since S531L is
the most common rpoB mutation in our isolates, application of the SSCP method for
rapid rpoB screening for RIF susceptibility can not be recommended at least in Latvian
MTC isolates.
The rpoB mutations located in codon Ser531 (up to 54%) and in H526 (up to
40%) of the RIF resistant isolates are the most frequently described woldwide (Traore
et al., 2000; Fan et aI., 2003, Vue et aI., 2003). A comparison of these results shows
that the Ser531Leu mutation predominates also in Latvia. In contrast, the frequency of
mutations at codon 516 (25 of 109 (23%), involving both single and double mutations
in our region is slightly higher than that ofH526 (10 of 109 (9.2%)).
The katG gene (Appendix 1,3) fragment sequencing showed a single
nucleotide change at codon 315 in 108 (99.1 %) of the 109 MDR M tuberculosis
isolates (see Table 1). In 104 (95.4%) isolates it was a AGC ~ACC change, and in 4
(3.7%) isolates it was a mixture of ACC and ACA. In all 108 strains, the nucleotide
change from AGC to ACC or ACA resulted in the substitution of Serine (Ser) for
Threonine (Thr). In 1 (0.9%) of the 109 isolates the 704bp long katG gene fragment
did not contain a mutation. No mutations were found in the katG gene of 19 drug
susceptible isolates.
Additionally, the restriction analysis was performed with Acil (NEB, USA) on
704bp fragment of the katG gene of 35 of 109 MDR Mtuberculosis isolates. The
analysis accurately showed a nucleotide change at codon 315 in all cases.
A high percentage of Ser315Thr mutation among INH-resistant M. tuberculosis
isolates was observed also in St-Petersburg area of Russia (92%), Lithuania (85.7%)
and Netherlands (89%) (Marttila et aI., 1998, Bakonyte et aI., 2003, Van Doom et aI,
2003). However, a wider mutation spectrum was observed in the USA and other
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European countries (Nachamkin et aI., 1997, Fang et al., 1999). Van Soolingen et al
(2000) discuss about codon 315 mutations being associated with the high level
resistance to INH as a result of inappropriate therapy. Our results suggest that Serine
substition at codon 315 of the katG gene is a characteristic of INH resistant strains and
therefore can serve as a genetic marker for INH resistance in our region. Surprisingly,
substitution at codon 315 was absent only in one INH resistant strain. This can be
explained by the observation that there are more genes which can be responsible for
lliN resistance - inhA, oxyR-ahpC, kasA (Wilson et aI., 1996; Lee et aI., 1999), ndh
(Lee et aI., 2001), recently described mabA, Rv1772, fadE24, Rv1592, Rv0340, and
iniBAC genes (Ramaswamy et aI., 2003). However, mutations in these genes are of
lower frequency than in the katG gene. A more detailed analysis of the mentioned
genes could reveal mutations additional to Ser315Thr at the katG gene.
The 306bp fragments of rpsL gene (Appendix 5) from 66 SM resistant DNA
isolates were analysed by digestion with Mboll endonuclease and by automatic
sequencing. Cleavage of the 306bp fragment, observed in 26 (39%) isolates, indicates
the presence of the wild type codon K43. In opposite, absence of cleavage in 40 (61%)
of the isolates indicated a nucleotide change at codon K43. Nucleotide sequencing of
the same 40 isolates confirmed nucleotide change from AAG to AGG (K~R) at
position 43 (K43R) (see Table 1). Digestion with MboII, therefore, confirmed wild
type nucleotide sequence at codon K43. 26 isolates with the wild type rpsL sequence
were further examined for mutations in two regions of the rrs gene encoding for the
16S rRNA. Analysis of the 912 region showed the wild type sequence in all the
isolates tested. In contrast, 16 or 24% of all tested 26 isolates showed substitutions in
the 530 loop region at nucleotide positions 513A~C (n=ll) and 516C~T (n=5). The
remaining 10 of these isolates or 15% of the all isolates tested showed the wild type
sequence in these regions of the rpsL and rrs genes. In summary, 56 (85%) of the
tested 66 SM resistant isolates, had nucleotide substitutions either at amino acid
position K43 of rpsL gene or at nucleotide positions 513A or 516C of the rrs gene.
A percentage of the rpsL (61%) and the rrs (24%) gene mutations in part
correlates with the previous reports, where alterations in the rpsL gene have been
detected in 52.0 to 56.8% and mutations in the rrs gene detected in 8.0-15.6% of the
analysed SM-resistant isolates (Morris et aI., 1995; Sreevatsan et al., 1996). Mutations
in the rrs gene could confer SM resistance in the isolates lacking rpsL gene mutations.
Mutations have been very rarely found in both genes simultaneously; possible interplay
of mutations was proposed in several such examples (Meier et aI., 1996; Sreevatsan et
aI., 1996). By Meier et al (1996), a high level of phenotypic resistance to SM in vitro
(>500IJ.glrnl) is associated with mutations in the rpsL gene, whereas mutations in the
rrs gene occur only in isolates with the low-level resistance to SM (MICs, lOug/ml).
Interestingly, no one of our isolates showed mutation either at rpsL codon K88 or at rrs
gene 912 region, both of those have been widely described by other investigators
(Kempsell et aI., 1992; Musser, 1995).
A slightly higher prevalence of K43R mutations may be explained by the high
prevalence of Beijing genotype among Latvian MDR Mtuberculosis strains, as
described later in Section 4.3. It is also based on the observation that in our study only
strains with the Beijing genotype (confirmed by RFLP analysis and spoligotyping) had
the K43R mutation, whereas isolates with non-Beijing genotype showed the wild type
sequence in the analysed fragment of the rpsL gene (data not shown).
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The single-stranded DNA conformation polymorphism (SSCP) method was
applied to the embB gene (Appendix 5) fragment of the 33 EMB-resistant and 33
EMB-susceptible isolates. Using I03bp fragment SSCP analysis substitutions in embB
gene were found in 15 (45%) and by sequencing in 17 (52%) of 33 EMB resistant
isolates (Table 1). Surprisingly, SSCP revealed nucleotide mutation at codon Met306
in five (15%) of33 in vitro EMB susceptible MDR isolates. Similar results have been
reported from Northwestern Russia, where mutations at codon Met306 were found in
14 (48.3%) of 29 EMB-resistant strains and in 48 (31.2%) of 154 EMB susceptible
strains (Mokrousov et aI., 2002). Like in our study, the discrepancy between the results
of phenotypic and genotypic EMB resistance tests was found in MDR strains only.
Mokrousov hypothesise that there could be a drug target in tubercle bacilli, different
from the one encoded by the embB; it could be affected by the EMB during the
treatment with other first-line anti-TB drugs.
Compared to nucleotide sequencing, SSCP accurately showed mutations ATG
~GTG (Met306VaI) and ATG ~ATC (Met306I1e) but not the change in codon 306
from ATG to ATA, also resulting in lie. It is not surprising, that only 52% of the
analysed isolates showed nucleotide alterations in the embB fragment, as at least 12
candidate genes were shown to confer EMB resistance (Ramaswamy et aI., 2000).
Therefore, nucleotide sequencing or SSCP analysis of alterations in the embB gene
used to detect EMB susceptibility are of limited value and should not be recommended
for rapid screening of clinical specimens.
In present study, 28 of 66 MDR Mtuberculosis isolates were resistant to PZA.
Therefore, the pncA gene (Appendix 6) was analysed including upstream and
downstream regions in 28 PZA-resistant and 10 PZA susceptible (control group) MDR
isolates by the nucleotide sequencing. Point mutations in the pncA gene were found in
ten different codons in 23 (82%) of 28 PZA resistant isolates (see Table 1). No
mutations were detected in 10 of the PZA susceptible MDR M.tuberculosis isolates.
All the mutations found lead to an amino acid change. In addition, one mutation
resulted in the premature termination of pyrazinamidase synthesis. In PZA resistant
isolates, codons T76 and Y103 were the most frequently affected (43%). One isolate
showed a mixture of the wild type and a mutant sequence, with mutations at two
codons, C14 and Y103. Since double mutations have not been previously described in
the pncA gene, we propose that each of the mutations arose independently in this
strain. Five (18%) of the isolates showed the wild type pncA gene sequence indicating
another mechanism for PZA resistance. It might be a change in cell wall permeability
or evolving pyrazinamide metabolism pathways, for example, due to mutations leading
to the modification of pyrazinoic acid target (Huang, 2003). Such strains provide an
opportunity for further studies of alternative PZA resistance mechanisms.
From the analysis of 28 PZA resistant Latvian M tuberculosis isolates,
mutations found at 7 of the 10 codons have been previously described in seven studies
(Cheng et aI., 2000; Lemaitre et aI., 1999; Marttila et aI., 1999; Mestdagh et al., 1999;
Morlock et al, 2000; Scorpio et al., 1997; Sreevatsan et aI., 1997). Mutations at three
other codons (CI4Y, D63G and V180F) are first reported in this study. A survey of
data from seven previous studies from different parts of the world show that mutations
in the pncA gene are predominantly found at codons R140 (n=21, 13%), L85 (n=15,
9.1%) and T47 (n=12, 7.3%). On the other hand, in the present study, the most
commonly occurring mutations were found at codons T76 and YI03. Seven of the
mutated codons (QI0, C14, P62, D63, C72, T76 and C138) detected in our study, were
located in these hypothetically hot regions (Scorpio et aI., 1997) while three other
33
codons (L85, YI03 and V180) were located outside these regions, partially confirming
that hypothesis.
Since the loss of the pyrazinamidase activity leading to PZA resistance is
mostly caused by mutations randomly dispersed in pncA gene and touch the coding
region or gene expression regulating part, nucleotide sequencing remains the most
appropriate tool for the analysis ofthe pncA gene at the molecular level.
To summarise, this study was focused, first of all, on M tuberculosis rpoB and
katG genes, as mutations in these genes mean resistance to RIF and IHN, e.i. multi-
drug resistance. The results showed a good correlation of mutations in particular genes
that in more than 96% was associated with in vitro determined resistance results.
Therefore, molecular screening of these two genes can be recommended for reliable
and rapid drug susceptibility testing in specimens prior culturing. The remaining
isolates with wild type sequence should be evaluated according to results of in vitro
susceptibility testing. Mutations in the rpsL/rrs, embB and pncA genes, associated with
resistance to SM, EMB and PZA, respectively, were found at lower frequency,
especially in embB, than in rpoB and katG genes. That fact can be explained by the
additional mechanisms of resistance, associated with other candidate genes, not
involved in this study, or such as a change in membrane penetration or drug efflux.
Therefore, rapid screening of the mentioned genes may be of lower clinical value,
except for special cases when the presence of point mutation can be employed as an
obvious marker of drug resistance. However, that way susceptibility results will be
unclear for the remaining M tuberculosis isolates with wild type sequences. Of course,
an extended study of other candidate genes could solve this problem.
In general, the proportion of mutations found in the analysed genes correlates
with the previous findings. However, some exceptions took place. For example, in the
katG gene, codon 315 was affected in all studied Latvian INH-resistant Mtuberculosis
isolates, except one. That demonstrates the importance of codon 315 in development of
INH-resistance in Latvia. Not surprisingly, three novel mutations have been shown in
the pncA gene, as mutations have a disseminated character in that gene. Some genes
(rpoB, pncA) had mutations at already known codons at higher frequency when
reported from other studies. Particularly, higher occurrence of double mutations has
been shown in the rpoB gene including four double mutations not previously
described. This fact, altogether with high prevalence of mutations at particular codons,
may be explained by the history of chemotherapy in Latvia (like INH or RIF
monotherapy regimes in past), as well as by ongoing transmission of particular
M tuberculosis strains. However, it is obvious that in genes like katG, rpsL and embB,
where mutations were shown to affect a single codon only, particular codon mutations
could be selected as more effective to withstand antibacterial pressure and, at the same
time, not to be fatal for bacteria. A hypothetical effect of some mutations on
mycobacterial virulence will be discussed later, proceeding from spoligotyping results.
Various molecular methods, commercial INNO-LIP A kit (rpoB gene
mutations), SSCP (rpoB and embB genes) and endonuclease digestion (katG and rpsL
genes) analyses have been evaluated for rapid detection of mutations. Nucleotide
sequencing was used to confirm the obtained results. So, INNO-LiP A was accurate for
the detection of most common rpoB gene mutations, but failed to reveal double
mutations as well as unusual mutations. However, in the two last cases kit indicated on
RIF-resistant genotype. SSCP method was not effective for the most common Leu531
mutation in the rpoB gene fragment; it was precise for the Met306Val/Ile alteration in
the embB, but not for ATG306ATA change, also resulting in aminoacid lie. Site-
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specific endonuclease digestion reaction was shown as a reliable and rapid method
when the location of mutation is well known, e.g. Ser315 in the katG gene or Lys43 in
the rpsL gene. However, it is not effective in the case of multiple mutations or when
mutation affects other locus. A dispersed nature of pncA gene mutations proved true
selection of nucleotide sequencing as a reliable method to study PZA-resistance. To
conclude, nucleotide sequencing, used for the identification of mutations, and
evaluating the methods described above, was shown as the most precise. It was also
rapid and less cumbersome since the automatic reader of sequencing results was
applied.
4.2. Identification of M.tuberculosis complex by IS-6110-based
peR (APPENDIX 2)
In this study, 170 specimens obtained at STLDC during the time period from
1998 to 2000, were analysed by IS6110-PCR. IS611O-PCR revealed the highest
number of MTC positive specimens (40.6 %) in comparison with commercial LCx
assay (27.6 %) and with commonly used methods as bacteria growth in BACTEC
system (20.6 %) and on Lowenstein-Jensen medium (15.3 %). The smear microscopy
(bacterioscopy), a method reliable to detect MTC bacteria only if it is present in a high
amount, was the least sensitive. This group of 13 BACTEC-positive specimens was
also positive for MTC by all the remaining methods (l00 % specificity for smear-
positive specimens).
IS611O-PCR was the most sensitive method in comparison with LCx assay and
with other clinical laboratory methods. Sensitivity and specificity of PCR was
estimated on the basis ofBACTEC results. Thus, 91 PCR negative results and 26 PCR
positive results (together 68.8 %) were in accordance with BACTEC system, and were
considered as true negative and true positive, respectively. In 44 (25.8%) cases PCR
was positive instead of negative BACTEC results. 12 of 44 PCR-positive results
correlated with LCx assay, but were discordant to the results ofBACTEC.
Instead of it, nine (5.2 %) discrepant PCR-negative and BACTEC-positive
results were observed, thus an estimated overall PCR sensitivity was 72 %. False
positive results in LCx or BACTEC may be caused by laboratory contamination. False
negative results may be explained by the absence of IS611 0 fragment in the M
tuberculosis pathogen also.
As PCR is able to detect both dead and live MTC bacteria, some patients may
remain PCR-positive for mycobacterial DNA several months after treatment.
Therefore, 44 discrepant PCR-positive and BACTEC-negative samples were further
evaluated in the context of the clinical findings.
Clinical material isolated from CSF was studied as well. Seven smear and
culture-negative specimens of CSF showed negative results by both amplification
methods (IS6110-PCR and LCx). The results correlated with the clinical findings.
Several specimens were received from patients with suspicion of TB or of tuberculous
meningitis, though having smear-negative results. The specimens were processed using
Boom (Boom et. al. 1990) method to increase DNA concentration. In three cases
(CSF-3024, CSF-3025 and L-202) our search results were in fine agreement with the
clinical findings and were used for the elaboration of the therapeutic strategy. In one
case (L-204), PCR methods showed a weak amplification signal and atypical genetic
pattern in Mixed Linker PCR. The reliability of rpoB and katG gene was shown on
several CSF specimens, however, it should be additionally evaluated in a larger scale
study. However, according to our preliminary observations, PCR-based methods such
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as INNO-LiP A and rpoBlkatG gene sequencing are highly sensitive and specific.
Particularly, INNO-LiP A is already implemented in laboratory practice in SCTLD to
detect RIP -resistance on clinical specimens.
The amplification of nucleic acids gives a good chance of detecting MTC in
smear negative samples. IS6110-PCR is a rapid and relatively simple method; PCR
results are available in 1 or 2 days instead of several weeks needed to grow
mycobacteria in BACTEC system. IS6110-PCR was shown to be able to detect
mycobacterial genome in variable clinical material - sputum, bronchial lavage, CSF
etc. The method correlated with several studies evaluating PCR for diagnosis of
(mainly pulmonary) TB, which reported sensitivity and specificity ranging between 70-
100 % when culture of MTC was taken as the golden standard (Forbes 1997).
However, in practice, many problems occur due to inhibition or due to cross-
contamination with the products from previous PCRs (Nordhoek et aI., 1994).
4.3. Molecular typing of M. tuberculosis by spoligotyping
(APPENDIX 3)
To evaluate the predominant genotype groups in Latvian MDR M.tuberculosis
and to compare prevalent mutations in the rpoB and katG genes among the different
genotype groups, 109 MDR isolates of M tuberculosis were genotyped by the
spoligotyping method. In addition to that, a set of 34 drug susceptible isolates were
analysed by spoligotyping. To note, random selection of our samples reflected the rate
of primary (33%) and relapsed (61,5%) MDR TB in general population with M
tuberculosis infection between 1999 and 2001. Selected cultures represented about
25% of all MDR cultures obtained annually at STLDC.
20 variants of spoligopatterns were distinguished on 109 MDR isolates. In total,
95 out of the 109 isolates were located in 6 different clusters having 2 to 63 isolates, of
which the two largest clusters accounted for 63 and 19 isolates each. The remaining 14
isolates did not show clustering. 109 isolates could be subdivided into two main
groups, one containing 63 and the other 46 isolates. The largest one, called "Beijing
genotype" group was formed by 63 (58%) isolates, all showing Beijing-characteristic
nine-spacer spoligopatterns SP 1 (Appendix 3, Figures 1 and 2). Another main group
called "non-Beijing" was formed by 46 isolates with 19 variants of spoligopatterns.
Within this group, the second largest cluster after Beijing consisting of 19 isolates
(SP12) appeared. All, except one, non-Beijing isolates shared >72% pattern similarity
within the group. Genotyping of drug susceptible Mtuberculosis isolates was not the
main aim of this study, however, it is important to note, that Beijing genotype was
identified in 12 of34 tested drug susceptible isolates, and the predominant spoligotype
in that group was SP12 (Appendix 3, Figures 1 and 2).
In this study, the Beijing genotype of M tuberculosis was not associated with
the younger age of patients, as it was previously reported. The average age of Latvian
patients hosting the Beijing genotype was 46 years; most (35.2%) of these patients
being between 41-50 years of age. It is obvious that the distribution of age groups for
the Beijing and non-Beijing genotypes follows the general trend of TB in Latvia,
where the highest incidence is found among the population of 44-54 years of age (160
per 100.000 in 2000). The ratio of females to males in our study in both Beijing and
non-Beijing groups was 1:3, which reflects the incidence of TB in females and males
in the general population.
The rpoB and katG gene fragment sequencing results on MDR M tuberculosis
isolates were compared between Beijing and non-Beijing genotype groups. In both
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genotype groups, the following rpoB gene mutations predominate: Ser531Leu in
52.2% and Asp516Val in 14.7% of 109 isolates. 63 Beijing isolates showed a higher
percentage of double mutations (eight, 12.7%) in comparison to the group of 46 non-
Beijing isolates (one, 2.2%) (P<0.05). Notably, IS6110-RFLP analysis showed
different patterns for isolates with the same location of double mutations (data not
shown). All isolates with the Beijing genotype had the same the katG gene
substitution: Ser315Thr.
In addition, a genetic polymorphism at codon 463 of the katG gene was
detected. All 63 isolates comprising in the Beijing group had Leucine (Leu) (CTG) at
position 463 of the 704bp fragment of the katG gene, whereas 45 of 46 isolates from
the non-Beijing group showed Arg (CGG) at position 463. That mutation is not
associated with INH resistance, but together with neutral polymorphism present at
codon 95 of the gyrA (a subunit of DNA gyrase) gene can be used to assign strains of
M tuberculosis to three phylogenetic groups, as shown by Sreevatsan et al (1997).
Therefore, all our isolates of the Beijing genotype having Leu at codon 463 could be
assigned to the phylogenetic Group 1. The remaining strains that constituted the non-
Beijing group with Arg at codon 463 could be assigned either to Group 2 or to Group 3
on the basis of polymorph isms at codon 95 of the gyrA gene.
So, the spoligotyping method correctly identified the major genotype families
in Latvian MDR Mtuberculosis isolates, as compared with IS6110-RFLP results
obtained from the same isolates in our laboratory, Biomedical Research and Study
Centre (data not shown). The prevalence of a particular genotype group, named
Beijing, in MDR isolates can be explained by the active transmission of TB in Latvia
as well as by more virulent nature of pathogens from that genotype group. Since the
prevalence of Beijing genotype was identified, spoligotyping results were further used
for comparison of mutations in the rpoB and in katG gene between Beijing and non-
Beij ing genotype groups. In this study, a possible impact of particular codon mutations
on virulence was evaluated for Beijing genotype, which was shown to be more able to
spread (Bifani et al, 2002; Glynn et al., 2002). However, it was recently shown that
Beijing genotype strains do not have ability to gain drug resistance more rapidly than
other genotype strains (Wemgren & Hoffner, 2003). In the present study, a comparison
of two genotype groups showed that there is no difference in the rpoB and katG gene
mutations. However, Beijing type isolates showed a higher prevalence of double
mutations than non-Beijing isolates. It is not known yet, how long Beijing genotype
has been present in Latvia, but the occurrence of double mutations in M.tuberculosis
isolates of that genotype may be commented only by the prolonged exposure to RIF
chemotherapy. In the present study, spoligotyping was mainly done on culture-isolated
DNA. However, it has been already introduced in our laboratory on clinical specimens
as reliable method for simultaneous MTC detection and typing.
4.4. Detection of methicillin resistance by mecA gene peR
(APPENDIX 4)
Altogether, 102 staphylococcal cultures isolated in HTO from 2000 to 2003
were analysed for the presence of the mecA gene. Among them, there were 36
coagulase-positive Siaureus (28 MRSA and eight MSSA) and 66 CoNS, including 65
MET -resistant isolates (44 50 epidermidis, 15 S. haemolyticus, one 50 hominis, one S.
capitis and one S. wameri) and one MET -susceptible S.epidermidis isolate.
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Nucleotide sequencing identified the nucleotide sequence of the 310bp mecA
PCR fragment as a part of the S.aureus SCCmec type element, containing mecA gene.
According to PCR results, all phenotypically Met-resistant 28 S. aureus and 65 CoNS
showed the presence of the 310-bp fragment of the mecA gene, thereby confirming
MET resistance (the method's sensitivity = 100%). For 8 of the 9 control strains,
respectively, phenotypically MET-susceptible eight MSSA and one Sieptdermtdis, the
PCR response was negative - the mecA gene was absent. One MET -susceptible S.
epidermidis isolate, exhibiting oxacillin MlC 1 ug/rnl, proved to possess the mecA
gene and should be recognized as methicillin-resistant. That fact could be explained by
higher sensitivity of the PCR method in comparison with standard methods, as PCR
allows "to touch" bacteria at the genome level. Therefore, the discordance of PCR and
disk diffusion methods could be caused by the heteroresistant nature of the
staphylococci or by absence of mecA gene expression on phenotype level (Berger-
Bachi, 1997; Frebourg et aI., 1998). Our results correlated well with the previous
studies, where detection of mecA gene was shown as more reliable than the disk
diffusion method, agar screen plate and some commercial MRSA tests (Louie et aI.,
2000; Ferreira et aI., 2003; Kipp et aI., 2004).
There is no doubt that at least two methods should be applied in parallel for the
detection of MET resistance. In addition to oxacillin disk diffusion method, MET
resistance in Staphylococci can be detected by two gold standard methods
recommended by the NCCLS, namely oxacillin screening plate test and detection of
the mecA gene by PCR (Goettsch et aI., 2000). At the same time, mecA-PCR may be
especially useful to reveal heteroresistant or borederline resistant strains, which appear
phenotypically MET -susceptible.
Mechanisms of drug resistance in S.aureus and CoNS raise special interest due
to occurrence of MET -resistant strains in hospitals, causing nosocomial and
community-acquired infections. In comparison with Mituberculosis, staphylococci
have various ways to gain drug resistance. Particularly, the mechanism of resistance to
~-lactams in staphylococci provides more simple molecular detection in comparison
with the methods required for the detection of mutations associated with drug
resistance in Mttuberculosis. This study showed high sensitivity of mecA-PCR
detection, and it is already implemented in routine laboratory practice for the detection
of MET -resistance in both coagulase-positive and -negative staphyloccci.
Transposon and plasmid mediated horizontal transfer of drug resistance gene
remains predominant in many bacteria. However, resistance of staphylococci to several
antibacterials, e.g., rifampin and fluoroquinolones occurs due to chromosomal gene
mutations and will require other detection methods.
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CONCLUSIONS
1) Molecular mechanisms of M.tuberculosis resistance to the first-line anti-
tubercular drugs (RIF, INH, EMB, PZA and SM) were studied. Resistance-
associated mutations were characterised by several methods in the rpoB,
katG, embB, pncA, rrs and rpsL genes of the Latvian MDR Mituberculosis
DNA isolates. Novel mutations were found in the pncA and rpoB (double
mutations) genes. Most of the examined molecular methods were shown
reliable and contributing to the further use in clinical laboratories.
2) The high level of double mutations was detected in the rpoB gene (12.7%)
among RIF-resistant isolates, possibly, indicating the consequences of the
prolonged monodrug chemotherapy and different evolutional pathways of
MDR strains in Latvia.
3) A single point substitution Ser315Thr in the katG gene (99.1 %) was found
to be typical for Latvian MDR isolates, therefore, it can be used together
with rpoB mutations as a local molecular marker ofMDR resistance.
4) The molecular analysis of PZA resistance is of special clinical value taking
into account problems of the classical susceptibility testing. For that aim,
nucleotide sequence analysis of the pncA gene could be recommended,
being aware on the fact that in 12% of PZA-resistant Mtuberculosis
isolates mutations were not found.
5) The low percentage of mutations detected in the embB gene should
contribute to the development of EMB-resistance determining methods
based on simultaneous screening of various associated genes, e.g.
macro arrays.
6) The prevalence of Beijing genotype (58%) among Latvian MDR
Mtuberculosis isolates from primary and relapsed TB cases was shown.
The prevalence occurred, more likely, due to recent transmission, therefore,
partially confirming the hypothesis about higher virulence of Beijing
genotype. This underlines the need for rapid detection and typing of MTC
bacteria from uncultured specimens, e.g., by spoligotyping.
7) The mechanism of drug resistance different from Mtuberculosis was
studied in the genus Staphylococcus. Chromosome-integrated mecA gene,
determining the resistance to methicillin and other ~-lactams, was detected
by the PCR. mecA-PCR showed high specificity and could be
recommended as confirmatory analysis in addition to the standard
laboratory methods. Further understanding of the pathways of molecular
evolution of particular methicillin-resistant strains requires more thorough
studies including genotyping and evaluation of epidemiological links.
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To cbaracterize the genetic basis of drug resistance in Mycobacterium tuberculosis in Latvia, mutations
involved in rifampin (rpoB gene) and isoniazid (kaJG gene) resistance in DNA from 19 drug-susceptible and 51
multldrug-reslstaet M. tuberculosis complex isolates were analyzed. The most frequent rpoB gene mutations
found by tbe tine Probe assay were tbe S531L (14 or34 isolates), D51!6V (7 o(34), H526D (4 of 34), and D516Y
plus P535S (4 of 34) mutations. Direct sequencing of seven isolates witb unclear results from Line Probe assay
showedtbe presence of the L533P mutation and tbe QSI0H plus HS26Y {I of 34) and D516V plus P535S (4 of
34) double mutations, neitber of whicb bas been described previously. Single-strand conformation polymor-
pbism analysis sbowed strand mobility differences between the rifampin-susceptible and -resistant samples for
tbe D516V, H526D, and D516Y plus P535S mutations but not for tbe S531L mutation. Nucleotide substitution
at codon 315 (AGC~ACC) of the IalIG gene was found ,in 48 of 51 multldrug-resistant samp'les 'by sequencing.
Furthermore, IalIG gene restriction fragment lengtb polymorpbism analysis with endonuclease Acil confirmed
the nucleotide cbange in codon 315.
The incidence of tuberculosis (TB) in Latvia, as in the rest of
the world, has followed the same increasing trend! (3). From
199] to 19'}8, the incidence of TB in Latvia increased, reaching
a rate of 74 per 100,000 inhabitants. Since then, it has re-
mained at about this level. At the same time, drug resistance
among 'TB patients in Latvia seems to be the highest in the
World(12), with primary multidrug resistance found in 8.6% of
newcases and in 34.5% of all TB patients in the year 2000. In
comparison, the average primary rate of multidrug resistance
In Europe as a whole is only 4%. Mutations in the 81-bp
hypervariable region of the rpoB gene encoding the RNA poly-
merase fl-subunit are the cause of rifampin (RIF) resistance in
96% of the cases. Among these, missense mutations in codons
5531,H526, and D516 are the most frequent (11, 19). Isoniazid
!INH) is most often used for 1'8 treatment because of the very
highsensitivity of Mycobacterium tuberculosis to this drug (2).
In 60 to 70% of the cases, INH resistance is associated with
mutations in the catalase-peroxidase-coding katG gene at
COdon315 (Ser~ Thr) (7). In this study, we characterized the
'PoR and kntG gene mutations that are dominant in the
LHVianisolates of multidrug-resistant (MDR) M. tuberculosis
!.II»by commercial Line Probe assay (UPA), direct sequenc-
Ingof PCR products, and single-strand conformation polymor-
~hism(SSCP) and PeR-restriction fragment length polymor-
Dhismanalyses. We suggest that this approach using molecular
,11Jrkers could be useful for predicting rnultidrug resistance in
'II. tuberculosis.
. Corresponding author. Mailing address: Laboratory of Molecular
~l"~rubiology. Biomedical Research and Study Centre, University of
,:1",,,, Ratsupites I, Riga, LV-I067 Latvia. Phone: 371-7llOll21H. Fax:
11·7442407, Email: tatjanap@biomed.lu.lv_
Seventy patients from different regions of Latvia admitted to
the State Centre for Tuberculosis and Lung Diseases between
1999 and 2000 with clinical symptoms of lung or renal tuber-
culosis or tuberculous meningitis were included in this study.
Diagnosis was confirmed by microscopy and by culturing (18).
Patients with a primary infection were preferably selected.
They were typical of TB patients in Latvia in that they ranged
in age from 25 to 60 years and in that two-thirds of them were
male. Cultures of the M. tuberculosis complex were grown on
Lowenstein-Jensen medium for 4 to 6 weeks. Drug suscepti-
bility was determined by using the absolute concentration
method on slants with the H37Rv strain of M. tuberculosis as
the positive control and by using the BACfEC system (6, 13).
With the absolute concentration method; resistance was de-
fined as growth on solid media containing graded concentra-
tions of drugs with more than 20 CFU at a specific drug
concentration. The breakpoints for INN were 0.2 and 2.0
J-Lg/mlon Lowensteia-Jensen medium and 0.1 J-Lg/m1,on the
BAC!~ BC system; for RIF, they were .w.O lLg/lcl on LOwen-
stein-Jensen medium and 2.0 lLg/lcl on the BACfEC system.
Of the 70 strains examined, 19 were drug susceptible and 51
were M~DR, i.e., resistant to RIF and INH at least. Due to the
small amount of DNA from some of the isolates, it was nor
possible to perform all of the analyses on all 70 isolates. There-
fore, only 19 drug-susceptible and 34 MDR M. tuberculosis
isolates were analyzed by UPA All 51 MDR isolates, however,
were analyzed for the kntG gene mutations by nucleotide sc-
quencing. High-molecular-weight genomic DNA was isolated
from the 70 mycobacterial, cultures by the lysozyme/protciuasc
K ceryltrimethylammonium 'bromide procedure and precipi-
tated with isopropanol (20). Purified DNA was dissolved in 2(1
to 50 ILlofTE buffer (10 mM Tris HC1~1 mM EDTA [pH i'l)
~7H9
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DNA isolated from M tuberculosis MT14323 and Mycobacte-
rium bovis BCG strains was used for controls.
A conunercial INNO-uPA Rif kit (Innogenetics NY,
Ghent, Belgium) was used for the detection of rpoB gene
mutations. First, a 256-bp fragment of the gene was amplified
withbiotinylated primers 71.B (5"-GGTCGGCATGTCGCGG
.\TGG-3") and 72.B (5'-GCACGTCGCGGACCTCCAGC-
3) flanking the 81-bp region of the rpoB gene (14). Ten to
twenty nanograms of DNA diluted in TE buffer was added to
the PCR mixture to a final volume of 50 fLl [containing PCR
huffer with (NH4hS04' 2.5 mM MgCI2, 200 fLM concentra-
tions of each dNTP, and 1 U of Taq DNA polymerase (Fer-
mentas, Vilnius, Lithuaniaj], Ten picomoles of each primer
wasused for one reaction mixture. The optimized cycling pro-
tocol was used in a Progene thermal cycler (Techne, Cam-
hridge, England). PCR products were analyzed in 1.2% aga-
rosegel. In each set of reactions, one negative control and one
positivecontrol (from a sensitive strain of M bovis BCG) were
included. Ten microliters of each PCR product was used for
the LiPA hybridization, which was performed according to the
manufacturer's instructions. Each of the LiPA strips used
contained one probe specific for the M. tuberculosis com-
plex, five partially overlapping wild-type probes, and four
probes specific for the most common rpoB mutations within
the 509- to 534-amino-acid region (D516V, H526Y, H526D,
and S531L) (Innogenetics NY). Manual sequencing of the
rpoS gene was performed by using a Cycle Reader DNA se-
quencing kit (Fermentas). Radioactively labeled primers used
for manual sequencing were identical to those used for the
peR amplification.
SSCP analysis is based on the ability of single-stranded DNA
to undergo a conformational change when a single nucleotide
isaltered. Such alterations or mutations can then be detected
because of the change in DNA mobility in polyacrylamide gel.
Here, the 256-bp rpoB fragment was used for SSCP analysis.
For better strand separation, we used one biotinylated (re-
verse) primer, 72B (17). The biotinylated DNA s.trand was
leparated from the unbiotinylated strand by Dynal streptavidin
magnetic beads by using the single-stranded DNA purification
kit (Labsystems, Helsinki, Finland). In brief, 80 fLl of the
beads,suspended in 40 fLlof binding buffer, was mixed with an
equal,volume of the PeR product at room temperature for 15
min.After washing the beads with 80 fLlof washing buffer, die
bound DNA was denatured and incubated for 10 min at room
temperature in 80 fLl of 0.1 M NaOH. The alkaline solution
COntainingthe unbiotinylated strand was aspirated and used
fur SSCP analysis. The beads with the bound biotinylated
Strandwere washed once with washing buffer and then sus-
"ended in 20 fLlof concentrating solution. After being heated
for 5 min at 96°C with an equal volume of loading buffer
(11.05%bromophenol blue, 0.05% xylene cyanol, and 95% for-
rnamide), the biotinylated and unbiotinylated DNA samples
~ere snap-cooled and immediately 'loaded onto the gel. The
SSCP analysis of DNA fragments was ,performed in 6% poly-
~trylamide gel containing 5% glycerin at 35 rnA and 500 V on
".17. by 28-cm gel plate cooled to SoC [Bio-Rad, Hercules,
CaliL).After 81h of electrophoresis, ~Iheseparated DNA bands
~cre visualized by silver staining.
A 704-bp fragment of the katG gene (GenBank accession
nu X68(81) (23) was amplified by peR using direct primer 74
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TABLE I. Mutations in the rpoB gene of 34 RIF-resistant isolates
INNO·!.iPA pattern No. of isolates
~S5, RS, (plus R4a", R4b")
~S2, R2
~54, R4b
~S2, aS5, 54"
I1S2
aS5, R4a", R4b"
R4b
I1SI, a54, R4a
~S4, R4a
S531L
D516V
H526D
D516Y, P535S'
D516Y, P535S"
LS33P"
Wild type plus H526D
Q51OH, H526Y'
H526Y
14
7
4
3
1
2
1
1
1
II Zone is faint.
I, Detected only by nucleotide sequencing.
(5' -CGGGATCCGCTGGAGCAGA TGGGC-3'), targeting
the 52 terminal nucleotides before codon 315, and reverse
primer 75 (5'-CGGAATTCCAGGGTGCGAATGACCT-3'),
positioned 158 nucleotides downstream from codon 463 (4).
The 50 fLlof the PCR mixture that was used contained PCR
buffer with (N~hS04' 2.5 mM MgCI2> 200 fLM concentra-
tions of each dNTP, and 1 U of Taq DNA polymerase (Fer-
mentas). A 12.5-pmol portion of each primer was used for one
reaction mixture. The standard cycling protocol was applied in
a Progene thermal cycler (Techne). Amplification products
were visualized in 1.5% agarose gel, purified, and used for
sequencing and for digestion reactions.
Sequencing of the 704-bp katG fragment was performed
with fluorescence-labeled dideoxynucleotide terminators by
using an ABI PRISM Big Dye terminator cycle sequencing
ready reaction kit (Applied Biosystems, Foster City, Calif.) and
the same primers as those used for the PCR amplification.
Nucleotide sequences were analyzed by an ABI PRISM 310
genetic analyzer (Applied Biosystems). PCR was performed on
the relevant 704-bpkatG fragment, followed by restriction with
endonuclease AciI (New England BioLabs, Beverly, Mass.).
One INH-sensitive M. tuberculosis sample, BCG, and the
MT14323 strain were used as. controls. AciI is a rare endonu-
clease that can recognize 5' -C' CGC-3' and 5' -GCG' G-3' se-
quences and can therefore be used for determining changes in
codon 315. Four microliters of PCR product was added to the
restriction mixture containing 1 fLlof l-Ox restriction buffer 3
(New England BioLabs), 1 fLl,of Acil endonuclease (5 U/fL1),
and 4 fLl of H20. After 2 h of incubation at 37°C, the AciI
digestion products were separated in 6% polyacrylamide gel
and stained with ethidium bromide.
Nineteen drug-susceptible and 34 MDR DNA isolates were
analyzed by the reverse hybridization-based LiP A to determine
RIF susceptibility. The remaining 17 RIF-resistant samples
from a total of 51 MDR patients were not analyzed by LiPA
because of insufficient amounts of DNA.
The UPA confirmed that the 19 drug-susceptible isolates
were RIF susceptible and that the 34 MDR isolates were R1!F
resistant. The presence of M. tuberculosis complex was con-
firmed by identification of the oligonucleotide zone specific for
this complex. The results obtained with LiPA correlated com-
pletely with the in vitro susceptibility results obtained from the
culturing. One of the analyzed isolates, however, was a mixture
of wild-type and mutant (H526 Y) strains. Nine different LiPA
patterns were found for the 34 Rtf-resistant samples (Table
1). The most frequent rpoB gene mutations were S531L (found
VOL 40, W02
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FIG. 1. SSCP analysis of the 256-nucleotide rpoB gene fragments
fromRJF-resistaDtM. tuberculosis isolates. Lanes: 1,3,4,5, and 7, rpoB
gene fragments with the D516Y plus P535S (lane 1), S531L (lanes 3
and 7), D516V (lane 4), and H526D (lane 5) mutations; 2 and 6,
'fragmentsfrom the RIF-sensitive H37Rv strain of M. tuberculosis.
IiI 14of the 34 isolates), DS]6V (7 of 34), and H526D (4 of 34).
One isolate showed the H526Y mutation in rpoB. Mutations
were clearly demonstrated in 27 of the 34 Rlf-resistant sam,
pies by LiPA The remaining seven RIF-resistant samples with
unclear LiPA patterns were examined fuIither by manual nu-
cleotide sequencing (Table 1). The sequencing results showed
the D516V plus P535S double mutation in four of these iso-
lates and the Q510H plus H526Y double mutation in another
isolate; these double mutations have not been described pre-
viously (11). Altogether, five double mutations of the rpoB
gene were found in the 34 MDR isolates examined. Sequenc-
ing results for tile remaining two (of the 34) samples with
unclear but similar UPA patterns (£\S5, R4a, and R4b; faint
zones) showed the L533P mutation.
As an alternative to LiPA, the SSCP method was used to
examine 23 of the DNA isolates, 8 from drug-susceptible and
15 from RIF-resistant M. tuberculosis cultures. Drug-resistant
isolates with the most common rpoB gene mutations in Latvia,
inclUding five isolates with the S531L, three isolates with the
D516V, two isolates with the H526D, and five isolates with the
D516Y plus P5335S substitutions, were selected to evaluate
the discriminative power of the SSCP method. Computer mod-
eling (DNA Star) was used for the approximate calculation of
the folding of a 256-nucleotide rpoB plus-strand DNA frag-
ment at 37"C for both the wild-type and mutant variants. Three
virtually designed folding models of this fragment containing
the most frequently observed mutations worldwide, S531L
(TCG_ITG), DS16V (GAC->GTC), and H526D (CAC-
GAC), were analyzed. Double mutations were not included in
this modeling. Computer modeling altered the folding of sin-
gle-stranded DNA in the fragments with the D516V and
H526D mutations but not in the fragment with the 8531L
mutation, where the TCG-ITG change hypothetically should
not influence loop interaction (data not shown). The SSCP
analysis showed a strand mobility difference between theRIF-
Susceptible and RIF-resistant samples, except for the five sam-
ples with the 8531L mutation (Fig. 1). Since 8531L is the most
COmmonrpoB mutation in our isolates, the employment of the
SSCP method for rapid rpoB screening for RIF susceptibility
cannot be recommended, at least in Latvia.
Fifty-one MDR M. tuberculosis complex isolates showing
[NH resistance in addition to RIF resistance were analyzed for
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TABLE 2. Mutations in codon 315 of the kalG gene detected by
nucleotide sequencing of 51 INH-resistaDt samples
Amino acid resulting No. of
from substitution samples
AGC-+ACC
AGC-+ACC and ACA mix
AGC-+AGC and ACC mix
None
Ser-+Thr 46
Ser-e-Thr 2
Ser (wild type} and Thr mix 2
Ser (wild type) 1
katG gene mutations. Since mutations in the katG gene have
not been observed previously in IHN-susceptible M. tubercu-
losis, only MDR isolates were included in this study. Automatic
sequencing of the 51 INH.resistant samples showed a nucleo-
tide substitution at codon 315 in 48 of the 51 cases, of which 46
cases bad a codon change from AGC to ACC and 2 cases had
a mixture of AGC changes (to ACe and to ACA). In two other
cases, a mixture of AGC and ACC from wild-type and resistant
strains was found (Table 2). In all 48 cases, the nucleotide
change to ACe or ACA resulted in a change of the amino acid
from serine to threonine. In one case, no mutation was found
in the analyzed fragment. Initially, two methods, automatic
sequencing and AciI restriction analysis, were used to examine
the 704-bp katG gene fragment. Later, however, only sequenc-
ing, which was found to be more informative and precise for
the detection of mutations, was done. Restriction analysis per-
formed withAciI on 35 samples showed a nucleotide change at
codon 315 in all samples.
The aim of our study was to determine the frequency of
mutations underlying drug resistance in M. tuberculosis isolates
in Latvia, where a rapid increase in the numbers of rn cases
and MDR M. tuberculosis isolates has been seen over the last
10 years. Previously, the most frequently described mutations
in the rpoB gene were S531L (47% of isolates) and H526Y
(12%) (19). A previous study has shown the presence of the
S5311..,H526Y, and H526D mutations in 44.5, 10, and 10% of
RIF-resistant isolates, respectively (14). Comparison of these
results with the results of our study shows that the S531L
mutation also predominates in Latvia. In contrast with the
resuJts of the previous reports (14, 19), the frequency of the
D516V mutation (7 of 34, or 20%) is now higher in Latvia. A
high frequency of the D516V mutation (37.9%) has also been
described recently in MDR M. tuberculosis isolates from East
Hungary (1). Our findings correlate well with this study from a
region where less common or novel mutations also occur more
frequently. The LiPA was effective in identifying the four most
common rpoB mutations: D516V, H526D, H526Y, and S531L.
Unfortunately, the method did not identify the types of muta-
tion in the five isolates with double mutations and in the two
isolates with the rare L533P mutation, all of which required
nucleotide sequencing for identification. Therefore, in a region
with a high percentage of double mutations of the rpoB gene,
LiPA resuJts may be insufficient. Also, UPA is relatively ex-
pensive (approximately 10 times more expensive than SSCP),
and only RIF-resistant isolates were selected for LiPA toward
the end of this study.
The high percentage of mutations at position 315 of the
katG gene (48 of 51 isolates, or 91%) demonstrates the impor-
tance of this codon for the development of INH resistance
in M. tuberculosis in Latvia. A high percentage of mutations
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;11 codon 315 has also been observed in Russia, where 22 of
~~ INH-resistant isolates carried a mutation at codon 315
.Ser-s-Thr}, 1 had a mutation at codon 88 (Gly-s-Arg), and I
hJd a mutation at codon 155 (Tyr-s-Ser) (10). According to
another study, the Arg-s-Leu mutation at position 463 in the
(LitC gene was found in 30 to 40% of the INH-resistant isolates
11:1). Further studies of the mutations at codon 315 seem to
hold more promise for understanding INH resistance, since
the mutation at codon 463 was also found in M. bovis BCG, a
-train that is inherently INH sensitive. One MDR isolate
showeda lack of mutations in the /wtG gene fragment analyzed
here. According to previous studies, there are more genes
responsible for INH resistance, such as the inliA, ahpC, and
(lisA genes (8, 22) as well as the recently described ndh gene
(9). Therefore, mutations responsible for INH resistance in
[hisisolate may be present in any of these genes. The restric-
[Ionenzyme AciI was used on the 704-kb PCR product and
confirmed the high frequency of nucleotide change at codon
:115 in the INH-resistant isolates. The AGC~ACC (Ser~Thr)
nucleotide change is the mutation most often observed, but
other substitutions at codon 315 [AGC~AAC (Ser-s-Asn),
AGC-->ATC (Ser-s-Ile), and AGC-->CGC (Ser-s-Argj] have
been found in some studies (5). The AGC-->CGC (Ser-s-Arg)
substitution cannot be distinguished by AciI restriction analy-
sis.Therefore, nucleotide sequencing of the 704-kb /wtG gene
fragment seems to be a more reliable method for detecting the
gene responsible for INH resistance. Taking into account the
highprevalence of substitutions at codon 315, we propose the
useof a shorter /wIG fragment for the detection of resistance
[0 INH. The high prevalence of the S315 mutation in the /wtG
gene in INH-resistant isolates is clearly associated with multi-
drugresistance, since all of the isolates with this mutation were
also found to be MDR in in vitro susceptibility tests. These
data are consistent with the results of a study from The Neth-
erlandswhere the S315 mutation was found in more than 50%
of the INH-resistant isolates (21).
We speculate that one of the reasons for the high level of
d'rugresistance in M. tuberculosis isolates in Latvia may be the
selection of strains that develop drug resistance more rapidly.
This may explain the high percentage of certain /wIG gene
mUtat!ionsusually associated with a high level of multidrug
tesistance in our samples. More-detailed molecular studies
Withstrictly defined patient groups may further elucidate this
hYpothesis.Molecular markers are a valuable tool for predict-
Ingdrug resistance in epidemiological studies. At present, un-
[Orlunately, most molecular typing and mutation detection
methods can only be applied to cultivated bacteria [about 10-'
copiesof the genets] are needed to obtain good results in these
assays].Development of methods for uncultivated clinical ma-
;erial will accelerate their introduction in clinical practice
lhroughout the world.
! This work was supported! by grants from the European Community,
'\CO-Copernicus Project ERBICI5-C1f9R-0328 (Sven Hoffner, Coor-
J:n"tor), and the Council of Sciences of Latvia (program no. 12-9-1410.
We thank I1va POll; for the DNA isolation and Liana Pliss for
::thnical assistance, We are also grateful to Petras Stakenas and Daiva
,;"koilyte (Institute of Biotechnology, Vilnius, Lithuania) for advice
I~J to Eskikl Peterson (Statens Serum Institut, Copenhagen, Den.
~l'''k)and Vitauts Kalnins (University of Toronto, Toronto. Canada)
"'I '(heir help in preparing the manuscript.
J. CUN. MlcRORIOL
REFERENCES
I. Bartfa" z., A. Somoskovi, C. Kodmon, N. Szabo, E. Puskas, L Kosztolam,
E. Farago, J. Mester, L M. Parsons, and M. Saltinger. 2001. Molecular
characterization of Mycobaeten"um tuberculosis from Hungary by DNA sc-
queueing and the Line Probe assay. J. Clin. Microbiol. 39~1767-3769.
2. Bernstein, J., W. A. Lott, B. A. Steinberg, and H. L Yale. 1952. Chemother-
apy of experimental tuberculosis. lsonicotinic acid hydrazide (nydrazid) and
related compounds, Am. Rev. Tuberc 65:357-304.
3. Darzins, E. 1958. The bacteriology of tuberculosis. University of Minnesota
Press, Minneapolis.
4. Dobner, P., S. Rusch-Gerdes, G. Brelzel, K. Feldmannn, M. Rira •• T. LOs-
cher, and H. Rinder. 1997. Usefulness of M. tuberculosis genomic mutations
in the genes kalG and inh.A for the prediction of isoniazid resistance. Lnt. J.
Tuberc. Lung Dis. t:365-369.
5. Haas, W. H~ K. Schilke, J. Brand, B. Amtbor, K. Weyer, P. B. Fourie, G.
Brelzd, V. Sticbt-Gron, and H. J. Bremer. 1997. Molecular analysis of katG
mutations in strains of Mycobacten"um tuberculosis complex from Africa.
Antimierob. Agents Cbemotber. 41:1601-1603.
6. Hawkins, J~ R. Wallace, and B. Brown. 1991. Antibacterial susceptibility
tests: mycobacteria, p. 113&-1152. In A Balows, J. Hausler, K. Herrmann, H.
Isenberg, and H. Shadomy (ed.), Manual of clinical microbiology, 5th ed.
American Society for Microbiology, Washington, D.C.
7. Heym, B~ Y. Zhang, S. Paule I, D. Young, and S. Cole. 1993. Characterization
of the katG gene encoding a catalase-peroxidase required for isoniazid sus-
ceptibility of Mycobacten"um tuberculosis. J. Bacterial. 13:4255-4259.
8. Lee, A., I. Urn, L Lynn, H. Tang, A. Telentl, and S. W. Wong. 1999.
Contribution of lanA analysis to detection of isoniazid-resistant Mycobacte-
rium tuberculosis in Singapore. Antimierob. Agents Cbemother. 43:20R7-2OIl9.
9. Lee A. S., A. S. Teo, and S. Y. Wong. 2001. Novel mutation in ndh in
isoniazid-resistant Mycobtu:ten"um tuberculosis isolates. Antimicrob. Agents
Chemotber. 45:2157-2159.
10. Martilla, H~ H. Soini, E. Eerola, E. Vysboevskaya, B. Vysbnevskiy, T. Otten,
A. Vasilyd, and M. Viljanen. 1991l. A Ser315Thr substitution in KatG is
predominant in genetically heterogeneous multidrug-resistant M. tuberculo-
sis isolates originating from the St. Petersburg area in Russia. Ant im ic rob.
Agents Chernother. 42:2443-2445.
II. Mnsser, J. M. 1995. Antimicrobial agent resistance in mycobacteria: molec-
ular genetic insights. Oin. Microbiol. Rev. 8:4%-514.
12. Pablos-Mendez, A., M. C. Ravlglone, A. Laszlo, N. BinlUo, H. L. Rieder, F.
Bustreo, D. L Cohn, C. S. B. Lambregts-van Weezenbeek, S. J. Kim, P.
Cbaulet, and P. NUDD. 1998. Global surveillance for antituberculosis-drug
resistance. N. Engl. J. Med 338:164I-t049.
13. Roberts, G., E. Kaoeman, and K. Kim. 1991. Mycobacterium, p. 304--349. III
A Balows, J. Hausler, K. Herrmann, H. Isenberg, and H. Shadorny (ed.),
Manual of clinical microbiology, 51h ed, American Society for Microbiology,
Washington, D.C.
14. Rossau, R., H. Tnore, H. Beeuboower, W. MI,js, G. Jannes, P. Rijk, and F.
Portaels. 1997. Evaluation of the INNO-LiPA Rif. TB assay, a reverse
hybridization assay for the simultaneous detection of Mycobacterium tuber-
culosis complex and its resistance to rifampin. Antimicrob. Agents Che-
mother. 41:2093-2098.
15. Rouse, D. A., Z. 'll, G. H. Bai, and S. L Morris. 1995. Charactetization of the
kJJJG and inM genes of isoniazid-resistant clinica] isolates of Mycobacterium
tuberculosl. r. Antimicrob. Agents Chemother. 39:2472-24TI.
16. Sander, P~ and 'E. C. BOttger. 1999. Mycobacteria: genetics of resistance and
implications for treatment, Chemotherapy 45:95-108.
17. Selvalwmar, N~ S. M. WIlson, R. McNeme" and P. R. Nanyanan. 1997.
Single strand conformation polymorphism profiles with biotinylated PCR
products to detect mutations in rpoD gene of Mycobacterium tuberculosis.
Curro Sci. 73:77~777.
18. Stroll& B~ and G. Kubica. 1981. Isolation and identification of MYcobacte-
rium tuberculosis, A guide for the level U laboratory. DHHC publication no.
(CDq 81=8390. Centers for Disease Control, Atlanta, Ga.
19. Teleoti, A., P. Imboden, F. MarchesI, D. Lowrie, S. Cole, J. Colston, L.
Matter, K. Schopfer, and T. Bodmer. 1993. Detection of rifampicin-resistant
mutations in Mycobacrcium tuberculosis. Lancet 341;647-M0.
20. Van Sooliogeo, D., P. E. W. Haas, ,P. W. M. IHermans, and J. D. A. van
EmMell. 1999. RFLP analysis of mycobacteria. Manual for fingerprinting of
M. tuberculosis strains. National Institute of Public Health and Environmen-
tal Protection, Bilthoven, The Netherlands.
21'. Van Sootingen, D~ P. E. W. Ha as, Hi. R. van Doom, E. Kuijper, H. Rinder.
and M. W. Borgdorl[ 2000. Mutations at amino acid position 315 of the kate:
gene are associated with high-level resistance 10 isoniazid, other drug resis-
tance, and successful transmission of Mycobactt:.rium tuberculosis in The
Netherlands. J. Infect. Dis. 1'82:1788--1790.
22. WilSQD, 1'., .nd D. Collins. 1990. AhpC, a gene involved in isoniazu! rcsis-
tance of the Mycobacten"um tuberculosis complex. Mo]. Microbiol. 19:102"-
1034.
23. Zhang. Y., and D. VOUDg. 1994. Strain variation lin the kate; regu m ll:
Mycobaeten"um tuberculosis. Mo.1. Microbiol. 14:301-301\.

Acta Universitatis Latviensis. 2003, Vol. 662, pp. 17-24
Evaluation of the insertion-sequence-6110-
based polymerase chain reaction for detection of
pathogenic mycobacteria
Viesturs Baumanis', Inta .Jansone', Lonija Broka", Anda Nodleva",
Mihails Bratkovskis", Tatjana Tracevska"
'Laboratory of Molecular Microbiology, Biomedical Research and Study Centre, University of
Latvia, Ratsupttes iela I, Riga, LV-I067, Latvia
2SlateCentre of Tuberculosis and Lung Diseases, Stopini, RIgas rajons, LV-2118, Latvia
]RTgaStradins University, Dzirciema iela 16, RIga, LV-lOO7,Latvia
*Corresponding author, E-mail: latjanap@biomed.lu.Jv
Abstract
The insertion sequence IS6110 is a mobile genetic element typical forMycobacterium tuberculosis
complex (MTC) bacteria. Due to its narrow host range, this insertion element can be used for rapid
identification of pathogenic mycobacteria. The aim of this study was to evaluate the diagnostic
value of the IS6110 element in comparison with common molecular and microbiological methods.
A total of 170 clinical specimens from tuberculosis (TB) patients were tested for the presence
of IS6110 by polymerase chain reaction (PCR). Detection of MTC by lS611o-PCR revealed the
highest number of MfC positive specimens (40.6 %) in comparison to commercial Lex assay
(27.6 %) and to the commonly used methods for estimating bacteria growth: BACfEC system
(20.6 %) and on Lowenstein-Jensen medium (15.3 %). IS6110-PCR was shown to be a rapid and
specific method for identification of the Mycobacterium tuberculosis complex. It was found to be
especially useful for confirming diagnosis in cases of smear- and culture-negative results, when the
clinical expansion of tuberculosis was obvious.
Key words: Identification, insertion sequence 6110, Mycobacterium tuberculosis complex,
polymerase chain reaction.
Introduction
Mobile genetic elements like insertion sequences (IS) and transposons are found
in bacteria, archaebacteria and eukaryotes. Insertion sequences are DNA fragments
encoding their own ability to transpose within the genome. The function of most mobile
genetic elements is unknown and they are usually considered to be genome parasites. In
the genus Mycobacterium, there are three groups of IS, which are usually host specific.
IS are between 880 bp and 2260 bp long and are found in one to more than 20 copies in
the chromosome (Guilhot et, al. 1999). One of those, a 1361 bp long insertion sequence
named 156110, first described by Thierry et al (1990), is present in the Mycobacterium
tuberculosis complex (MTC) only. MTC contains four genetically and serologically
related pathogens causing disease in human and in cattle: M. tuberculosis. M. bovis, M.
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africanum and M. microti. The majority of investigated MTC strains contained between
5 and 20 copies of IS611 0 located in various places of the genome (van Soolingen et al.
1993).
Recent achievements in molecular microbiology such as complete genome
sequencing of the M. tuberculosis H37Rv strain opened new perspectives in the study
of mycobacteria (Cole et al. 1998). At the same time, a dramatic increase of tuberculosis
(TB) incidence worldwide in the last decades induced an urgent need for new molecular
markers enabling rapid detection of MTC, a mean causative agent for TB. It is known that
smear examination may not be effective in non-pulmonary, pediatric or paucibacillary
disease, or where HIV is prevalent (Rigouts, Portaels 2(01). Recently developed
molecular methods based on detection of mycobacterial proteins (protein antigen B),
16S rRNA or DNA fragments, are dissolving this problem. Of these methods, the
amplification of insertion sequences is most commonly used. IS611O-based PCR enables
detection of nucleic acids from MTC directly in clinical specimens: sputum, bronchial
washings, urine etc. (Eisenach et al. 1988; Hance et al. 1989). IS6110- PCR is a more
rapid, sensitive and specific in comparison to other methods routinely used in clinical
laboratories; such as smear microscopy, and culturing on solid and on liquid media
(American Thoracic Society Workshop 1997). Detection of MTC in cerebrospinal fluid
(CSF) from patients suspected to have tuberculous meningitis is of great value since
cultivation and microscopy may often fail to reveal a low amount of bacteria.
In this study, IS6ll0 was chosen due to several reasons. Firstly, a narrow host range
of the IS6110 allows use of this element for precise identification of MTC. Secondly, it
is usually present in more than five copies and can be used as a molecular marker for
strain differentiation in epidemiological studies (van Soolingen et al. 1993). The aim
of our study was to evaluate the sensitivity and specificity of the IS6110 amplification
method on smear-negative samples, in comparison with smear microscopy and culturing
on solid Lowenstein-Jensen medium. We expected a higher sensitivity of IS611O-PCR
in comparison to commercially available systems for TB detection and MTC culturing,
such as the Abbott LCx assay and BACfEC. LCx assay is a DNA-related TB diagnostic
system based on protein antigen b gene fragment amplification (Andresen, Hansen
1989), but perhaps, is not as sensitive as IS6110-PCR since only one copy of the antigen
b gene is present in the MTC genome. BACfEC is a precise radiometric system for
mycobacteria growth detection, but it usually requires several weeks to grow a sufficient
amount of bacteria.
Materials and methods
In total more than 250 specimens of bronchial washings (76 %), sputum (11 %),
cerebrospinal fluid (4.3 %), urine (3.5 %), smear (2.6 %) and stomach washings (2.6 %)
were obtained from Latvian patients admitted in 1998-1999 to the State Centre of
Tuberculosis and Lung Diseases with suspected and confirmed TB. The patients had
clinical symptoms of lung diseases or had suspicion of pulmonary/extrapulmonary
tuberculosis shown by clinical and/or X-ray examination. Each patient was represented
by one specimen or, in several cases, by various specimens from different locations. The
specimens were directed for TB detection by the Abbott Lex (Ligase Chain Reaction)
commercial kit (Abbott laboratories. Illinois, USA), mostly in cases when bacteria growth
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was negative on the BACTEC system (Becton-Dickinson, Sparks, USA) or with repeated
smear-negative bacterioscopy results. In our study, 157 smear-negative specimens were
selected, allowing to test whether IS6110-PCR is more sensitive in comparison to the
commonly used methods. A small control group of 13 specimens with smear-positive
bacterioscopy results was included. The results of our study were interpreted in the
context of the clinical findings, TB history and the efficiency of chemotherapy.
All specimens were collected and processed by the standard N-acetyl-L-cysteine-
NaOH procedure (Kubica et al. 1963). Smears were analyzed by fluorescent microscopy
and the corresponding samples were inoculated on solid (Lewenstein-Jensen) and liquid
(BACfEC) mediums. The LCx assay was performed at the Centre of Tuberculosis in
accordance with the manufacturer's recommendations (Ausina et al. 1997). DNA isolates
for LCx reaction contained 0.5 ml LCx buffer, 27 mM MgCl2, NaN) and glass beads. After
the Lex analysis IS6IIO-PCR was directly applied to samples. The DNA concentration
method (Boom et al. 1990) was used for extraction of DNA from several smear-negative
specimens of CSF and bronchial washings received in year 200 I.
The 245 bp fragment (from 633 to 877 nucleotide positions of the IS6IlO sequence)
was amplified in house using primers 5'-CGTGAGGGCATCGAGGTGGC-3' and 5'-
GCGTAGGCGTCGGTCACAAA-3' (Hermans et al. 1990). Initially, the nested PCR
method was used. At the first step, a 1224 bp fragment (from 47 to 1270 nucleotide
positions) ofIS61 10 was amplified and was used as a reaction template at the second step,
where a 245 bp fragment was produced. Later, the first step of nested PCR was omitted
since it did not show any advantages and the 245 bp fragment was directly amplified
from specimens. Five jJl of DNA isolate in LCx buffer was added to the PCR mixture
[containing PCR buffer with (NH4)2S04' 200 jJM of each dNTPs, 10 pmoles of each
primer and 1 U ofTaq DNA Polymerase 9MBI Fermentas, Vilnius, Lithuania)] to a final
volume of 25 jJI. The optimized cycling protocol was used a Progene cycler (Techne,
Cambridge, England) with initial denaturation at 95 "C for 2 min, followed by 40 cycles
(95 "C for 15 s, 65°C for 20 s, 72 "C for 1 min) and a final extension (72 "C for 10 min).
PCR products were analyzed by electrophoresis in 2 % agarose gel (BioRAD, Hercules,
USA) and were visualized with ethydium bromide. A positive PCR signal indicated the
presence of the MTC genome. In each set of reactions, one negative control and one
positive control (DNA from the M. bovis BCG vaccine strain) were included. The reaction
specificity was confirmed by digestion with Pvull (MBI Fermentas, VIlnius, Lithuania)
and by hybridization with an appropriate 32S-labeled fragment. Testing was repeated on
specimens with negative amplification results, with an external addition of control DNA
from the M. bovis BCG strain in order to evaluate the presence of a PCR inhibitor.
Results
The detection limit of IS6IIO-PCR, estimated by amplification of serial dilutions of DNA
from the M. bovis BCG strain containing only one copy of IS6110, was 5 fg per probe.
This amount of DNA can be isolated from two bacterial cells, meaning that our PCR
method is able to detect at least two bacteria, each containing one copy of IS611O. The
fact that MTC usually contains more than one IS6110 copy increases the detection level
of our in house method.
The comparative results of MTC detection in 170 specimens are shown in Table I.
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Table 1. Comparison of the in house IS6110-PCR method and TC clinical laboratory results
obtained for 170 specimens. ". number of PCR false positive after adjustment with LCx results and
samples suspected in cross contamination
Method used MTC positive
(total n= 170)
13 (7.6 %)
26 (15.3 %)
Discrepancy (PCR-positive
and 1-4 method-negati ve)
56 (32.5 %)
39 (22.9 %)
Bacterioseopy
Growth on
Lowenstein-Jensen medium
Growth in BACfEC system
Lex assay
IS611O-PCR
35 (20.6 %)
47 (27.6 %)
69 (40.6 %)
44/25* (25.8 % /14.7 %*)
32 (18.8 %)
Detection of MTC by IS611O-PCR revealed the highest number of MTC positive
specimens (40.6 %) in comparison to Lex assay (27.6 %) and to the commonly used
methods for estimation of bacteria growth: on BACfEC (20.6 %) and on Lowenstein-
Jensen (15.3 %) mediums. Smear microscopy (bacterioscopy), which is reliable in
detecting MTC bacteria only when present in high amounts, was the least sensitive with
13 (7.6 %) MTC positive specimens. This group of 13 specimens was MTC positive by
all of the remaining methods (100 % specificity for smear-positive specimens).
IS6110-PCR was the most sensitive method in comparison to Lex assay and to other
clinical laboratory methods. However, the lack of a "golden standard" for amplification
methods does not exclude false positive results. Therefore, cultivation on BACfEC
radiometric liquid system is still considered to be the most reliable tool for detection of
MTC (Nordhoek et al. 1994). Sensitivity and specificity of PCR was estimated on the
basis of BACfEC results (Elder et al. 1997). Thus, 91 PCR negative results and 26 PCR
positive results (together 68.8 %) were in accordance with BACfEC system, and were
considered as true negative and true positive, respectively. PCR gave positive results in 44
(25.8 %) cases. Of 44 PCR-positive results 12 were correlated with Lex assay results, but
not with BACfEC results, a method internationally considered as a standard method for
detection of M. tuberculosis. Therefore, these PCR results should be considered as false
positive, and the overall specificity for IS611O-PCR estimated as 67.0 %. After charging
of 32 PCR and Lex discrepant results plus seven suspected cross-eontaminated samples,
the total number of false positive results was 25 and the PCR specificity was 79.0 %.
Nine (5.2 %) discrepant PCR-negative and BACfEC-positive results were observed,
thus the estimated overall PCR sensitivity was 72 %. There were nine (5.2 %) discrepant
PCR-negative and LCx-positive cases and four (2.3 %) discrepant PCR negative and
Lowensten-Jensen culture-positive cases. False positive LCx or BACfEC results may
have been caused by laboratory contamination. False negative results may be explained
also by the absence of IS6110 fragment in the M. tuberculosis pathogen also. Inhibition
of amplification reaction by remains of clumps, blood and urine present in a specimen is
another probable cause for false negative PCR (Forbes 1997).
Clinical material isolated from CSF was studied as in this case there was an obvious
requirement for rapid and precise diagnostics. In our study, seven smear and culture-
negative CSF specimens showed negative results by both amplification methods (IS61 10-
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Table 2. Evaluation of PeR-based methods applied on clinical material isolated by Boom method.
SCF, cerebrospinal fluid; L, bronchial washing; -, negative PeR signal; +, positive PeR signal,
indicating the presence of MTC genome; ++, strong positive signal; +W, weak positive signal; Wf,
wild type (no resistance encoding mutation found). H37R v strain was used as a PeR positive con-
trol, Band C types are different groups of genetic patterns, revealed by molecular typing of MTC
bacteria
Clinical IS6110- Rifampin Rifampin Isoniazid Mixed Evaluation Clinical
number PCR suscept. suscept. suscept. linker based diagnosis
by Inno-LiPA by rpoB by katG PeR on PeR
kit gene gene typing results
sequencing sequencing pattern
CSF 3024 + wr wr wr Btype Drug Tuberculous
suscept. meningitis
TB
CSF 3025 ++ wr wr wr B type Drug Tuberculous
suscept, meningitis
TB
L-202 + wr wr wr Ctype Drug LungTB
suscept.
TB
L- 204 +w wr wr Atypical False Atypical
positive pneumonia
H37Rv ++ wr wr wr Typical
strain
PCR and Lex). The results were correlated with the clinical findings. Later, several
specimens were received from patients with suspicion of TB or tuberculous meningitis,
although they had smear-negative results. The specimens were analyzed using the Boom
(Boom et. al. 1990) method. by increasing the DNA concentration. All of these samples
showed positive IS611Q-PCR results, confirming the presence of MTC bacteria. In
addition to IS611Q-PCR, drug susceptibility molecular tests and PCR-based molecular
typing were performed in the Biomedical Research and Study Centre. The results ofPCR-
based methods for MfC detection, molecular drug susceptibility testing and molecular
typing of several specimens are summarized in Table 2. In three cases (CSF-3024,
CSF-3025 and L-202), our results were in good agreement with the clinical findings and
were used for elaboration of therapeutic strategy. In one case (L-204), the PCR methods
showed a weak amplification signal and an atypical genetic pattern in Mixed Linker
PCR. A suspicion of a false positive result was confirmed by the diagnosis of atypical
pneumonia. Unfortunately, Abbott LCx assay was not applied to these specimens, and
laboratory investigations, except as smear negative bacterioscopy, were not available.
Anti-TB chemotherapy was begun for these drug-susceptible persons.
Interestingly, only two of these methods, IS611O-PCR and Mixed-Linker PCR,
were initially designed for a low amount of DNA present in clinical material. The
described molecular methods for drug susceptibility testing (lnno-LiPA kit, rpoB and
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katG gene fragment sequencing) are usually applied for larger amounts of DNA isolated
from bacterial culture. In most cases, a low content of DNA is an obstacle for further
application of molecular methods in clinical material. In our study, these methods were
shown to be sensitive enough to give correct results for clinical material when DNA was
concentrated using the Boom method.
Discussion
Nucleic acid amplification gives the best chance of detecting MTC in smear negative
samples. IS61IO-PCR is rapid and relatively simple method; PCR results are available
in I or 2 days instead of several weeks needed to growth mycobacteria in the BACfEC
system. IS6l IO-PCR was shown to be able to detect a mycobacterial genome in variable
clinical material- sputum, bronchial lavage, CSF etc. The results were comparable with
other studies in which PeR was used for diagnosis of (mainly pulmonary) TB, where
the sensitivity and specificity ranged between 70-100 % when a culture of MTC was
taken as golden standard (Forbes 1997). However, in practice, many problems occur
due to inhibition or due to cross-contamination with the products from previous PeRs
(Nordhoek et al. 1994). We separated rooms and instruments used at each PCR step:
PeR mixture preparation, sample addition and PeR product analysis. Also, specimens
with negative PCR results were controlled for the presence of inhibitors. For this aim,
PeR-negative specimens were repeatedly tested with a parallel addition of M. bovis
DNA. Absence or weak. amplification of M. bovis BCG DNA indicated the presence of
inhibiting factor.
As PCR is able to detect both dead and live MTC bacteria, some patients may remain
PeR-positive for mycobacterial DNA several months after treatment. Therefore, 44
discrepant PCR-positive and BACfEC-negative samples were evaluated in the context of
the clinical findings. Clinical data was available for 38 patients. Fifteen (39.5 %) of them
had active TE, confirmed clinically and by X-ray examination. Eight patients had already
received a drug therapy course for a period from three days to several months and seven
patients have not started treatment. Interestingly, only four of those patients were detected
as MTC-positive by Lex assay. Eight (21 %) patients had inactive TB with after-effects,
thus confirming that PCR can detect dead or dormant mycobacteria. In general, the
clinical findings were in agreement with the shown presence of the MTC genome among
66 % of the false positive samples. Seven (18 %) specimens were, possibly, contaminated
during the bronchoscopy procedure. Extrapolation of the PCR results for the remaining
six (16 %) patients was problematic.
This study showed the advantages of PCR-based TB detection prior to mycobacteria
culturing and admitting of chemotherapy. It is likely that, in the cases of smear positive
results, there is no additional need in IS61l0-PCR, and it is useful only to distinguish
MTC from the other acid-fast bacteria. Therefore, IS611O-PCR can be recommended in
cases of smear- or BACfEC-negative results. Invention of PCR-based detection methods
may increase a number of recovered TB cases and may dramatically shorten the time
required for TB diagnostics.
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Kopsavilkums
Insercijas sekvence IS61 10 ir Mycobacterium tuberculosis kompleksam (MTC) raksturtgs mobilais
genetiskais elements. Saimnieku loks sirn insercijas elementam ir burs, un Uidel to var lietot
mikobakteriju a.trai noteiksanai. Darba me~s bija salrdzinat M genetiska elementa diagnostisko
vernbu ar paztstamam rnolekularam un mikrobiologiskam metodem. Dazadus ldTniskos paraugus no
170 tuberkulozes slimniekiem pa.rbaudTja uz IS61 10 klatbntni ar polimerazes ~edes reak.ciju (PCR).
MTC noteiksana ar IS6110-PCR deva visaugsUiko pozitrvo atbildi (40,6 %), salIdzinot ar Lex
testu (27,6 %) un Ui~ noteiksanas rnetodem ka.bakteriju kultivebna BACfEC sistema. (20,6 %)
vai uz Levensteina-Jensena barotnes (15,3 %). Paradns, ka IS611D-PCR ir lira un specifiska
MTC identifikacijas metode. Tai ir tpasa vertrba tajos gadIjumos, bel ir nepieciesams apstiprinat
rnikobakteriju klatbnmi, ja mikroskopiskll. izmeklesana un kuhivesana bijusas nesekmIgas.
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SETTING: Predominant genotypes of Mycobacterium
tuberculosis include the Beijing family, which has caused
large tuberculosis outbreaks and has been associated with
increased virulence and multidrug resistance (MDR).
OBJECTIVE: To search for the Beijing genotype among
latvian MDR patients to characterize their DNA iso-
lates at the molecular level.
DESIGN: 109 MDR isolates were spoligotyped and tested
for gene mutations by automatic nucleotide sequencing.
RESULTS: Of the 109 isolates examined, 95 were
located in six clusters of 2 to 63 isolates each. The 63
isolates in the largest cluster had an identical pattern
corresponding to the Beijing genotype. The remaining
isolates were of a non-Beijing genotype and formed
another large group whose similarity ranged from 72%
to 100%. Mutations in the rpoB and katG genes were
compared in the Beijing and non-Beijing strains. In both
groups, the rpoB gene mutations predominated in
codons S531L (52.2%) and D516V (14.7%). Double
mutations in the rpoB gene were observed in 8.2 % of the
isolates, most of them located among Beijing-type iso-
lates. The katG gene mutation S315T (98.4 %) was
prevalent among all isolates.
CONCLUSION: Molecular analysis of MDR isolates of
M. tuberculosis demonstrates that the Beijing genotype,
most likely due to recent transmission, is prevalent in
Latvia among MDR patients and that this genotype can
be associated with double mutations.
KEY WORDS: tuberculosis; drug resistance, multiple;
genotype; mutation; DNA fingerprinting
STRAINS OF the Beijing genotype of Mycobacterium
tuberculosis have been responsible for considerable
morbidity and mortality worldwide. I This genetically
highly conserved family of strains has caused large
outbreaks of tuberculosis (TB) predominantly affect-
ing young people. The Beijing genotype strains are
often resistant to isoniazid (INH) and streptomycin
(SM) and are associated with multi-drug resistance
(MDR).12 The Beijing genotype is also reported to have
a selective advantage over the other M. tuberculosis
genotypes] and induce a febrile response to treatment."
The Beijing genotype predominates in China and some
geographic areas of Asia and Eastern Europe.l-' and
now seems to be spreading ro other areas in the world.
Latvia IS one of the countries with the highest rate
of MDR-TB in the world." Between 1999 and 2001,
primary MDR-TB reached 9%, and since 1991 the
MDR incidence has increased 2.4 times. In a response
to these alarming numbers the DOTS (directly
observed treatment, short course) strategy was imple-
mented in 1995, and DOTS-Plus in 1997.7
The aim of the present study was to examine the
previously undetermined prevalence of the Beijing
genotype of M. tuberculosis in Latvian MDR isolates.
We also analyzed mutations in the katG and rpoB
genes of M. tuberculosis which are known in parr to
determine INHH and rifampin (RMP)~ resistance. We
compared the mutations in isolates of the Beijing ge-
notype with those in the other isolates to determine
whether specific predominant gene mutations can be
used as genetic markers for MDR in countries with a
high incidence of MDR-TB.
MATERIALS AND METHODS
Spacer oligonucleotide typing (spoligoryping) can be
regarded as the gold standard for the identification of
the Beijing genotype in strains of M. tuberculosis.!
Hybridization to spacers 35 to 43 in the polymorphic
DR region of M. tuberculosis DNA is 100% specific
for the Beijing genotype. In this study, 109 cultures
were randomly selected from typical Latvian MDR
TB patients (28 female and 81 male) with primary
(36%) and relapsed (64%) pulmonary TB cases. The
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random selection of our samples reflects rhe rare of
primary (33%») and relapsed (6J,5'Y,,). ,\lDR-TB III
general population. M. tuberculosis infection between
1999 and 200 1. Patients ranged in age from 2 I 10 71
Years, with a mean age of 44 Years. Each patient was
resistant ar least 10 RMP and JNH and contributed
only one isolate of M. tuberculosis. Selected cui lures
represenred about 25°1.. of all MDR culrur cs ohr.uncd
annually by the Stare Tuberculosis and l.ung Disease
Centre, where all Latvian TB parienrs are rnoni-
rored. Culrures were grown on l.owcnsrein-jensen
'Lj) medium slanrs for 4-6 weeks. Drug suscepribiliry
.vas derermined by using borh rhe BACTEC sysrem
(Becton Dickinson, Sparks, MDl and rhe absolure
concenrrarion merhod on slanrs.!"'! Critical concert-
rrarions for INH were 0.2 ug/rnl and 2.0 ug/rnl in LJ
medium and 0.1 ug/rnl in the BACTEC system, while
for RMP they were 40.0 ~g/ml in LJ medium and 2.0
ug/rnl in the BACTEC sysrem. Genomic DNA was iso-
lated from cultivated bacreria by an internationally
srandardized procedure!' and dissolved in TE buffer.
Spoligoryping was performed on the 109 Latvian
MDR isolates in the International Reference Labora-
tory of Mycobacteriology, Srarens Serum Institute,
Copenhagen, Denmark. For spoligoryping, a 20-fold
dilution of M. tuberculosis DNA was used for poly-
merase chain reacrion (PCR) and subsequent hybrid-
ization reacrions as previously described. I ; The H3 7R v
srrain was used as a positive control. Auroradiograms
were scanned and analyzed using the GeiCompar
software version 4.0 (Applied Marhs, Kortrirjk, Bel-
gium), and similarity analysis were based on the Jac-
card correlation coefficient (maximum rolerance 2.0%)
and the UPGMA clustering method. All spoligopat-
terns identified by the GelCompar software as more
than 80% identical were controlled visually. A cluster
was defined as two or more isolates having spoligo-
patterns that were 100% idenrica I.
Automatic nucleotide sequencing. The 109 M.
tuberculosis isolates were analyzed for mutations carry-
ing the RMP and INH resistance by nucleotide sequenc-
·ng of the rpoB and katG gene fragments. A 257 bp
fragment of the rpoB gene, that determines RMP
resistance in 96% of the cases," was amplified using
primers with the following sequences!": 71.8-5'-
GGTCGGCATGTCGCGGATGG-3' and 72.8-5'-
GCACGTCGCGGACC.TCCAGe-3'. A 704 bp frag-
ment of the katG gene was amplified using the direcr
primer 74-5' -CGGGATCCGCTGGAGCAGATGG
Ge-3', targeting to the 52 end nucleorides before the
codon 315 and the reverse primer 75-5'-CGGAAT
TCCAGGGTGCGAATGACCT-3', positioned 158
nucleorides downstream from codon 463." DNA
from M. bouis BCG-Connaughr strain W~IS used as the
drug susceptible control in both reactions. The purified
PCR producrs were applied for auromanc nucleotide
sequencing of both chains using the ARt PRISM Big-
Dyel" Terminaror Cycle Sequencing Reaction Kit,
and the results were read by rhe ABI PRISM \ I DO
DNA Analyser (Applied Biosysrerns. USA).
RESULTS
Spoilgotypmg
Twenty vananrs of spoligoparrerns were drstm
guished Oil 109 MDR isolares of M. tuberculosis tested
by spoligoryping (Figure 1). Of the 109 isola res, 95
were located in six different clusrers of 2 ro 63 ISO-
lares each, of which the two largest clusters accounted
for 63 and 19 isolates each (Figure 2). The remaining
14 isolates did nor show clustering. As indica red 111
the dendrogramme (Figure 2), rhe 109 isolates could
be subdivided inro two main groups, one containing
63 and the other 46 isolates. The largest one, called
the 'Beijing genotype' group, was formed by the 63
(58%) isolates, all showing Beijing-characrerisric
nine-spacer spoligopatrerns (spacers 35--43) and lack-
ing spacers 1-34 (Figure 1, SPI). The Beijing geno-
type group was the largest cluster of spoligopanerns.
Anorher main group, called 'non-Beijing', was
formed by the 46 isolates with 19 variants of spoligo-
patterns (Figure I, SP2-SP20) and is shown at the £01'
of the dendrograrnme (Figure 2). In this group is rhe
second largest cluster after Beijing, consisting of 19
isolates (Figure 1, SP12). All except one non-Beijing
isolate shared >72% pattern similarity within the
group. The one isolate had a spoligoparrern (Figure 1,
SP2), different from those in borh groups; its similar-
ity coefficient with the non-Beijing group was less
than 40%. This isolate was included in the non-
Beijing group, however, as it did nor share the spo-
ligopartern wirh the Beijing group and had Arginine
(Arg) at codon 463 of the katG gene (see below).
Automatic nucleotide sequencing
The rpoB gene 257 bp fragment sequencing results
for the 109 MDR M. tuberculosis isolates are shown in
the Table. Altogether, 16 varianrs in single and double
codon mutations were found in 102 (93.6%) of 109
isolates, including the isolate with the combination of
codon deletion and two codon mutations at positions
524-527. In both groups of Beijing and non-Beijing
genorype, the following rpoB gene mutations pre-
dominate: S53IL in 52.2% and D516V in 14.7% of
the 109 isolates. Altogether, nine double mutations
were detected, six of which were located at different
pairs of codons and eight of those were found in iso-
lares comprising Beijing genorype. Finally, the 63
Beijing isolates showed a higher percentage of double
mutations (12.7%) in comparison to the group of 46
non-Beijing isola res (2.2%) (P < 0.05). Several iso-
lares (6%) did nor comain mutations in the region
examined.
The katG gene fragmenr sequencing showed a Sill·
gil.' nucleoride change ar codon 315 in 107 (n.4'Yo) of
rhe 108 isolares for which sequencing results were
Figure 1 Computer-generated, nor-
malised irnaqe showing 20 represent-
ative variants of spoligopatterns,
H37Rv is the standard reference strain
and the rest, SPl to SP20, are variants
of spoliqopatterns.
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Figure 2 Results of sponqorvpinq of 109 MDR M tuberculovs Isolates and the correspondmg
dendrogram SPI and SP12 are spoliqopatterns of the isolates located rn the two largest clusters
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Table Mutations ,n 257 bp fragment of the rpoB gene found
In 109 MDR rsolates of M tooercotos«
Mutation
localization
Number of
rnuranons In
63 Isolates
with
Beijing
genotype
34 (54%)
B (12.6%)
5
4
57 (522)
16 (147)
5 (46)
4 (3 7)
5 (46)
3 (2.8)
2 (1.8)
1 (0.9)
1 (09)
1 (09)
2 (1.8)
1 (0.9)
1 (09)
1 (09)
1 (0.9)
Number of
rnutanons In
46 Isolates of
non-Beijmq
genotype
23 (50%)
8(17%)
Mutations in
all 109
M. tuoercutosis
MDR Isolates
5531L
D516V
D516Y + P3535
5531F
H526D
H526Y
D516Y
H526L
H526R
5531W
L53JP
Q51OH+H526Y
D516V+P535L
D516V+K519T
R529P+5531 L
Deletion + mut.
(524-527)
Wild type
5
2
5
1 (0.9)
7 (64)
1
2
available. in 103 (94.7% l isolates it was change AGe--+
ACC, and in four (3.7%) it was a mixture of ACC
and ACA. The 4 isolates with ACC and ACA mixture
position 315 had different IS611O-RFLP patterns
(data not shown). In all 107 strains, the nucleotide
change from AGC ro ACC or ACA resulted in substi-
tution of Serine (Ser) for Threonine [Thr). in one
(0.9%) of the 108 isolates the 704bp long kate gene
fragment did not contain a mutation. All isolates with
the Beijing genotype had the same substitution: S315T.
In addition, a genetic polymorphism at codon 463
of the kate gene was detected by automatic DNA
sequencing. All 63 isolates comprising in the Beijing
group had Leucine (Leu) (CTG) at position 463 of
the 704 bp fragment of the kate gene. Whereas 45
of the 46 isolates from the non-Beijing group showed
Arg (CGG) at position 463 including the isolate shar-
ing less than 40% similarity with other members of
this group (Figure 1, SP2). The remaining one isolate
(Figure 1, SP20) of 46 within the non-Beijing group
showed a mixture of Leu and Arg at position 463
indicating the presence of two strains in this sample.
Indeed, RFLP analysis showed a high number (n =
25) of 156110 bands for this sample (data not shown).
No further investigation of this sample was possible
since the corresponding culture was not preserved.
DISCUSSION
Spoligoryping of the 109 MDR M. tuberculosis iso-
lates revealed a high number of Beijing genotype
strains among MDR patients in Latvia. The specific
reason for the high prevalence of this genotype is
unknown, but explanations include: more recent
transmission of Beijing MDR strains, higher virulence
of Beijing MDR strains, higher evolutionary develop-
menr of strains with the Belling genotype and devel-
opmem of MDR strains as a result of prolonged inad-
equate chernorherapy.! It IS also unknown, whether
the Beijing genotype has a higher probability of
acquiring drug resistance than the other M. tuber-
culosis genotypes. A less likely explanation for the sit-
uation in Latvia could be the evolution of bacteria.
The high prevalence of the Beijing genotype among
MDR-TB patients in Latvia from 1999 to 20001 can
be partly explained by recent transmission. It was
shown that the sample of 63 MDR isolates of the
Beijing group described above have 8(}-100% identi-
cal IS611O-RFLP patterns (data not shown). It is also
known, however, that Beijing strains are genetically
closely related I and do not necessarily reflect ongoing
transmission. We don't know for how long time the
Beijing genotype has been present in Latvia, as collect-
ing and storage of M. tuberculosis strains was started
only in 2000. We have also identified the Beijing geno-
type by spoligoryping and IS611O-RFLP in 12 drug-
susceptible M. tuberculosis isolates obtained from
patients during 1999-200 1, but, in general, our obser-
vations suggest that Beijing is not particularly common
among drug-susceptible isolates in Latvia (data not
shown). These results are in agreement with reports
showing the spread of Beijing genotype over recent
years in neighbouring countries Estonia and Russia,
where it was also associated with recent transmission
of drug-resistant strains.1920
In this study, the Beijing genotype of M. tuberculo-
sis was not associated with younger age of patients, as
was previously reported'> The mean age of Latvian
patients hosting the Beijing genotype was 46 years;
most (35.2%) of these patients were aged between 41
and 50 years, In contrary, the younger patients, those
between 21-30 years of age, constituted only 11% of
the Beijing patients. A similar age distribution was
observed in non-Beijing group: the mean age was 42
years, 36% of patients were 41-50 and 18% were
21-30 years old. It is obvious that the distribution of
age groups for the Beijing and non-Beijing genotypes
follows the general trend of TB in Latvia, where the
highest incidence is found among the population 44-
54 years of age (160 per 100000 in 2000). This could
indicate that transmission of TB in Latvia occurs
within a specific age group. This observation is impor-
tant for diagnosis of TB in the cases where bacterial
cultures are unavailable but transmission is obvious.
For example, in 2000,34.7% of the new cases among
Latvian children were detected only during contact
investigation.
instead of specific age, there is known to be a higher
incidence of TB and a corresponding higher incidence
of MDR-TB among the males in Latvia. The ratio of
females to males in our study in both Beijing and non-
Beijing groups was 1:3, which reflects the incidence of
TB in females and males in the general population.
Clinical information was available tor 34 patients
irom Beijing group who received DOTS therapy at
State Tuberculosis and Lung Disease Centre in 1999.
Of these patients, IS (43%) completed treatment and
one has been cured, whereas seven patients continue
to produce culture-positive sputum and II (31 'X»)
have died. This information allows us to predict the
general trends resulting from TB t re.u ment and to
develop adequate TB monitoring methods 111 clinical
practice.
The most common R.MP-resistance determining
mutations detected in this study, 5531 Land 0516 V,
are in complete agreement with previous studies."·H
In both of these studies, it was shown that the same
mutations dominate in both Beijing and non-Beijing
strains as well as among other genotypes. The higher
occurrence of double mutations (12. 7% against 2.2 %)
in the rpoB gene was the most obvious difference
between Beijing and non-Beijing groups in our study.
It is likely that the two mutations in different codons
result from a prolonged exposure of bacteria to RMP.
Perhaps, double mutations induce change in protein
folding that give the MOR strain a survival advantage
in presence of RMP. In our study, 93.7% of the RMP
resistant isolates contained mutations occurring in
the highly variable 69 bp region of the rpoB gene.
This observation is also in agreement with the previ-
ous srudies.v" The presence of this highly variable
locus should stimulate the search for a new genera-
tion of antibiotics that are analogous to RMP.
A high percentage of mutations at position 315
(98.4%) in the katG gene among INH resistant strains
had also been observed in this srudy. Similar results
were obtained in St-Perersburg area of Russia,"! where
Sed15Thr substitutions were predominant (92%)
among MDR-TB isolates. However, a wider mutation
spectrum was observed in USA and in western Euro-
pean countries.U-" Van Soolingen er al. have dis-
cussed codon 315 mutations being associated with
the high level resistance to INH as a result of inappro-
priate rreatrnenr.!" Our results suggest that Serine
substitution at codon 315 of the katG gene is charac-
teristic of INH-resistant strains and can therefore
serve as a genetic marker for INH resistance in our
region. Surprisingly, substitution at codon 315 was
absenr only in one INH-resistant strain. This can be
explained by the observation that there are more genes
which can be responsible for IHN resistance--inhA,
ahpC and kasA,!\·!h as well as the recently described
ndh gene.!? but mutations in these genes are of lower
frequency than those in the katG gene. According to
Sreevarsan er al., all strains of M. tuberculosis can be
assigned to three phylogenetic grou ps based on func-
tionally neutral polymorphisms present at codon 463
of the katG gene and codon 95 of the gyrA (a subunit
of DNA gyrase) gene.!- Therefore, all our Isolates of
the Beijing genotype with l.eu at codon 463 could be
assigned to the phylogenetic Croup I. This correlates
with results from other investigations conhrrrung rh.ir
[he Beijing group shares a common ancestor With ,\.1
bOI'IS.I-.IX In this study, automatic sequencuu; ot rhe
k at C, gene fragment of the M. bOI'IS kC<. <r r.un
showed Ser (wild type) at codon 315 and l.eu ;1[ codon
463; the larter indicating its relationship [() phyloge
netic Group I. The remaining strains that constituted
[he non-Beijing group with Arg at codon 46, could
be assigned either to Group 2 or to Group 3 on [he
hasis of polyrnorphisms at codon 95 of the gyrA gene.
This could be the aim of further investigations.
This study demonstrates a high frequency of the
Beijing genotype among MDR TB patients in Latvia.
The double mutations in the rpoB gene among strains
may show that MDR Beijing strains were exposed ro
inappropriate RMP treatment for a long time, thereby
underlying a historical lack of health policy measures.
In Latvia, the highest incidence of TB, reaching 74
cases per 100 000 population, was observed in 1998."s
Since then, the application of the DOTS strategy and
individual treatment regimens have proven effective
for MDR-TB patients. As a result, the incidence of
MDR-TB in Latvia has stabilised, and the cure rate lor
new TB cases has increased from 70.0% to 77.9% in
the last 3 years.!H In addition, the creation of a MDR-
TB registry in 2000, in combination with the imple-
mentation of molecular typing methods, will provide a
strong basis for improved monitoring of TB in Latvia.
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__________________________________ R t SUM t
CONiT'EXTE: Les genotypes predominanrs de Mycobac-
terium tuberculosis decrirs de par Ie monde incluent la
famiUe Beijing qui a provoque de grandes epidemics de
tuberculose et est associee a une virulence aigue et a une
multiresistance (MDR) dans cette maladie.
OBJECTIIF: Recherc'her Ie genotype Beijing parmi les
patients MDR de Lertonie afin de caracreriser au niveau
moleculaire leurs isolars de DNA.
SCHtMA: On a pratique Ie spoligotypage sur 103 isolars
MDR et l'on a recherche lies mutations geniques par un
sequencage autornarique de nucleotides,
RtSULTATS: Sur les 109 isolats examines, 95 apparte-
naient a six grappes cornportant de 2 a 63 isolars -au sein
de chaque grappe. Les 63 isolats de la plus grande de ces
grappes avaient un rype similaire correspondant au geno-
l)lpe Beijing. Les isolats resranrs eraient d'un genotype
non-Beijing et formaient un autre grand groupe dont la
similarite s'etalait entre 72% et 100%. Les mutations
dans les genes rpoB et katG om ere comparees entre les
souches appartenant au genotype Beijing et a un geno-
type non-Beijing. Dans [es deux groupes, lies mutations
geniques rpoB ont predornine dans les codons S531L
(52,2%) et D516V (14,7%). Des mutarions doubles
dans Ie gene 7poB ont ere observees dans 8,2 % des iso-
Iats, la plupart d'entre dies etant localisees parmi les
isolats du type Beijing. La mutation S315T du gene katG
(98,4%) etait prevalente dans tous les isolats.
CONClUSION: L'analyse moleculaire des isolars MDR
de M. tuberculosis demonrre que Ie genotype Beijing, Ie
pilus probablernent diJ a une transmission recente, est
prevalent en Lertonie parmi les patients MDR et que ce
genotype peur aller de pair avec des mutations doubles.
7______________________________________ R E SUM E N
CONTEXTO: Los genoripos predominantes de Mycobac-
terium tuberculosis descritos en rodo el mundo incluyen
la familia Beijing, que ha causado grandes brores epiderni-
cos de tuberculosis y que ha sido asociado con eI aumento
de la virulencia y con la multirresisrencia a los medica-
mentos (MDR) de esra enfermedad
OBJETIVO: Buscar el genotipo Beijing en los pacientes
MDR en Leronia, para caracterizar sus aislados de ADN
a nivel molecular.
DISENO: En 109 aislados MDR se realize una espoli-
goripificacion y tests de mutacion genica por secuenci-
acion autornatica de nucleotidos.
RESULTADOS: De los 109 aislados examinados, 95
pertenecian a 6 conglomerados, con 2-63 aislados en
cada conglomerado. Los 63 aislados del conglomerado
mas grande tertian, en un 100%, un tipo similar corre-
spondienre al genoripo Beijing. Los aislados restantes
eran de un genotipo no-Beijing y formaban otro gran
grupo, cuya similaridad iba de 72 a 100%. Se com-
para ron las mutaciones en los genes rpoB y kate entre
las cepas con genotipo Beijing y aquellas con genotipo
no-Beijing. En ambos grupos, las mutaciones del gen
rpoB predominaban en los codones 5531 L (52,2%) Y
D516V(14,7%). La doble rnutacion en el gen rpoB se
observe en el 8,2 % de los aislados, la rnayoria de ellas
habiendo sido localizadas en los aislados de tipo Beijing.
La rnutacion 5315T del gen kate (98,4%) era preva-
lente en todos los aislados.
CONClUSION: EI analisis molecular de los aislados
MDR de M. tuberculosis demuestra que el genoripo
Beijing, el mas probablemente debido a una infeccion
reciente es prevalente en Letonia en los pacientes MDR y
que este genoripo puede estar asociado con mutaciones
dobles.
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Grampositivie koki, tai skaitii meticilinrezistentie stafilokoki - S. aureus un koaguliizes
negativii S. epidermidis grupa ir kluvus! par nozimigiem hospitiilo infekciju ierosiniitiijiem.
Tii kii siem mikroorganismiem ir raksturiga polirezistence, to preciza diagnostika
klinikii ir loti nozimiga. Darbii izmantotas sekojosas meticilinrezistences noteiksanas metodes:
disku difiizijas metode, mecA gena noteiksana ar polimeriizes Ifedes reakciju, E-tests. Rezultiitu
apstipriniisanai izmantotas 2 automiitiskiis sistemas - Sceptor un Mini Api. Rezultiiti pariida, ka
disku difiizijas metode ir absoliiti preciza, noverota J 00% rezultiitu sakritiba ar "standartu?-
mecA gena noteiksanu. E-testa rezultiiti cetros gadijumos atskiriis un neuzriidija rezistenci, kas
bija pieriidita ar piirejiim 4 metodem. Visas izdalitas meticilinrezistentiis kultiiras bija
polirezistentas - nejutigas pret klinikii bietiik lietojamiem antibakteriiilajiem prepariitiem.
Introduction
Antimicrobial resistance continues to threaten the clinical use of antibiotics. Among the
organisms currently causing the greatest problems are a whole range of gram-positive cocci such
as Staphylococcus spp., Streptococcus pneumoniae, Enterococcus spp. etc. These are the
organisms that are most frequently isolated from clinical specimens in surgical hospitals (Bax et
aI., 2001; Gravenitz, 200 1; Zilevica et aI., 2001).
Staphylococci are pathogens that can cause a wide variety of diseases ranging from
localized wound infections to life-threatening systemic diseases. In the last decades the
multitude of resistant strains of S. aureus have developed and spread globally. Multiresistance is
commonly associated with the occurrence of methicillin resistance, an intrinsic resistance to
virtually all beta-Iactarns (Deplano et aI., 2000; Oliveira et aI., 2002).
Methicillin-resistant Staphylococcus aureus (MRSA) strains were first detected in the
UK in 1960, shortly after the introduction of penicillinase-resistant penicillins into the clinical
practice. Since then MRSA has become one of the leading causes of nosocomial infections
worldwide (Witte et al., 1997).
The incidence of MRSA among the clinical isolates of S. aureus varies from country to
country. Some countries such as Denmark and Iceland (> 0.2%) as well as Switzerland (1.8%)
have managed to keep MRSA at a controllable level. However, in some countries, the MRSA
incidence level is high - in France, Spain and Italy, more than 30% of hospital isolates of S.
aureus are resistant to methicillin (Murchan et aI., 1988; Blanck et aI., 2002; Pascual, 2002).
Coagulase negative Staphylococci (CoNS), particularly the S. epidermidis group, have
emerged as significant pathogens in nosocomial infections since the 1980s.
One of the factors that contributed to this phenomenon was increased use of indwelling
devices and prosthetic implants as well as poor catheterization techniques, followed by other
reasons such as more aggressive chemotherapy, advances in the cardiac and implant surgery,
and lastly, the awareness and improvement in microbiological teclmiques, which has made the
identification of these pathogens easier and more precise.
TIle proportion of methicillin-resistant S. epidermidis (MRSE) among hospital CoNS
has increased from 8 to 30% in the 1980s to 38% and even 90% nowadays (Mehtar, 1994;
Bouza, 2002, Carratala, 2(02). MRSE strains are considered reservoirs of antimicrobial
resistance genes that can be transferred to other Staphylococci, so contributing to the
development of methicillin resistance among microorganisms (Kragsbjerg et a!., 20(0).
To control the spread of resistance among Staphylococci, appropriate infection control
practices should be applied in hospitals, including precise microbiological diagnosis and
detection of antimicrobial susceptibility of isolated agents (Leclercq, 2000).
This study was undertaken for evaluation and comparison of several methicillin
resistance identification methods in Staphylococci and detection of antimicrobial susceptibility
of isolated MRSA and MRSE to a panel of antimicrobials.
Materials and methods
Bacterial strains
A total of 117 methicillin resistant Staphylococci strains isolated from clinical
specimens in a surgical hospital and collected within 1998-2002 were included in this study.
Among them, there were 25 coagulase-positive MRSA and 92 coagulase-negative methicillin-
resistant Staphylococci, including 63 strains of S. epidermidis (sensu stricto), 17 strains of S.
haemolyticus, 9 strains of S. hominis, 2 strains of S. warneri.
Most of these isolates were from indwelling artificial devices, blood, abscesses, etc. All
isolates were gram-positive clustering cocci. They were identified to a species level by
conventional tests such as coagulase test-tube reaction, phosphatase activity, haemolysis,
susceptibility to novobiocin, etc. and the automated BBL Crystal system (Becton-Dickinson).
22 methicillin-sensitive strains were included as control strains.
Antimicrobial susceptibility testing
Antimicrobial susceptibilities for all isolates were tested by the disk diffusion method
according to the National Committee for Clinical Laboratory Standards (NCCLS) guidelines
using Mueller-Hinton agar (MHA, Oxoid., UK) against the following panel of antibiotics:
penicillin, gentamicin, cefazolin, erythromycin, clindarnycin, vancomycin, ciprofloxacin,
trimethoprim-sulfamethoxazole.
Methicillin resistance was identified by the standard agar diffusion teclmique with a
commercial oxacillin disk (potency I ug of oxacillin). Because of the difficulties in detecting
cross-resistance among penicillinase-resistant penicillins (methicillin, oxacillin), the oxacillin
disk is now the recommended choice for detecting methicillin-resistant Staphylococci (Koneman
et aI., 1997).
Plates were incubated at 35°C for 24 h when zones of incubation were measured. Plates
with CoNS cultures were incubated for 48 h.
S. aureus ATCC 29213 was used as a methicillin-susceptible control strain, NCTC
8325 as a methicillin-resistant control strain.
To confirm the results of the disk diffusion method, detection of the mecA gene by the
polymerase chain reaction (PCR) and E-test were used.
Detection of the mecA gene
At present, the detection of the mecA gene, which is responsible for methicillin
resistance in practically all clinical methicillin-resistant Staphylococcal strains, is considered the
oxacillin resistance reference test. This is introduced in practice as an altemative to another
"gold standard" - the oxacillin agar screen plate test used in our and many other clinical
laboratories worldwide. PCR detection of mecA was started in Latvia in January, 200 I.
66 clinical isolates of Staphylococci were included in this study. Both coagulase-
positive and coagulase-negative Staphylococci (S. aureus - 24 strains, S epidermidis - 3 I
strains, S. haemolyticus - 8 strains, S. warneri - I strain) and S hominis - 2 strains were used
for detection of the mecA gene by PCR amplification. 54 strains from them were preliminary
methicillin-resistant, 12 strains - methicillin sensitive.
DNA isolation
Chromosomal DNA was extracted by the lysostaphin-CT AS method as described by
Jones, with modifications (Jones et al., 1953; Hookey et al., 1998). The cell cultures were
separated from Mueller-Hinton medium by centrifugation at 7000 rpm for 2 min, suspended in I
ml ofTE-glucose (25mM Tris-HCl [pH 8.0], 1.0% [wt/vol] D-glucose), and centrifuged at 7500
rpm for 5 min. The cells were resuspended in 100 ul of lysostaphin (I mg/ml in TE-glucose;
Sigma) - 50 ul lysozyme (50 mglml in TE-glucose; Sigma) and incubated at 3TC for 1 h. 80 J.1I
of NaCl-cetyltrirnethylammonium bromide (CTAS) solution (0.7M NaC!, 10% [wt/vol] CTAS;
Sigma) was added with mixing and incubated at 65'C for 10 min. Sodium chloride (100 J.1Iof a
5M stock solution, SDS (30 J.1Iof 10% [wt/vol] SDS; Sigma), and proteinase K (4 mg of
proteinase K; Sigma) were added with mixing and incubated at 55'C for 30 min. The lysate was
extracted with equal volumes of phenol-chloroform, and the DNA was precipitated from the
aqueous phase with one volume of isopropanol and diluted in 100 ul of sterile distilled water.
TIle DNA concentration was determined by UV spectrophotometry at A2f1J, and the
extract was stored at 4'C. Approximately 50 to 100 ng of DNA was taken for PCR
amplification. Extraction took place from 1 to 2 days.
PCR amplification of the meGA gene
PCR was performed with the following primers, previously designed by Geha et al.
(Geha ET al., 1994): mecAI (5'-GTA GAA ATG ACT GAA CGT CCG ATA A) and mecA2
(5' - CCA ATI CCA CAT TGT TIC GGT CTA A). The PCR reagent mixture consisted of 200
JlM concentrations of dNTPs, lOmM Tris (pH 8.3), 50mM KCI, 1.5mM MgCI2, a 0.25 JlM
concentration of each primer, and 1.25U of Taq polymerase (Fermen tas, Lithuenia). DNA
amplification thermal cycling profile ("Progene", Techne, UK): initial denaturation at 94'C for 5
min, followed by 30 cycles of amplification (denaturation at 94'C for 15 sec, annealing at 55'C
for 15 sec, extension at 7rC for 30 sec), ending with the final extension at n'c for 2 min. A
positive result was indicated by the presence ofthe 31O-bp amplified DNA fragment revealed by
electrophoresis on a 1.5% agarose gel. Results were obtained within 4 h. Each PCR included
methicillin- resistant strain as a positive control and water as a negative control.
E-test (AS Biodisk) was used as a quantitative technique for determination of
antimicrobial susceptibility and minimal inhibitory concentration (MIC) (Bolmstrom et al
1988). Mueller-Hinton medium, supplemented with 2% NaCL was used for inoculation.
Incubation time with E-test strips was 24 hand 48 h for S. aureus and CoNS, respectively.
In cases when incomparable results were obtained using the disk diffusion technique.
PCR and E-test, two automated systems were used: the automated Sceptor system and Mini-Api
system.
Results
TIle collection of methicillin-resistant Staphylococci (MRS) strains was carried out 011
the basis of the results of the oxacillin disk method. 66 of them - 24 S aureus (from them 18
MRSA, 6 MSSA) and 42 CoNS strains (36 MRS, 6 MSS) were analysed for the presence of the
mecA gene. According to peR results, all 18 strains of S. aureus and 36 strains of coagulase-
negative Staphylococci, phenotypically resistant to methicillin, showed the presence of the 310-
bp fragment of the mecA gene, thereby confirming methicillin resistance (the method's
sensitivity = 100%) (Fig. I).
Figure I, 2% agarose gel electrophoresis analysis of 3iO-bp fragments of the mecA gene from
DNA isolates of Staphylococcus sp.
M - molecular mass standard. "100bp Ladder Plus", slots No. 1-7- strains from SiT, slot No.8
- PCR negative control, slot No. 9 - PCR positive control (methicillin-resistant strain). PCR
results show that strains No.1, 3, 5, 6 and 7 are mecA-positive, strains No. 2 and 4 - mecA
negative.
E-test, used in parallel with PCR, demonstrated different results: 4 from methicillin-
resistant Staphylococcal strains, which exhibited methicillin resistance in both basic methods,
i.e. the disk method and PCR, showed a methicillin-sensitive pattern.
These four cultures were tested additionally for methicillin resistance in automated
Sceptor and Mini Api systems (Table I). As can be seen from Table I, all 4 strains proved to be
methicillin-resistant.
Table I
Methicillin resistance in Sta ohylococci accor 109 to erent me 10 so etecuon
No Patent Micro- Method for detection of methicillin resistance
organisms
Sceptor Mini Api
Oxacillin E- mec- MIC break
disk test gene mcg/m1 point
meg/nil
1 C. S epidermidis R S R R >4 R >0.25
2 S-s S epidermidis R S R R 4 R >0.25
3 A. S. epidermidis R S R R 4 R >0.25
4 S-a Swameri R S R R >4 R >0.25
I d· diffi tJ d fd
For 11 of the 12 control strains, the PCR response, phenotypically sensitive to
methicillin, was negative - the mecA gene was absent. One strain, exhibiting oxacillin MIC 1
ug/ml, proved to possess the mecA gene and should be recognized as methicillin-resistant. One
of the possible explanations for this fact can be a higher sensitivity of the PCR method in
comparison to standard methods, as PCR allows "to touch" bacteria at the genetical level.
Another explanation could be the heteroresistance of bacteria.
Methicillin-resistant Staphylococci are invariably regarded as resistant to all other beta-
lactam antibiotics. In addition, many clinical isolates demonstrate multi-resistant patterns. In our
studies of antimicrobial susceptibility of methicillin-resistant Staphylococci strains, a high-level
resistance to many commonly used antibiotics was registered (Table 2). 100% of S aureus, S.
haemolyticus, S hominis were resistant to erythromycin, 100% of S hominis were resistant to
gentamicin. 35-75% of isolated strains were resistant to Trimethoprim I Sulphamethoxazole, 68-
95% to clindamycin. No vancomycin resistance was documented.
Susceptibility of MRS to antimicrobials
Micro-organism No. Antimicrobials
of
cul-
tures
Cipro- CLinda- Erytro- Genta- Trimetho-
floxacin mycin mycin micin primlSulpha-
methoxazol
S - 88% S -32% S-O S -76% S - 65%
Siaureus 25 R-12% R-68% R-100% R-24% R- 35%
S. epidermidis 63 S -73% S -4.8% S -11% S -60.3% S - 29.8%
R-27% R- 95.2% R-89% R- 39.7% R-70.2%
S. haemolyticus 17 S -62.5% S-O S-O S -62.5% S - 25%
R-37.5% R-100% R-100% R-37.5% R-75%
S.hominis 9 S - 89% S - 22% S-O S-O S - 45%
R - 11% R-78% R-100% R-IOO% R- 55%
CoNS 93 S -73% S - 5.5% S - 8.8% S -63.7% S- 30.5%
total R- 26.4% R - 94.5% R - 91.2% R- 36.3% R - 69.5%
Discussion and conclusions
Antimicrobial susceptibility tests measure the ability of an antimicrobial agent to
inhibit bacterial growth in vitro.
The disk diffusion method (the modified Kirby-Bauer method), originally described in
1966, is recommended for clinical and surveillance purposes in view of its teclmical simplicity
and reproducibility. The method is well standardized, has been widely evaluated and is suitable
as a general method for all rapidly growing pathogens (Acar, 1980;Hasselman et al., 2000).
Methicillin resistance in Staphylococci can be detected by using an oxacillin disk, and
two gold standard methods are recommended by the European Antimicrobial Resistance
Surveillance System (EARSS), namely, oxacillin screen plate and detection of the mecA gene by
PCR (Goettsch et al., 2000).
The precise diagnosis of methicillin resistance is technically different because of the
hetero-resistant nature of MRS. However, it is of greatest importance - MRS are resistant to all
other beta-lactarns regardless of the in vitro results obtained. These beta-Iactarns include all
penicillins, cephalosporins, amoxicillin-clavulanic acid, arnpicillin-sulbactarn, imipenem.
We have used 3 basic methods for identification of methicillin resistance in
Staphylococci, namely, the standard agar diffusion (disk) test, detection of mecA gene, E-test.
It is well known that the most reliable is the detection of the mecA gene, a genotypic
marker of resistance by PCR - the high level of resistance to penicillinase-resistant penicillin
requires the presence of the mecA gene that encodes the penicillin-binding protein PBP 2a
(Frebourg et al., 1998; Lowy, 1998; Goettsch et al., 2000).
According to our results, the disk diffusion method has a high specificity - only one of
the cultures evaluated as methicillin-sensitive due to the disk method proved to have a resistant
pattern in the PCR test. This could be explained by the hetero-resistant nature of microorganisms
(Berger-Bachi, 1997; Zilevica, Vmgre, 2001).
The E-test proved to be less reliable. However, its value is in the quantitative
determination of resistance (MIC).
Undoubtedly, at least 2 methods are necessary for detection of methicillin resistance.
We recommend the use of PCR for detection of the presence of the mecA gene in methicillin-
sensitive strains.
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Summary
Gram-positive cocci, particularly the methicillin-resistant Staphylococcus aureus and
coagulase-negative Staphylococcus epidermidis group, have emerged as major agents of
nosocomial infections. Owing to the multi-resistance of these agents, precise diagnosis of the
methicillin resistance of Staphylococci is of greatest clinical importance. In our studies, the
following methicillin resistance identification methods were used: the disk diffusion method,
detection of the mecA gene by peR, E-test The results were confirmed using the automated
Sceptor and Mini Api systems.
Our findings indicate that the results of the disk diffusion method were identical to
"standard" PCR results. In 4 cases, the E-test showed different results and did not detect the
resistance confirmed by the other four methods. AIl the MRS strains were multiresistant to most
commonly used antibacterials.
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To characterize molecular mechanisms of first-line drug resistance in Mycobacterium
tuberculosis and to evaluate the use of the molecular markers of resistance (gene point mutations), we
have analyzed 66 multi-drug resistant (MDR) isolates from Latvian tuberculosis patients. The)' were
all resistant to rifampin (RIF), isoniazid (INH) and streptomycin (SM), 33 were resistant to ethambutol
(EMB). Enzymatic digestion by Mboll and nucleotide sequencing of the rpsl. gene fragment revealed
single nucleotide substitution K43R in 40 (61%) of the 66 SM resistant M.tuberculosis isolates. Of the
other 26 SM resistant isolates, 16 (24%) had mutations at positions 513A-)-C and 516C~ T of rrs gene
and 10 (15%) had the wild type sequence. The single-stranded DNA conformation polymorphism
(SSCP) method was applied to the embB gene to detect EMB resistance. Using 103bp fragment SSCP
analysis substitutions in embB gene were found in 15 (45%) and by sequencing in 17 (52%) of the 33
EMB resistant isolates. SurprisingJy, SSCP revealed nucleotide mutation at codon M306 in five (15%)
of 33 in vitro EMB susceptible MDR isolates.
Key words: Mycobacterium tuberculosis, drug resistance, gene mutations.
1. Introduction
For approximately 50 years chemotherapy was effectively used against tuberculosis (TB) caused by
the Mycobacterium tuberculosis complex [2]. Unfortunately, inappropriate treatment regimens compounded
by non-compliance of patients in completing the prescribed course of treatment have lead to the appearance
of drug-resistant strains. Today a high proportion of TB patients in Latvia harbour multi-drug resistant
(MDR) strains, i.e., strains resistant at least to rifampin (RIF) and isoniazid (lNH). In a survey of 1751
pulmonary TB patients in 2000, 9.3% of the patients had primary MDR and 27.1% had acquired MDR
Mtuberculosis bacilli [7]. Many of the culture isolates from MDR Mtuberculosis patients show resistance
not only to RIF and INH, but also to other first-line antituberculous agents: streptomycin (SM), ethambutol
(EMS) and, less frequently, to pyrazinamide [7].
The mode of action of anti-TB drugs and the molecular mechanisms of drug resistance have been
extensively studied. In most cases gene mutations in Mtuberculosis were found to be responsible for
resistance to first - and to second -Iine drugs [16,20]. We have previously reported results from the study of
MDR M. tuberculosis isolates from Latvia showing that mutations in the rpoB and katG genes, associated
with RlF and INH resistance, were found in 93.6% and 98.4% cases, respectively [23,24]. Therefore,
mechanisms of mycobacterial resistance to SM and EMS should be also investigated.
SM which was shown to be an effective anti-Tfl drug in 1944 [2J. acts by binding to the 305
ribosomal subunit, thereby interfering with polypeptide synthesis by inhibiting translation [261. Two genes,
rpsl. and rrs, encoding the ribosomal protein 512 and the 165 rRNA are known to be responsible for the SM
resistance [6.8J. EMB is another effective and highly specific agent used in chemotherapy in combination
with other drugs 131 It is believed that EMS is targeting arabinosyltransferases that catalyse the
incorporation of arabinan into cell wall polymers arabinogalactan and Iipoarabinomannan [5, 271. Mutations
associated with resistance to EMS have been found in the embB (arabinosyltransfcrase) gene, especially, at
codon M306 122)
It would be interesting to know the molecular mechanisms of drug resistance to M'tubercutosis in a
region with a high level of MDR such as Latvia and to compare it with that in other parts of the world.
Therefore, we examined rpsl; rrs and embB genes known to be associated with resistance to SM and EMB.
respectively, in Mtuberculosis isolates from Latvian MDR patients. Knowledge of frequently occuning
mutations at specific codons that correlate with the genetic relatedness of MDR strains should contribute to
our understanding of resistance to first-line anti-TB drugs both at regional and at international levels. This
information might be further used in order to develop and adopt molecular methods for testing drug
susceptibility directly in clinical specimens.
2, Materials and Methods
2.1. Cultures and susceptibility testing. For this study, 66 cultures of Mituberculosis from patients
with a primary and relapsed pulmonary MDR-TB were randomly selected. They were typical TB patients
from different regions of Latvia admitted to the State Centre of Tuberculosis and Lung Diseases between
2001 and 2002. Cultures of the Mycobacterium tuberculosis complex were grown on Lowenstein-Jensen
medium for 4-6 weeks. Drug susceptibility was determined both by the absolute concentration method on
slants with the H37Rv strain as the positive control and by the BACTEC radiometric method (Becton
Dickinson, Sparks, Md.) [9,19]. In the absolute concentration method, resistance was defined as growth on
solid media containing graded concentrations of drugs greater than a 20CFU at a specific drug concentration.
The minimal inhibiting concentrations on Lowenstein-Jensen medium were 0.21lglml and 2.0llglml for INH,
40.01lglml for RIF, 4.01lg/ml for SM and 2.01lglml for EMB. All 66 cultures were resistant to RIF, INH and
SM, 33 were resistant to EMB.
2.2. DNA isolation and PCR. Native DNA was isolated from the mycobacterial cultures by
lysozyme/proteinase K, CTAB procedure and precipitated with isopropanol [25]. Purified DNA was
dissolved in 20-50~ ofTE buffer (IOmM TrisHCI, !rnM EDTA [pH 8]). DNA isolated from MTl4323 and
Mycobacterium bovis BCG strains was used for controls.
The 306bp fragment of Mtuberculosis rpsL gene (GenBank accession number L08011) was
amplified using primers SMI-CCAACCATCCAGCAGCTGGT and SM2-
ATCCAGCGAACCGCGGATGA. Modified primers SM3-GATGACGGCCITCGGGTTGT and SM4-
TCT AGCTGCCCGT ATCGCC and primers SM5-GT AGTCCACGCCGT AAACGG and SM6-
AGGCCACAAGGAACGCCTA were used for analysis of the 530 loop (238bp fragment) and region 912
(240bp fragment) of the rrs gene [11, 12]. The 103bp fragment of the embB gene (GenBank accession
munber Z80343) was amplified using primers adopted in part from Rinder et al. [18]: 46-
CTGCTCTGGCATGTCAT and 47-AGCGGAAATAGTTGGAC. The 1O-20ng of DNA diluted in TE buffer
was added to the PCR mix containing PCR buffer, <NH4hS04, 2.5 mM MgCh, 200JlM each of dNTP and 1U
Taq DNA Polymerase (Fermentas, Lithuania) to a final volume 50111.Ten pmols of each primer were used
for one reaction mix. The optimized cycling protocol was used for each set of primers in the "Progene"
thermal cycler (Techne, England). PCR products were analysed in 1.5% agarose gels. In each set of reactions
one negative control and one positive control (M bovis BCG-Connaught strain DNA) were included.
2.3. Analysis of the rpsL and rrs genes. 306bp fragments of the rpsL gene from each of the 66 SM
resistant DNA isolates were digested with MboIJ endonuclease (Fermentas, Lithuania) for 15 min at 37°C and
separated on 6% PAAG. Fragments of the rrs gene encoding the 16S rRNA 530 loop and 912 region were
analyzed by automatic nucleotide sequencing.
2.4. Analysis of the embB gene. The 33 EMB resistant and 33 EMB susceptible MDR
Mtuberculosis isolates were analyzed for presence of mutations in the 103bp fragment of embB gene by the
single-stranded DNA conformation polymorphism method (SSCP). After heating for 5 min at 96°C with an
equal volume of loading buffer (0.05% bromphenol blue, 0.05% xylene cyanol and 95% formamide) the 103bp
fragments were snap-cooled and immediately loaded onto the gel. The SSCP analysis of the DNA fragments
was performed in a 6% polyacrylamide gel containing 3.5% glycerin at 200V on a 14x 16xO.2cm gel plate
cooled to 10°C (BioRad, USA). After 3h of electrophoresis the separated DNA bands were visualized by
ethidium bromide and by silver staining.
2.5. Nucleotide sequencing. Automatic nucleotide sequencing was used to confirm the results of
SSCP and Mboll digestion methods. Both DNA chains of the purified PCR products were sequenced using the
ABI PRISM BigDye™ Terminator Cycle Sequencing Reaction Kit, and the results were read using the ABI
PRISM 3100 DNA Analyser (Applied Biosystems, Inc., Foster City, Calif.). The data were assembled using
Applied Biosystems software and nucleotide sequences were compared to the published sequences of the
genes.
3. Results
3.1. SM resistance. The J06bp fragments of rpsL gene from the 66 SM resistant DNA isolates
were analysed both by digestion with Mboll endonuclease and by automatic sequencing TIle Mboll digestion
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patterns are shown in Fig. 1. Cleavage of the 306bp fragment, observed in 26 (39%) isolates, indicates the
presence of the wild type codon K43. In opposite, absence of cleavage in 40 (61%) of the isolates indicated
nucleotide change at codon K43. Nucleotide sequencing of the 40 isolates confirmed change from AAG to
AGG (K~R) at position 43 (K43R). Digestion with Mboll was, therefore. confirming wild type nucleotide
sequence at codon K43. The 26 isolates with the wild type rpsl. sequence were further examined for
mutations in two regions of the rrs gene encoding for the 16S rRN A. Analysis of the 912 region showed the
wild type sequence in all the isolates tested. In contrast. 16 or 24% of all tested 26 isolates showed
substitutions in the 530 loop region at nucleotide positions 513A~C (n= II) and 516C~ T (n=5) The
remaining 10 of these isolates or 15% of the all isolates tested showed the wild type sequence in these
regions of the rpsL and rrs genes. In summary, 56 (85%) of the tested 66 SM resistant isolates. had
nucleotide substitutions either at amino acid position K43 of rpsL gene or at nucleotide positions 513A or
516C of the rrs gene.
3.2 EMB resistance. SSCP analysis was applied to 103bp fragments of the embB gene from 33 EMB
resistant MDR isolates. The analyzed fragments included codon M306 known to undergo nucleotide changes
Results of the SSCP analysis were then compared to results from nucleotide sequencing of the same
fragments. The SSCP analysis showed patterns in 15 (45%) of the 33 EMB resistant isolates that were
different from that of the EMB susceptible isolates (Fig. 2). The remaining 18 (55%) of the EMB resistant
isolates showed SSCP patterns indistinguishable from those of the EMB susceptible isolates. Automatic
sequencing of the 15 EMB resistant isolates that differed in SSCP patterns from the susceptible ones showed
a nucleotide point mutation at codon 306 ATG~GTG or ATG~ATC resulting in the substitution of amino
acid Methionine for Valine or Isoleucine. Nucleotide sequencing of the 18 EMB resistant isolates that could
not be distinguished from the EMB susceptible isolates by SSCP analysis, showed the wild type sequence in
16 (48%) of the isolates and mutations in 2 (6%) isolates: ATG~ATA (M306I) in one and GGC~GAG
(Gly314Glu) in the other. Obviously, these nucleotide substitutions don't change conformation of the 103bp
single-stranded DNA fragments under the used electrophoresis conditions of the SSCP analysis. In summary,
single nucleotide substitutions were detected by SSCP in 15 (45%) and by sequencing in 17 (52%) of the 33
EMB resistant isolates. The SSCP method revealed 15 (88%) of the 17 isolates that had mutations in the
studied fragment of the embB gene showing good correlation with sequencing results.
SSCP method was also used to examine the 33 EMB susceptible MDR isolates. lnterestingly, 6 (18%)
of the 33 isolates showed SSCP patterns different from patterns given by a typical wild type sequence.
Subsequent nucleotide sequencing revealed mutations in all 6 isolates: the mutation ATG~GTG (M306 V) in
four isolates, mutation ATG~ATC (M306I) in one isolate and the silent mutation GGC~GGT (Gly294) in
another.
4. Discussion
The high MDR-TB level in Latvia can be explained by mono drug treatment regimens in the past
century compounded by present social conditions today such as inadequate housing, poor nutrition and,
generally, low socio-economic levels conductive to increase of MDR-TB cases. How could these factors
influence the mechanism by which drug resistance in Mtuberculosis develops? Therefore, the alterations in
mycobacterial genome should be studied and the correlation with the in vitro susceptibility testing results
should be evaluated The PCR-based methods are very useful for that aim since are able to detect specific
nucleotide changes in sequences present in a low copy numbers. At the same time, the correct information on
drug susceptibility is crucial for the clinicians and should be available for slowly growing mycobacteria in a
short period of time. We have confirmed the suitability of the different methods for detection of changes in
the already known genes in order to apply those further to clinical specimens of the Mtuberculosis. The
results of our previous studies on prevalent mutations in the rpoB and katG genes in MDR isolates showed
possibility to apply molecular methods directly to clinical specimens as it was later introduced in State Centre
of Tuberculosis and Lung Diseases (23).
We have studied two genes, rpsL and rrs, known to be partially responsible for SM resistance. A
percentage of the rpsL (61%) and the rrs (24%) gene mutations in part correlates with the previous reports.
where alterations in the rpsL gene have been detected in 52.0 to 56.8% and mutations in the rrs gene were
detected in 8.0-15.6% of the analysed SM-resistant isolates [10, 15,2l). A slightly higher prevalence of K-t3R
mutations may be explained by the high prevalence of Beijing genotype among Latvian MDR M'tuberculosis
strains (24). It is also based on observation that in our study that strains with the Beijing genotype (confirmed
by RFLP analysis and spoligotyping) had the K43R mutation, whereas isolates with non-Beijing genotype
showed the wild type sequence in the analyzed fragment of the rpsl. gene (data not shown). lntcresungly.
there was one exception. when isolate with non-Beijing type, confirmed by the previously mentioned
methods. had mutation K43R. This case is in contrary to previous founding III and should be addiuonallv
studied. Mutations in the rrs gene could therefore, confer SM resistance in the isolates lacking rpsl. gene
mutations Mutations have been very rarely found in the both genes simultaneously: possible interplay of
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mutations was proposed in several such examples [13,21). By R.Cooksey [4). [13) a high level of phenotypic
resistance to SM in vitro (>500~glml) is associated with mutations in the rpsL gene, whereas mutations in the
rrs gene occur only in isolates with the low-level resistance to SM (MlCs, IOug/ml). Interestingly, none of
our isolates showed mutation neither at rpsL codon K88 nor at rrs gene 912 region, both of those have been
widely described by the other investigators [12,16). Again, obtained results can be explained by the
prevalence of particular genotypes in Latvian strains. At least, 10 (15%) remaining isolates may have
alternative low-level resistance mechanisms mediated by drug-modifying enzymes or by reductions in drug
uptake.
Many of the EMB resistant isolates could be rapidly identified by the analysis of the embli gene
encompassing codon 306. We have evaluated SSCP method for analysis of the embE gene short fragment.
Compared to nucleotide sequencing, SSCP is sensitive enough to reveal mutations M306Y and M3061 but
not the change ATG306A TA, shown in one isolate and also resulting in He. Not surprisingly, that only 52%
of the analysed isolates showed nucleotide alterations in the embli fragment. Therefore, analysis of
alterations in the embE gene in order to detect EMB susceptibility is of limited value and should not be
reconunended for fast screening of clinical specimens. Ramaswamy [17) have analysed sequences of 12
genes that could be involved in EMB resistance and had showed that 68% of the isolates had mutations in the
embli gene. At the same time, 51% of the isolates had mutations associated with EMB resistance in the only
1 of the 12 genes indicating multiple molecular pathways leading to the EMB resistant phenotype.
Surprisingly, in our study SSCP analysis revealed mutations at codon M306 in the embB gene of the
five in vitro EMB susceptible MDR isolates. Similar results have been reported from Northwestern Russia
where mutations at codon M306 were found in 14 (48.3%) of the 29 EMB-resistant strains and in 48 (31.2%)
of the 154 EMB susceptible strains [14). Like in our study, the discrepancy between the results of phenotypic
and genotypic EMB resistance tests was found in MDR strains only. Authors hypothesize that there could be
a drug target in tubercle bacilli, other than one encoded by the embB; it could be affected by the EMB during
the treatment with the other first-line anti-TB drugs.
In general, our data confirms the findings of the previous studies made on genes associated with
resistance to first-line anti-TB drugs in a majority of Mtuberculosis isolates. More studies should be done to
identify additional mechanisms of drug resistance in Mtuberculosis bacilli. Combined with the studies of
Mtuberculosis genome (insertion sites, repetitive units, direct repeat region etc.) it should contribute our
understanding of TB spread in population and of evolution of mycobacteria.
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Figure 1. Digestion of the J06bp fragment of the rpsL gene with endonuclease Mholl. Lane M, DNA
molecular weight marker "pUC19 DNNMspJ (HpaID"; lanes I - 10, digested rpsL gene fragments of SM
resistant Mtuberculosis DNA isolates. Lanes I, 2, 3, 5 and 8 contain undigested 306bp PCR products
indicating a mutation at codon L43. Lanes 4, 6, 7, 9 and 10 contain digested PCR product (171bp and 135bp
fragments) indicating the wild type codon L43 in this position.
Figure 2. PCR-SSep analysis of a lOJbp fragment of the embB gene in 6% PAAG. S - 103bp fragment
of the embB gene from EMB susceptible M tuberculosis isolate; R - ~03bp fragment of the embB gene from
EMS resistant isolate; R!' - W3bp fragment of the emhB gene form EMB resistant isolate with a SSCP
pattern undistinguishable from S.
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Pyrazinamide (PZA) is a vel)' effective anti-tuberculous agent particularly when used in
combination with rifampin (RIF) and isoniazid (INH) (2). PZA becames active when bacterial
pyrazinamidase converts it to toxic pyrazonoic acid (29). PZA resistance inMycobacerium tuberculosis
strains is associated with the loss of pyrazinamidase activity mainly due to mutations in the 561bp long
pncA gene gene coding region or in gene expression regulating part (13,26).
The molecular basis of resistance to PZA inMtuberculosis have been extensively studied in
last years. Nevertheless, an additional studies should be done in order to evaluate molecular methods
for drug susceptibility testing directly in clinical specimens, since PZA susceptibility testing in vitro is
complicated (Scorpio 97). In order to understand the molecular basis of PZA resistance, we examined
pncA gene in 28 PZA resistant and 10 PZA susceptible cultures of MDR (multi-drug resistant)
Mtuberculosis isolates from 38 Latvian MDR patients. In last decades, situation in Latvia can be
characterised by a high TB morbidity and MDR-TB level (Surveill). Cultures were collected in State
Centre of Tuberculosis and Lung Diseases between 2001 and 2002. No PZA monoresistant cultures
were observed during that period. Cultures of the Mtuberculosis were grown on Lowenstein-Jensen
medium for 4-6 weeks. Drug susceptibility was determined both by the absolute concentration method
on slants and by the BACTEC method (Becton Dickinson, Sparks, Md.) (9,24) All 38 cultures were
resistant to RIF, INH and SM, and 28 of 38 were resistant to PZA. Native DNA was isolated as
previously described (28). We used primer set PIIP6 (27) to amplify the nO-bp fragment of the 558bp
pncA gene and the surrounding DNA regions. PCR products were further analysed by automatic
sequencing of both DNA chains using the ABI PRISM 3100 DNA Analyser (Applied Biosystems, Inc.,
Foster City, Calif.).
Results from automatic sequencing of the 28 PZA resistant isolates are shown in Table I.
Altogether, point mutations were found in 23 (82%) of the 28 PZA resistant isolates and were located
in ten different codons within open reading frame of the pncA gene leading to an amino acid change. In
addition, one mutation also resulted in premature synthesis termination. Codons T76 and Y103 were
most frequently affected (43%). One isolate showed a mixture of the wild type and a mutant sequence.
with mutations at two codons, CI4 and Y103. We propose that the two mutations in this strain arose
independently, because RFLP and spoligotyping analysis showed a single strain pattern (data not
shown). Five of the isolates showed the wild type pncA gene sequence indicating alternative
mechanism for PZA resistance. No mutations were detected in ten of the PZA susceptible MDR
M tuberculosis isolates.
In comparison to previous reports. we have detected mutations at three novel codons: CI4Y.
D63G and V180F; the remaining seven mutated codons have been previously described
(3,14,15,17,19,27,31). In our study. most frequently mutations occurred in codons T76 and Y103, in
spite of the R140, L85 and T47 codons, reported previously (3,14,15,17,19,27,31). Seven of our
mutated codons (QIO, C14, P62, D63, cn, T76 and Cl38) were located in pncA gene three hot
regions, as suggested by Scorpio (27), partially confirming his hypothesis.
To conclude, nucleotide sequencing remains the most appropriate tool for the analysis of the
pncA gene where mutations are randomly dispersed. Taking in account a high percentage (82%) of
mutations found in the pncA gene in Latvian isolates, we propose a direct sequencing on clinical
specimens a screening method for molecular testing ofPZA susceptibility.
This work was supported by the Latvian Council of Sciences (grant Nr 02.0011.15). We thank
Vitauts Kalnins (University of Toronto. Canada) for his essential help in preparing this manuscript.
TABLE 1. Mutations detected in pncA gene of PZA resistant M.tuberculosis isolates
Change(s) in :
Nucleotide sequence
A--+C at position 226
T --+C at position 307
A--+G at position 188
C--+D at position 216
T --+G at position 254
C--+T at position 28
G--+A at position 41
C--+A at position 184
A--+T at position 308
G--+A at position 413
G--+T at position 537
wr / C--+ G at position 42 + T --+C
at position 307
5 (18%) wr
Ter* - chain synthesis terminating codon
wr -wild type
Number of isolates Amino Acid
D6--+P
YI03--+H
D63--+G
C72--+W
L85--+R
QIO --+Ter*
CI4--+Y
P62--+T
Y 103--+S
C138--+Y
VI80--+F
wr / CI4--+W + YI03--+H
5 (18 %)
5 (18%)
2
2
2
I
I
I
I
1
I
1
wr
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